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Asbestos exposure is known to cause a number of pleural pathologies. Despite a ban of asbestos use 
over 30 years ago, the incidence of asbestos related pleural disease continues to increase due to the 
prolonged lag period from exposure to disease development. In this thesis I explore a number of gaps 
in the literature relating to asbestos related benign and malignant pleural pathology.     
 
Methods 
The first study is a prospective case series of diffuse pleural thickening. Full respiratory function of 
patients with different distributions of pleural thickening on CT were compared against a matched 
control population. The results confirm a significant reduction in lung function in patients with all 
forms of diffuse pleural thickening by size criteria, including those with no costo-phrenic angle 
involvement.  
The second study assesses the role of MRI as an exploratory tool in those with equivocal pleural 
thickening on CT. Early differentiation of malignant from benign pleural thickening is crucial to offer 
patients the best clinical management. MRI was investigated as a potential non-invasive method of 
diagnosing patients with equivocal CT findings. 
The third study is a multi-centre randomised controlled study (RCT) to investigate whether a Positron 
Emission Tomography (PET)-CT targeted biopsy is superior to a standard CT guided biopsy, for patients 
with suspected pleural malignancy, who have had one non-diagnostic biopsy. 52 patients have been 
recruited to date and the trial will finish recruitment in September 2018. 
The fourth study is a multi-centre RCT investigating the feasibility of delivering zoledronic acid or 
placebo concurrently with chemotherapy for patients with Mesothelioma. Whilst we did not meet our 
primary feasibility outcome of randomising 50 patients across 3 sites in 13 months, we did obtain 
valuable information that would help us in designing a full phase-III trial.  
The final study is a prospective cohort study investigating the role of serial mesothelin biomarker 
monitoring of patients with MPM, who are receiving best supportive care. A 10% rise in mesothelin 
can reliably predict progressive disease.   
 
Discussion 
The findings discussed as a part of this thesis add to our current knowledge on asbestos related pleural 
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Asbestos refers to a group of fibrous silicate materials, well known for their properties of high 
tensile strength, thermal and electrical resistance. The term ‘asbestos’ is somewhat 
commercially coined rather than a mineralogical term and is derived from the Greek words 
for ‘unquenchable’ or ‘inextinguishable’, due to the unique properties exhibited by the 
material [1].  Once known as the ‘magic mineral’, the history of asbestos spans a number of 
centuries. The earliest documented reports of its use date back to 2500 BC when it was used 
in the Finnish pottery industry[1]. Widespread mining and commercial use started in the 19th 
century, with the discovery of asbestos deposits in Quebec and Ural mountains of Russia  [2].  
Asbestos fibres are of varying length, diameter and shape. They are broadly sub-classified into 
2 groups; chrysotile and amphibole [3]. The amphibole group consists of 5 sub-types: 
crocidolite, amosite, anthophyllite, tremolite and actinolite [1, 3].  
Chrysotile has an approximate chemical composition of Mg3Si2O5(OH)4. Chrysotile fibres are 
curvy cylindrical fibrils with a central hollow, and splayed end  [4]. They are extremely heat 
resistant, being able to withstand temperatures up to 575 Centigrade [1]. Due to its length, 
curvy, linear structure and natural tendency to clump in bundles, these fibres are often 
intercepted at the carina of the bronchial tree when inhaled, and a majority are therefore 
cleared within hours to weeks[3].    
Amosite and Crocidolite, also widely known as brown and blue asbestos, are the 2-main 
amphibole types of asbestos used commercially. These shorter needle shaped structures 
penetrate the lung tissue more readily than chrysotile fibres and, due to their relative 
insolubility and increased bio persistence tend to last decades before being cleared from the 
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lungs [3]. Fibres can often be found in post-mortem lung tissue as asbestos bodies in the lung 
parenchyma [5, 6].  Tremolite, actinolite and anthophyllite were less widely used for 
commercial purposes.        
Chrysotile was the commonest commercially used from of asbestos with approximately 90% 
of the industries using this type [7]. At its peak in the mid to late 20th century, a number of 
industries including shipbuilding, manufacturing, insulation and construction, relied heavily 
on asbestos incorporated products, which led to an increase in the number of deaths 
attributed to asbestos in those working within these industries [8].  
Asbestos has also been used as  a major component of a number of day-to-day products such 
as flooring,  roofing, textiles, plastics and cement [7]. Asbestos is most dangerous as a dust 
when it is readily inhaled. If the asbestos fibres are held within a matrix of another material 
(eg. within cement or plastic), the risk of inhalation is lower, unless the material is damaged 
allowing the fibres to be released [3].   
1.2 The Pleura 
 
The pleura is the thin membranous covering of the lung and the chest cavity, comprising of 
the visceral and parietal pleurae, which in reality are one contiguous layer [9]. The visceral 
pleura encases the lung parenchyma including the fissures, while the parietal pleura covers 
the inside of the thoracic cavity, pericardium, thoracic surface of the diaphragm, and the 
mediastinal structures. Composed of a single layer of mesothelial cells, the pleura is rich in 
microvilli, while a layer of connecting tissue rich in blood vessels and lymphatics sits beneath 
the layer of mesothelial cells [9]. The space between the visceral and parietal pleurae (known 
as the pleural space) contains a small volume of fluid (approximately 0.26ml/kg  in each hemi-
thorax) [10]. This fluid is constantly produced by the pleural capillaries in the parietal pleura 
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and reabsorbed via the pleural lymphatics [9].  Pleural fluid is thought to lubricate the  pleural 
surfaces,  allowing them to glide smoothly over each other during respiration [11]. 
Animal studies investigating the pleura in an attempt to understand the composition and 
functions have discovered that the visceral pleura is thicker than parietal pleura, measuring 
25-83 µm vs 10-25 µm for parietal pleura, in sheep [9]. Injuries and insults can lead to 
thickening of the pleura, particularly the parietal pleura, which is more susceptible to the 
effects of injury. The mesothelial cell layer is fragile and when injured will be repaired by 
migration of neighbouring cells and secretion of growth factors, analogous to epithelial cells 
[12]. Mesothelial cells can be easily dislodged from the pleura and can often be found in fluid 
aspirated from the pleural cavity. 
1.3 Biological aspects of asbestos related disease 
 
Several factors are closely interlinked in the pathogenicity of inhaled asbestos dust particles 
[13]. The main factors responsible for the biological consequences and bio-persistence of 
asbestos particles are fibre dimension (diameter and length), chemical composition and the 
surface state of the fibres [13, 14]. Large inhaled particles/fibres are cleared by the muco-
ciliary system in the upper airways and the larger bronchioles [4]. Smaller fibres, often if less 
than 20µm, can migrate to the alveoli [4]. Once in the alveoli several processes can take place 
that may decide the fate of the fibres. They could remain in the alveoli indefinitely or be 
ingested by macrophages (if the fibres are smaller than 5µm). Some fibres can be partially or 
completely dissolved over a prolonged period of time. This is rare in amphibole structures due 
to their relative insolubility but chrysotile fibres which have a higher Magnesium content, may 
succumb to the gradual leaching process [4]. Finally, some fibres may migrate further from 
the alveoli – on their own or via macrophages – to the pulmonary interstitium or to the pleura 
[13, 15, 16].   
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The parietal pleura’s increased susceptibility to the carcinogenic effects of asbestos fibres is 
not completely understood but their bio-persistence and a chronic inflammatory response 
may play a major role [15-17]. In addition, asbestos can cause DNA damage directly by 
interfering with the segregation of chromosomes during mitosis [18]. Asbestos fibres are 
ingested by macrophages but may not necessarily be completely dissolved. As the 
macrophage life span is only about 50 days, when they die, the undissolved fibres are re-
ingested by other macrophages and this cycle repeats itself. Fibre size also has a role in 
carcinogenicity [19]. Smaller particles are ingested and dissolved by phagocytosis. Larger 
fibres are intercepted in the tracheo-bronchial tree by the muco-ciliary system and cleared 
this way. This then leaves the intermediate length fibres, which are particularly resistant to 
degradation. The intermediate fibres can penetrate the cell membranes of the macrophages 
when they are ingested, discharging lysozymes and other enzymes from macrophages leading 
to surface reactions on the asbestos fibres. The electrically charged surface states have a role 
in generating free radicals and biological responses [15]. Amphibole fibres in particular, have 
a higher content of iron which leads to the formation of reactive oxygen species causing 
mutagenic oxidative lesions which may also play a role in the development of malignant 
pleural mesothelioma (MPM) [16].  
Approximately 60-70% of pleural mesothelioma cases are related to prior asbestos exposure 
[20], while the remainder maybe as a consequence of chest radiation, genetic predisposition 
or spontaneous occurrence [21]. Novel genomic analyses have defined a range of molecular 
alterations that drive pleural mesothelioma. BRCA associated protein 1, or BAP1 has been 
identified as one of the commonest genes, where deletion or truncation of BAP1 gene is 
commonly seen in pleural mesothelioma [22, 23]. Similarly, the absence of CDKN2A and NF2 
genes also predispose more towards pleural mesothelioma, in comparison to mesothelioma 
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of other organs such as peritoneal, pericardial and tunica vaginalis [22, 24]. As in other 
malignancies it is the inactivation of tumour suppressor genes that appear to play a crucial 
role in the development of the disease [23]. Further work is ongoing to explore the genetic 
predilection and how this can be incorporated in the diagnostic and prognostic aspects of 
mesothelioma [24]. 
A study by Yang et al. demonstrated that asbestos fibres can lead to necrotic cell death 
resulting in the release of Highly Motile Group Box – 1 (HMGB1) which causes a chronic 
inflammatory response with the accumulation of macrophages and secretion of tumour 
necrosis factor alpha (TNFα) [25]. TNFα on one hand protects human mesothelial cells from 
asbestos induced cell-death but on the other hand promotes the growth of human 
mesothelial cells that have accumulated damaged-DNA from asbestos exposure [17].    
The dose-response relationship between asbestos fibre exposure and development of related 
disease has been well recognised [2]. At the International Meeting of Experts of Asbestos, 
Asbestosis and Cancer, in January 1997 in Helsinki, the exposure criteria were standardised 
taking into consideration the evidence available at the time [26]. These criteria are now 
known as the ‘Helsinki criteria’ and in brief they state, 1 year of heavy exposure (such as 
manufacture of asbestos products, spraying asbestos, insulation work with asbestos lagging 
and demolition of old buildings) and 5-10 years of moderate exposure (for example 
construction and shipbuilding) is likely to equate to a greater than 25 fibre/ml/years of 
exposure. At this level of exposure, the risk of lung cancer is more than doubled [26]. This is 
also the minimal dose at which asbestosis – interstitial fibrosis of the lung parenchyma - can 
occur. MPM can occur at much lower exposure levels [27]. These criteria are now routinely 
used when attributing disease causation to asbestos[27] .    
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1.4 Asbestos related benign pleural disease  
 







As this thesis is concentrating on asbestos related pleural disease, the pleural pathologies are 
discussed in more detail below. 
1.4.1 Pleural Plaques 
Pleural plaques are focal areas of fibrosis limited to the parietal pleura (Figures 1-1 and 1-2). 
Pleural plaques are harmless and do not transform to a malignant process, however a ‘large 
plaque load’ signify heavy exposure, and can be associated with development of malignancy 
due to a similar dose-response relationship [28]. The presence of pleural plaques is 
pathognomonic of asbestos exposure. Pleural plaques appear on chest radiographs 
approximately 12 years after exposure and can take up to 20 years before calcifying [29, 30]. 
Pleural plaques are often found in the areas of greatest friction between the lung and chest 
wall. They tend to spare the apices and are commonly found on the diaphragm.  They can be 
of varying sizes and shapes and, occasionally so extensive that they involve almost the entire 
hemi-thorax resulting in a restrictive respiratory impairment [31]. Often pleural plaques are 
an incidental finding on chest radiography and given their benign course they do not require 
on going monitoring or follow-up. However, their presence signifies previous asbestos 
Benign pathologies Malignant pathologies 
Pleural plaques Mesothelioma 
Benign asbestos related pleural effusions  Lung cancer 
Diffuse pleural thickening  
Asbestosis  
Table 1-1: Asbestos related pleuro-parenchymal diseases 
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exposure and hence patients are at increased risk of other asbestos related pathologies, 
including malignancy. 
 





Figure 1-2: Pleural plaques (PP) as seen at thoracoscopy 
 
1.4.2 Benign asbestos related pleural effusions 
 
Benign asbestos pleural effusion (BAPE) is a diagnosis of exclusion in patients with pleural 
effusions and evidence of previous asbestos exposure. Presenting symptoms are variable with 
some patients being completely asymptomatic and the discovery of the effusions being 
incidental, or symptoms of an active inflammatory pleuritis with fever, breathlessness or 
pleuritic chest pain  [16, 32].  The reasons behind the development of these effusions are 
poorly understood, however, the literature suggests an acute inflammatory reaction 
secondary to asbestos exposure as a potential cause [33]. The lag period for developing BAPE 
is much shorter (10 years from exposure) than that for other asbestos related disease such as 
mesothelioma or asbestosis (30-40 years) [32]. Due to the high risk of malignancy in this 
cohort of patients, this should be excluded by means of a pleural biopsy and sufficient follow 




effusion for symptom relief. BAPE also has been cited as the trigger for visceral and parietal 
pleural fibrosis which can lead to diffuse pleural thickening (discussed below) [32, 33]. It is 
prudent to observe these patients for a number of years to ensure that the diagnosis is in fact 
BAPE and not a misclassification of an early stage MPM.  
1.4.3 Diffuse pleural thickening (DPT)    
 
DPT refers to extensive fibrosis of the visceral pleura, forming frequent adhesions to the 
parietal pleura, leading to obliteration of the pleural space [34]. As mentioned above, it is 
thought to be the sequel of an exudative effusion (BAPE) and develops in approximately 7% 
of those with historical asbestos exposure [35, 36]. In most cases DPT is an incidental finding 
on radiological investigations performed for other reasons. Historic literature used plain chest 
radiographic (CXR) appearances for confirming the presence of DPT, due to ease of access to 
CXR at the time. The international labour organisation (ILO) still relies on the CXR appearances 
for classifying pleural thickening as ‘diffuse’ [37] not taking into account the current gold 
standard imaging modality for assessing the pleura – computed tomography (CT) [38].  
The ‘American Thoracic Society (ATS ) guidelines on diagnosis and initial management of non-
malignant diseases related to asbestos’  use the definition set out by the International Labour 
Organisation (ILO) for diagnosing DPT; obliteration of the costophrenic angle (CPA) by pleural 
thickening on a postero-anterior chest radiograph [29]. There is still no consensus on a unified 
definition for DPT. Many authorities cite the definition of DPT on CT proposed by Lynch et al. 
based on size criteria; continuous thickening of the pleura measuring ≥5 cm wide, ≥8 cm long 
craniocaudally and 3 mm in thickness, with or without CPA involvement [39]. Regardless of 
the radiological definition, the important clinical implication of DPT is the significant 
respiratory disability [34, 40-42]. When DPT is related to asbestos exposure, it is currently 
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recognized as a compensatable disease under the Industrial Injuries Disablement Benefit 
(IIDB) scheme in the United Kingdom (UK) [43].           
1.5  Malignant Pleural Mesothelioma  
 
Malignant primary tumours of the pleura as an entity was somewhat controversial in the early 
20th century when some pathologists denied their existence [44]. Scattered case reports of a 
primary malignant tumour of the pleura, ‘mesothelioma’, started surfacing towards the mid-
20th century coinciding with the increasing use of asbestos [45, 46].  Not until 1960 when 
Wagner et al published a landmark study, explicitly describing the association between 
asbestos exposure and mesothelioma in a cohort of workers from the north west Cape of 
South Africa, did mesothelioma earn its reputation as a malignancy attributable to asbestos 
[6]. They described 33 cases of primary pleural tumours in patients with a definite asbestos 
history and characteristic pathological findings. They also reported the possibility of a 
prolonged lag period between 20 to 40 years or more, from exposure to development of 
mesothelioma, as observed in some of their cases [6]. Another observation at the time was 
those working predominantly with amphibole type asbestos had a much higher risk than 
those working with mixed asbestos or chrysotile alone.  
Shortly after this publication, there was an increased interest around controlling inhaled 
asbestos exposure. The 1969 asbestos regulations came into force on the 14th of May 1970, 
which imposed stringent requirements around limiting asbestos inhalation in any industries 
that used asbestos in the UK [47]. In 1985 the import of crocidolite and amosite asbestos was 
banned in the UK [48]. Since then, several asbestos control regulations have come into effect 
and have been updated regularly [49]. Due to the long latency period the incidence of 
malignant pleural mesothelioma (MPM) is still on the rise and is expected to hit a peak in 2025 
[50]. The reasons behind the prolonged latency period is still not completely understood.  
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MPM is an aggressive and universally fatal tumour, the incidence of which is still considerable 
in many parts of the world [51, 52]. In the UK it currently accounts for 1% of malignant disease, 
with a majority developing mesothelioma as a result of previous asbestos exposure [53]. At 
its early stages MPM is believed to follow an indolent course therefore, patients may not 
present with symptoms until their disease is advanced [54]. Common symptoms at 
presentation are non-specific such as chest pain, shortness of breath (in the presence of a 
pleural effusions), fatigue and weight loss [55]. Asbestos exposure and the presence of above 
symptoms warrant urgent further investigation.     
There are 3 main histological sub-types in mesothelioma - epithelioid, sarcomatoid and 
biphasic - with further sub-classification within groups as shown in Table 1-2 [56]. As the 
histological subtype can provide prognostic information - sarcomatoid MPM has a much 
worse survival than epithelioid - histological subtyping at the time of diagnosis is essential 
[57, 58].  
 
















Conventional, spindle cell 
Desmoplastic 





Table 1-2: Histological sub-types and patterns of mesothelioma 
 
 
1.5.1 Investigation and diagnosis 
1.5.1.1 CT 
 
Although simple and easily accessible, chest radiographs (CXR) are neither sensitive nor 
specific at diagnosing MPM. Early CT is recommended for detailed examination of the pleura 
[29]. Specific radiological criteria such as pleural nodularity, pleural thickening measuring > 
10mm and thickening extending over the mediastinum on CT, can aid in the distinction 
between benign and malignant pleural thickening [59, 60]. In its early stages when pleural 
thickening is subtle, or in the absence of above features, the sensitivity of CT for diagnosing 
MPM is low [61, 62]. On morphological criteria alone, the sensitivity and specificity for 
detection of MPM is 72% and 83%, respectively [59]. Novel methods of analysing CT such as 
volumetric CT are currently being investigated [63].   
1.5.1.2 Magnetic Resonance Imaging (MRI) 
 
MRI is a safe, readily accessible radiation free imaging modality. Its superiority at delineating 
soft tissue, and spatial resolution makes MRI an attractive radiological investigation, but its 
role in pleural malignancy is yet to be fully defined. Historically movement from respiratory 
motion and cardiac impulses created significant artefact when analysing MRI images, but with 
modern breath holding techniques, respiratory and navigator gating this issue is largely 
overcome [64]. Different image acquisition methods providing qualitative and quantitative 
analyses can all help in obtaining a range of data that can be potentially useful in assessing 
the pleura.    
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Diffusion weighted imaging (DWI) MRI is one such technique that relies upon the random 
(‘Brownian’) motion of water molecules within a voxel (a region of tissue that corresponds to 
a pixel on an image), with the switching of the magnetic field [65]. The associated signal loss 
resulting from the restricted motion of water molecules can be quantified using the apparent 
diffusion coefficient (ADC), which in turn provides information regarding cellularity of 
neighbouring tissue [66]. In the last two decades a number of small studies have tried to 
evaluate the role of DWI-MRI in patients with established pleural malignancy [67, 68], yet its 
role in the diagnostic pathway of MPM is yet to be fully defined.  
In dynamic contrast enhanced (DCE) MRI, sequential images are acquired during 
administration of a gadolinium-based contrast agent [69]. The uptake and washout of the 
contrast by tissue gives information about the micro vascularity and permeability of the 
tissue, which in turn can be mapped to provide information regarding the benign/malignant 
nature of the tissue under consideration [69, 70]. The persistent gradual uptake of contrast is 
suggestive of benign tissue, whilst the rapid uptake and washout type is suggestive of 
malignant tissue, reflecting the increased vascularity of malignant tissue. The plateau type 
represents an intermediate type [71].   
A recent small study using visual assessment of the DWI scans suggested a technique called 
pleural pointillism may be useful in the setting of early pleural malignancy [72]. This technique 
involves assessing the pleura on b-0 and b-1000 DWI images. Multiple hyperintense areas 
seen on b-1000 images are suggestive of pleural pointillism. This technique to date has only 
been described in one study and further evidence is needed to clarify its role.    
Early studies using MRI in pleural malignancy have demonstrated promising results, but these 
studies have not been easily reproducible, with low patient numbers, often retrospective with 
no adequate control populations [65, 67].  
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1.5.1.3 18Fluorodeoxyglucose – Positron emission tomography (FDG-PET)  
 
Metabolically active cells such as malignant cells, foci of infection and acute inflammatory 
cells have a high affinity for glucose. PET scanning exploits this affinity of glucose to 
metabolically active areas.  A radio-labelled 18-fluorodeoxyglucose (FDG) is administered 
intravenously and the PET scan is performed after a short period of sedentary waiting (usually 
60 minutes) when the FDG can be detected on the PET scan highlighting areas of possible 
neoplastic tissue or infected/inflammatory tissue [73]. This imaging modality is increasingly 
used in other cancers to inform management. From a diagnostic perspective in MPM, a 
number of small studies have consistently shown that integrated PET-CT does perform well 
with accuracy levels for diagnosis consistently approaching 90% for radiological diagnosis [74, 
75]. A systematic review of 16 studies of 745 patients by Treglia et al., found a pooled 
sensitivity of 95% and specificity of 82% for FDG-PET in differentiating benign from malignant 
pleural lesions [76]. Despite the encouraging results PET-CT is currently not routinely used for 
diagnostic purposes in pleural malignancy.   
1.5.1.4 Staging of MPM 
 
MPM staging provides crucial information for the management of patients, particularly those 
being considered for surgery, and for prognostication. Although radiological staging is least 
invasive and often used, the gold standard for MPM staging is surgery, reflecting the origins 
of the surgically derived Tumour, Node, metastases (TNM) classification system currently 
used in MPM [77]. The recently updated staging system currently in its 8th edition is shown in 








Stage N0 N1 N2 
T1 IA II IIIB 
T2 IB II IIIB 
T3 IB IIIA IIIB 
T4 IIIB IIIB IIIB 
M1 IV IV IV 




1.5.1.5   Pleural fluid cytology for diagnosis of MPM 
 
Data from the Bristol Academic Respiratory UNIT (ARU) confirm over 80% of MPM patients 
have a pleural effusion at presentation, 40% of these are large (manuscript under review for 
publication). Other studies have quoted higher incidence of effusion at presentation, 91% in 
a study by Tanrikulu et al [79]. Pleural fluid cytology analysis is a minimally invasive option for 
pathological confirmation of malignancy, with reported sensitivities between 50-60% in all 
malignant pleural effusions [80-82]. Yet the diagnostic sensitivity for MPM with cytology 
alone remains low, 20% to 32% quoted in some studies [80, 83]. Therefore, most patients 
would require a pleural biopsy for confirmation of disease.       
1.5.1.6 Pleural biopsy 
 
For patients presenting with a pleural effusion the first choice of biopsy is usually local 
anaesthetic thoracoscopy (LAT), as this could be a diagnostic and therapeutic procedure in 
one sitting (Figure 1- 3), performed under conscious sedation. Once the effusion is drained 
and biopsies obtained, patients will be pleurodesed (artificial obliteration of the pleural space 
by adhesion of the visceral and parietal pleurae) to prevent recurrence of effusion [80]. For 
pleural malignancy LAT has a high diagnostic yield with sensitivities over 90% [80]. Pleural 
biopsy with video assisted thoracoscopic surgery (VATS) is the gold standard for diagnosing 
pleural malignancy with a diagnostic yield > 95% [84]. However, due to associated 
complications and invasiveness, VATS biopsy is usually only considered when other less 
invasiveness options have failed to give a definitive diagnosis.       
In the absence of a pleural effusion most patients would have a percutaneous biopsy under 
image guidance. CT guided cutting needle biopsy is proven to be the most efficient biopsy 
technique for obtaining a pleural biopsy in this setting [85].  However, the yield is variable as 
only one small area of the pleural thickening is biopsied, leading to occasional false negative 
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results [86].  MPM is a heterogenous tumour where areas within the tumour may lack the 
level of cell differentiation or invasion required to distinguish benign from malignant 
mesothelial cell proliferation [56, 87]. Specific immunohistochemical markers   commonly 
employed for differentiating MPM from other cancers (particularly lung cancer variants) such 
as Calretinin, Wilms Tumour 1 (WT-1) and Cytokeratin 5/6 are often dependant on the 
histological sub-type of MPM and the other differential cancers under consideration [56]. 
Breast cancer associated protein 1 (BAP-1) is a tumour suppressor gene, mutations of which 
is associated with hereditary cancer syndromes [88]. Recent literature suggests the absence 
of this gene increases the risk of MPM [88, 89]. Loss of BAP-1 can be tested 
immunohistochemically and can be useful as an adjunct in the diagnosis of MPM [90]. A meta-
analysis by Wang et al. with 12 studies and 1824 patients demonstrated a pooled sensitivity 
of 56% and specificity of 100% for the loss of BAP-1, in diagnosing MPM [91]. Currently, some 
centres have access to and regularly use this test in the diagnostic pathway. Similar to BAP-1, 
the loss of p16 gene detected by Fluorescence in situ hybridization (P16 FISH) could help in 
the diagnosis of sarcomatoid mesothelioma, but larger studies are needed in this area before 





Figure 1-3: Diffusely abnormal parietal pleura as seen at thoracoscopy. Image A shows diffuse pleural nodularity (P) with 
partially collapsed lung (L). Image B shows widespread pleural irregularity (P) with an infiltrated appearance to the parietal 












1.5.1.7 Mesothelin for diagnosis  
 
Biomarkers are a non-invasive, reliable and efficient way of diagnosing and monitoring 
disease, and response to treatment. Biomarkers such as soluble mesothelin related peptide 
(SMRP) or mesothelin, Fibulin-3, megakaryocyte protein (MPF) and Osteopontin have all been 
evaluated for their role in the diagnosis, monitoring and screening of MPM [93, 94]. 
Mesothelin is a 40kDa membrane bound glycoprotein expressed by mesothelial cells that is 
detected in both serum and pleural fluid [95]. Tumours with epithelioid histological 
characteristics express mesothelin more readily compared to non-epithelioid sub-types and 
the level of serum mesothelin correlates to tumour bulk [96]. A review by Cui et al, of 28 
publications including 7550 patients found a pooled sensitivity of 61% and specificity of 87% 
for serum mesothelin for diagnosis of MPM [97]. The same study reviewed performance 
indicators for pleural fluid mesothelin and found a pooled sensitivity of 75% and specificity of 
85%, for diagnosing MPM. Given the lack of prospective validation, mesothelin is currently 
not used in isolation for the diagnosis of MPM. However, in the correct clinical and 
radiological context, it can however, support a diagnosis of MPM. 
1.5.2 Management of mesothelioma 
1.5.2.1 Surgery 
 
Surgery for mesothelioma has been a controversial subject for decades. The role of curative 
surgery as a life prolonging treatment in MPM is yet to be established [98]. One of the earliest 
and widespread surgeries to be performed in MPM, extra-pleural pneumonectomy (EPP) 
involved en-bloc resection of the lung, ipsilateral parietal pleura, pericardium and 
hemidiaphragm [99, 100]. Due to high mortality and post-op complications the 
appropriateness of this surgery in MPM has been questioned repeatedly [101]. The 
mesothelioma and radical surgery (MARS) feasibility trial attempted to answer this question 
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by randomising patients to EPP versus no EPP [102]. In this feasibility study the no-EPP group 
did better with a median survival of 19.5 months compared to those who had EPP, 14.4 
months. The feasibility trial did not progress to a full phase III trial due to concerns around 
safety of EPP. Despite compelling data from the MARS 1 study and a number of large surgical 
case series showing the detrimental effects of EPP, it continues to be performed in some 
centres in Europe, United States of America and Canada [98, 103-105]. Even more 
surprisingly, the recently published American Society of Clinical Oncology guidelines on 
treatment of mesothelioma made a strong recommendation that in select patients with early 
stage disease a maximal surgical cytoreduction (ie. EPP) should be performed [106]. On the 
contrary, the British Thoracic Society mesothelioma guideline on the investigation and 
management of MPM adopts a more conservative stance, recommending surgery only in a 
clinical trial setting [107]. To answer the important question regarding the role of surgery for 
extending survival, researchers in the UK are currently conducting the MARS-2 trial 
(NCT02040272) recruiting patients to surgery or no surgery (alongside chemotherapy) to 
assess if a less aggressive yet potentially  equally effective form of surgery such as 
pleurectomy/decortication (PD) or extended pleurectomy/decortication (EPD) would prolong 
survival.       
Apart from surgical cytoreduction to prolong survival, surgery is also performed for pleural 
fluid management. For patients with symptomatic pleural effusions, pleurodesis with talc 
slurry/poudrage was shown to be a better option over surgery with VATS partial pleurectomy, 
by the recently concluded MESO-VATS trial [108]. Another pilot and feasibility RCT 
(NCT03412357) is currently recruiting MPM patients with trapped lung, to indwelling pleural 
catheter (IPC) versus video assisted thoracoscopic surgery – pleurectomy/decortication 
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(VATS-P/D) to inform a full phase III study in the future which may shed light on whether there 
is any role for surgery in the trapped lung setting.     
1.5.2.2 Chemotherapy 
 
The current standard first line chemotherapy is with the combination of pemetrexed and cisplatin 
following the findings of a landmark study by Vogelzang et al., showing this combination conferred a 
3-month additional survival benefit compared to Cisplatin alone [109]. However, only about 40% of 
patients responded to this treatment and as mentioned, the survival benefit was only 3 months. The 
addition of an anti-angiogenic agent such as Bevacizumab is shown to extend survival by a further 2 
months, at the expense of significant side effects and toxicity [110]. Bevacizumab is currently not 
licensed in the UK and a search for other first line treatments in isolation or in combination with 
chemotherapy, continues. A range of phase I-III trials investigating cytotoxic chemotherapy 
treatments, anti-angiogenics and immunotherapy are currently underway both as first line, second 
line, combination and maintenance therapy [111].  
1.5.2.3 Zoledronic acid  
 
Zoledronic acid (ZA) is a nitrogen containing bisphosphonate which inhibits angiogenesis and 
apoptosis in certain cancers [112]. In vitro and animal studies have suggested a potential role for ZA 
in MPM [113, 114]. One human study investigating the effects of ZA in advanced MPM failed to show 
a significant advantage on disease control using ZA alone [115]. However, a synergistic role with 
existing chemotherapy treatment has not been examined.     
1.5.3 Monitoring treatment response in MPM 
1.5.3.1 CT 
 
Given the low response rate to conventional treatment, and uncertainty around the efficacy of newer 
therapies, the ability to accurately monitor disease is essential for oncologists and trialists. The current 
standard for monitoring is, as for many tumours, serial CT scans. However, unlike many tumours, MPM 
does not grow spherically, instead growing as a ‘rind’ encasing the thoracic cavity, making sequential 
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comparisons more difficult. An adaptation of the Response Evaluation Criteria in Solid Tumours 
(RECIST), used for comparison of CTs in other cancers, to the modified RECIST (mRECIST) criteria has 
only partially allowed for this unique morphology [116]. Other issues including low sensitivity to 
predict progression, subjectivity in radiologists’ choice of measurement sites and complications from 
the presence of pleural plaques or fluid, mean research into a more robust and reproducible 
radiological marker is ongoing [117]. In the absence of a better radiological or biomarker CT continues 
to be used for monitoring mesothelioma. 
Response assessment by mRECIST involves identifying 2 target pleural lesions that are more than 1 cm 
in thickness perpendicular to the chest wall, that can be measured at three different levels of the hemi 
thorax. The sum of the 6 measurements gives a univariate diameter which can be compared with 
subsequent CTs and scores to assess response or progression. Table 1-5 summarises mRECIST 
definitions and response criteria [118].   
 
mRECIST  Definitions  
Target lesions Tumour thickness measured in 2 sites at 3 different levels on 
transverse cuts of CT scan + up to 2 lymph nodes if short axis 
diameter measures ≥ 1.5cm 
Complete response (CR)  Disappearance of all target lesions with no evidence of 
tumour elsewhere 
Partial response (PR) At least a 30% reduction in the total tumour measurement  
Stable disease (SD) Those who don’t fulfill criteria for PR or PD  
Progressive disease (PD) At least a 20% increase in total tumour measurement 
Table 1-5: mRECIST definitions and response criteria 
 
1.5.3.2 Integrated PET-CT  
 
Studies have shown that serial FDG-PET scanning can be used to predict response [119] but is 
significantly limited by false positive uptake in inflamed tissue from surgical intervention or 
pleurodesis, as well as restricted availability and expense [120]. An adaptation of the mRECIST criteria, 
PERCIST (PET response criteria in solid tumours) allows quantitative comparisons of PET characteristics 
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such as maximum standard uptake value (SUVmax), mean SUV and total glycolytic volume (TGV) which 
assesses the metabolic activity of the whole tumour, on sequential scans [121]. Early studies using 
PET-CT to determine disease response or progression have all been promising [122-124] and this 
imaging modality is often used in clinical trial settings to assess treatment response.  
The optimal timing of when the PET-CT scan should be performed in the treatment cycle is unclear 
with some studies suggesting performing the scan after the first cycle, but after 10 days from 
treatment for best results [121, 122].      
1.5.3.3 Mesothelin 
 
In certain cancers such as prostate and colorectal, biomarkers have a role in monitoring 
treatment response and recurrence. A potential role as such for mesothelin was shown by 
Wheatley-Price and colleagues, in a small cohort of patients with MPM who had surgical 
cytoreductive surgery [125]. The elevated pre-surgery levels normalised after debulking, 
further strengthening the association between Mesothelin levels correlating to tumour bulk 
[125].  Another study by Grigoriu et al., with 40 patients who had treatment for MPM with 
best supportive care (BSC), palliative chemotherapy or an intrapleural adenovirus vector as a 
part of a Phase I trial, also demonstrated a falling level of Mesothelin correlated to CT and 
PET-CT findings and overall survival [126].   
A serum or pleural fluid biomarker that could reflect disease activity is an attractive option for MPM 
given the challenges with radiological assessment. The most investigated biomarker as such in MPM 
is mesothelin [127]. Mesothelin is found in the blood and pleural fluid of patients with MPM and levels 
correlate with tumour stage and bulk [96]. It lacks the sensitivity to be used as a diagnostic marker 
given reduced expression in non-epithelioid MPM. A systematic review we performed found 8 studies 
that had assessed serum mesothelin’s ability to monitor disease during chemotherapy, and found it 
correlated with radiological markers and survival [128]. No studies have assessed the utility of 






1.6 Research questions and thesis overview 
As discussed in this chapter there are clinical uncertainties surrounding the diagnosis and 
management of asbestos related pleural disease. This doctoral thesis attempts to explore 
the following clinically relevant questions: 
 
• What is the association between different distributions of diffuse pleural thickening 
on CT and respiratory impairment?     
• What is the role of DWI and DCE-MRI in the assessment of equivocal pleural 
thickening on CT? 
• Is a PET-CT targeted pleural biopsy better at diagnosing pleural malignancy than a 
standard CT guided pleural biopsy, in patients with suspected pleural malignancy 
who have already had one non-diagnostic biopsy? 
• Is it feasible to randomise 50 patients across 3 centres in a 13-month period to have 
zoledronic acid alongside standard first line chemotherapy for mesothelioma?  
• Is there a role for serial mesothelin in the monitoring of patients with mesothelioma, 






CHAPTER 2       THE PHYSIOLOGICAL CONSEQUENCES OF 
DIFFERENT DISTRIBUTIONS OF DIFFUSE PLEURAL THICKENING 
ON CT IMAGING. 
 
2.1 Background  
 
There is still no universally accepted radiological definition for diffuse pleural thickening (DPT). The 
International Labour Organization (ILO) [37] base their definition of DPT on chest radiographic (CXR) 
appearances, requiring obliteration of the costophrenic angle (CPA) to be present, not taking into 
consideration the extent of the thickening on CT, which is the current gold standard radiological 
investigation for imaging the pleura. We hypothesise that the radiographical changes on a postero-
anterior (PA) chest X ray are insufficient to appreciate the full extent of DPT.  
The aim of this study was to evaluate the impact of DPT defined by CT and correlate its distribution, 
specifically involvement of the costophrenic angle, with chest radiographic findings and 
contemporaneous lung function testing.   
2.2 Methods 
 
Patients with suspected pleural thickening who attended pleural clinic at North Bristol NHS Trust 
between 09/2011 and 10/2016 were screened for the study. Patients who were classed as DPT 
according to size criteria (>3mm thick, >5 cm axial width and >8cm craniocaudal length) [39] on CT 
and had contemporaneous CXR and lung function were included in the study. The study was approved 
by the Southwest Research Ethics Committee (Ref: 08/H0102/11).  
Data collected included patient demographics, previous asbestos exposure history including duration 
and level of exposure, smoking history and other comorbidities. Patients with breathlessness had their 
degree of breathlessness documented against the Medical Research Council (MRC) dyspnoea score, 
where a score of 1 = not troubled by breathlessness except on strenuous exercise, 2= short of breath 
when hurrying on a level or when walking up a slight hill, 3 = walks slower than most people on the 
level, stops after a mile or so, or stops after 15 minutes walking at own pace, 4 = stops for breath after 
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walking 100 yards or after a few minutes on level ground, 5 = too breathless to leave the house or 
breathless when dressing/undressing [129].  
2.2.1 CT scans 
 
The CT scans were performed for clinical reasons using a range of multi-slice detector CT scanners (GE 
HD750 Freedom edition, GE Optima – General Electric, Boston, USA; Toshiba Aquilion CX – Toshiba, 
Tokyo, Japan; Philips Ingenuity – Phillips, Eindehoven, Netherlands). Standard departmental protocols 
were used with volumetric datasets acquired with or without contrast as indicated clinically. All 
datasets were available with orthogonal isotropic reconstructions at 1-1.25mm collimation using soft-
tissue and lung algorithms. 
2.2.2 Lung function tests 
 
All patients included in the study had full lung function tests, which included spirometry, lung volumes 
(by helium dilution and body plethysmography) and gas transfer (single-breath carbon monoxide 
diffusing capacity). All patients had their height and weight recorded at the time of their lung function 
test.  Lung function tests within 12 months of the CT scan were used for analysis. Lung function testing 
was performed using NSpire UK (www.nspirehealth.com) body plethysmograph and HD2000 fast gas 
analyser. Lung Function indices were expressed as a percentage of predicted and standardised 
residual (SR) values.  Predicted values were European Reference values.  
2.2.3 Control group 
 
The control group comprised of patients with discrete pleural plaques only. Patients in this group were 
matched for age, body mass index (BMI) and smoking status, to the diffuse pleural thickening group. 
2.2.4 Radiology review 
 
Two experienced chest radiologists (with a collective experience of 34 years) independently reviewed 
all CT scans and chest radiography.  CT images were reviewed with orthogonal reformatted data and 
electronic callipers on a soft tissue algorithm using standard mediastinal window settings (40/400).   
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Diffuse pleural thickening was assessed according to Lynch’s size criteria whereby to qualify as DPT 
the thickening needed to be more than 3mm in thickness, 5 cm in width on axial CT slices and 8cm in 
length cranio-caudally [39]. In addition, to the size criteria, diffuse pleural thickening was 
characterised morphologically by its tapered margins and ancillary signs of visceral pleural fibrosis, 
namely the presence of adjacent folded lung or pleuroparenchymal bands [130, 131].  These additional 
CT criteria were applied in order to exclude patients with large areas of confluent discrete plaques.   
The plain chest radiographs were assessed for costophrenic angle obliteration and when present 
classified as unilateral (side specified) or bilateral.  
2.2.5 Statistical analysis 
 
Statistical analyses were carried out using the Stata statistical package, version 14.2 (Stata Corp, Texas 
USA). Patient demographics such as age, BMI, smoking history were expressed as means with standard 
deviations for each DPT group against the control group. Inter-observer agreement when assessing 
chest radiographs and CT imaging was assessed using a weighted kappa coefficient. A p value < 0.05 
was considered statistically significant unless otherwise specified in the text. Distribution for normality 







Eighty-five patients who were seen at the pleural clinic with suspected pleural thickening and or 
pleural plaques on their chest radiographs between 09/2011 and 10/2016 were included in the initial 
screening.  Patients were excluded if they had significant pleural effusions at the time of the CT (n=16); 
co-existent interstitial pulmonary fibrosis (n=5); or a subsequent diagnosis of pleural malignancy (n=6).   
Fifty-eight patients (37 with DPT and 21 with pleural plaques alone) were then evaluated, including 














Figure 2-1: Flow diagram of included patients 
 
The 37 patients who met diffuse pleural thickening by CT size criteria were classified into three 
separate groups; 
Group 1:  DPT by CT criteria with no CPA obliteration on chest radiograph, 
Number of patients screened for DPT 
or pleural plaques  
n= 85 
Reasons for exclusion (n = 27) 
-DPT and pleural effusion 16 
-DPT and pulmonary fibrosis 5 
-malignancy confirmed on initial 
investigations 6 
Number of patients with pleural 
plaques but no DPT 
n = 21 
Number of patients with DPT by CT 
size criteria 
n = 37 
DPT without CPA 
obliteration 
n = 10 
 
Unilateral DPT with 
CPA obliteration 
n = 15 
Bilateral DPT with CPA 
obliteration 
n = 12 
Control group 
 
n = 21 
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Group 2: DPT by CT criteria with unilateral CPA obliteration on the chest radiograph, 
Group 3: DPT by CT criteria with bilateral CPA obliteration on the chest radiograph. 
An example chest radiograph and CT of a patient with right sided DPT but no CPA obliteration and 
bilateral DPT are shown in Figure 2-2.  
Overall, there was good inter-observer agreement on radiological findings. There was moderate 
agreement for CPA obliteration on CXR with a weighted kappa value of 0.79 and good agreement for 
DPT by size criteria on CT, with a weighted kappa value of 0.82. Discrepancies were resolved by 





Figure 2-2:Images of DPT on chest radiograph and CT. Image A shows a postero-anterior chest radiograph of a 
patient with right sided DPT with no CPA obliteration. Image B is a sagittal CT view of the same patient showing 
DPT involving the posterior pleura. Image C is a patient with bilateral DPT and CPA obliteration. Image D is an 
axial image CT image confirming bilateral pleural thickening of same patient.  
 
A summary demographics table, including the control group (pleural plaques only) is shown in Table 
2-1. Fifty-six of the patients were male (97%), the mean age was 69.6 (CI: 67.3-71.9). The mean BMI 
was 29 (CI: 28-30) and the average pack year history was 22.9 (CI: 17.6-28.2).  There was no significant 




Demographic Control Group DPT with no CPA 
obliteration 
Unilateral DPT Bilateral DPT P value 
  n =21 n = 10 n = 15 n =12   
Age (years) (mean 95% CI) 69.4 (CI: 65.7-73.1) 69.5 (CI: 64.9-74.0) 70.2 (CI: 65.0-75.5)  69.0 (CI: 62.0-76.1) 0.99 
BMI (kg/m2)  (mean (95% CI) 28.2 (CI: 26.6-29.9) 30.5 (CI: 27.4-33.6) 28.7 (CI: 27.1-30.3) 29.4 (CI: 26.6-32.2) 0.45 
MRC grade (mean (95% CI) 3.5 (CI: 2.9-4.2) 3.9 (CI:2.8-5.0) 3.4 (CI: 3.5-4.3) 4.6 (CI: 3.6-5.6) 0.20 
Comorbidities (n (%))           
  -COPD 4/21 (19%) 2/10 (20%) 3/15 (20%) 3/12 (25%) 
  -CABG 1/21 (5%) 1/10 (10%) 4/15 (27%) 2/12 (17%) 
  -Other 3/21 (14%) 0 3/15 (20%) 1/12 (8%) 
  -nil 13/21 (62%) 8/10 (80%) 5/15 (33%) 6/12 (50%) 
Smoking history (pyrs) (mean 
(95% CI) 
20.5 (CI: 9.8-31.2) 24.2 (CI: 11.7-36.7) 22.4 (CI: 12.6-32.2) 27.0 (CI: 13.9-40.0) 0.85 
  -Current smoker (n (%)) 2/21 (9%) 1/10 (10%) 2/14 (14%) 4/11 (36%)   
  -Ex-smoker (n (%)) 13/21 (62%) 8/10 (80%) 10/14 (72%) 5/11 (46%) 
  -Never smoker (n (%)) 6/21 (29%) 1/10 (10%) 2/14 (14%) 2/11 (18%) 
  Table 2-1: Baseline characteristics by patient group (BMI – body mass index; MRC - Medical research council; COPD – chronic obstructive pulmonary disease; CABG – 
coronary artery bypass graft; DPT – diffuse pleural thickening; pyrs – pack years) P values obtained by comparing the DPT groups against the control group.    
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Most patients (53/58) had clear documentation of the predominant occupation that exposed them to 
asbestos (Table 2-2). The largest proportions exposed were in construction work (12.1%), civil 
engineering (8.6%) or heating and insulation engineering (8.6%). The miscellaneous group 15/58 
(25.9%), included factory workers, a dockworker, ship plater and a chemistry teacher. 
Occupation n Percentage (%) 
Construction worker 7 12.1 
Civil engineer 5 8.6 
Heating and Insulation engineer 5 8.6 
Electrician 2 3.5 
General labourer 2 3.5 
Mechanical Engineer 2 3.5 
Naval engineer 2 3.5 
Painter/decorator 3 5.1 
Para-exposure 3 5.1 
Plumber 3 5.1 
Miscellaneous 15 25.9 
No known asbestos exposure  4 6.9 
Not documented 5 8.6 
Total 58 100% 
 
Table 2-2: Occupation of exposure 
Predominant occupation where exposure occurred listed by frequency 
 
 
Seven (18.9%) patients in the DPT cohort had no pleural plaques on CT. Of these seven patients, 2 
patients have had a previous coronary artery bypass graft and 1 patient had a history of an eosinophilic 
pleural effusion, which was documented as the cause of their pleural thickening. The other 4 patients 
had no pertinent past history such as causative drugs or previous pneumonic illnesses to explain their 
pleural thickening. These 4 patients’ occupations were construction work, kitchen fitting, electrical 
wholesale and labourer (involved in cleaning pipes lagged with asbestos).  
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Lung function parameters with their means and standard deviations (SD) are shown in Table 2-3. The 
mean percentage predicted forced vital capacity (FVC%) was lower in patients with DPT and no CPA 
obliteration compared to control group; 83.5% vs 98.9%, respectively (p=0.045). The predicted FVC% 
were significantly lower in the unilateral and bilateral groups when compared to the control group; 
79.5% (p<0.001) and 66.7% (p<0.001) respectively (Figure 4).  
Similar differences were observed in the percentage predicted values for total lung capacity (TLC), 
between the control group 91.1%, and those with diffuse pleural thickening without CPA obliteration 
77.2% (p < 0.01) and the bilateral DPT group 66.7% (p<0.001) respectively. However, this relationship 
was lost between the control group and the unilateral DPT group.  
A scatter plot of the individual FVC and TLC percentages predicted are shown in Figures 2-3 and 2-4.   





Table 2-3: Lung function parameters by DPT group 
Mean and standard deviations shown for each parameter. FEV1- forced expiratory volume in 1 second; FVC - forced vital capacity; TLC – total lung capacity; TLCo – gas 
transfer; KCO–diffusion coefficient. * statistically significant when compared to the control group.
Parameter Control group 
n = 21 
DPT but no CPA 
involvement  
n = 10 
Unilateral DPT  
n = 15 
Bilateral DPT 
n = 12 
FEV1 (L) (mean ± SD) 2.5 ± 0.6 2.1 ± 0.5* 1.9 ± 0.5 * 1.7 ± 0.4* 
FEV1 % predicted (mean ± SD)  86.9 ± 19.3 72.0 ± 15.7* 65.7 ± 17.7* 57.7 ± 10.0* 
FVC (L) (mean ± SD) 3.8 ± 0.7 3.0 ± 0.9* 3.0 ± 0.6* 2.5 ± 0.8* 
FVC % predicted (mean ± SD) 98.9 ± 15.2 83.5 ± 25.9* 79.5 ± 13.0* 66.7 ± 15.6* 
FEV1/FVC ratio (mean ± SD) 68.1 ± 13.1 69.9 ± 13.9 63.9 ± 14.0 64.9 ± 11.8 
TLC (L) (mean ± SD) 6.2 ± 0.8 5.0 ± 0.9* 5.4 ± 1.3* 4.4 ± 0.6* 
TLC % predicted (mean ± SD)  91.1 ± 9.4 77.2 ± 16.4* 82.4 ± 20.8 66.6 ± 8.6* 
TLCo % predicted (mean ± SD) 80.1 ± 23.3 62.8 ± 15.2* 69.5 ± 17.5 61.4 ± 11.9* 
KCO % predicted (mean ± SD) 92.9 ± 24.9 96 ± 17.2 102.5 ± 22.4 104.8 ± 22.0 




Figure 2-3: Trend of percentage predicted FVC, by group. Individual FVCs as a percentage of their best 
predicted value is plotted for patients in each group. The line of best fit shows a downward trend from control 
group to bilateral DPT. (FVC – forced vital capacity; DPT – diffuse pleural thickening; CPA – costo-phrenic angle)    
 
Figure 2-4: Trend of percentage predicted TLC, by group. Individual TLC as a percentage of predicted value for 
individual patients in each group. Line of best fit shows a downward trend from control group to bilateral DPT 





Figure 2-5: Mean FVC percentage predicted with confidence intervals (denoted by upper lower horizontal 
lines) and trend of FVC percentage predicted. p values show level of significance when FVC for each group is 
compared with the control group. (FVC- forced vital capacity; DPT – diffuse pleural thickening; CPA – costo-







Figure 2-6: Mean TLC percentage predicted with confidence intervals (denoted by upper lower horizontal 
lines) and trend of TLC percentage predicted. p values show level of significance for TLC against for each 
group compared to the control group. (TLC- total lung capacity; DPT – diffuse pleural thickening; CPA – costo-






2.4  Discussion 
 
To date, this study is the first to examine the physiological impact of varied distributions of DPT using 
CT criteria, particularly including a large number of patients in whom there is diffuse pleural thickening 
without chest radiographic obliteration of the costophrenic angle.  Our data highlights the incremental 
deficit in lung function between bilateral, unilateral and DPT without radiographic obliteration of the 
CPA, compared to a control group with asbestos-related pleural plaques only.  We demonstrate a 
33.2% reduction in the FVC percentage predicted between the control group and those in the bilateral 
DPT group.  
A number of previous studies have investigated the respiratory impairment caused by DPT [34, 41, 
132-137].  However, the reliance on a chest radiograph to make the initial diagnosis has prevented 
analysis of individuals in whom there is DPT without obliteration of the CPA.  For instance, Singh et al. 
predicate their hypothesis that diffuse pleural thickening impacts upon lung function by involvement 
of the diaphragm based on a study of only seven patients all of whom had CPA obliteration [136].  
More recently, a study by Ameille et al, designed to evaluate the impact of size-based criteria for DPT 
vs involvement of the costophrenic recess (n=287) identified the poor correlation of size criteria on 
chest radiography with lung function [131].  However, assessment of true extent using chest 
radiography alone is very problematic and only allows for accurate cranio-caudal extent of laterally 
sited pleural thickening.  In this study, the authors acknowledge the superiority of CT over chest 
radiographs but aimed to provide data applicable to the current guidelines, which favour radiographs 
[11]. The relative merits of CT based size criteria over chest radiograph measurements is supported in 
a study by Fujimoto et al, [134] in which they found that size criteria using CT were predictive of 
respiratory deficit.  Finally, a CT based study by Copley et al. [41],  demonstrated that pulmonary 
function deficits are proportional to extent of diffuse pleural thickening (defined in their cohort only 
as pleural thickening with a tapering margin) 5 out of 50 patients had DPT without obliteration of the 
CPA.  A further shortcoming of the chest radiograph to diagnose DPT is the inability to discriminate 
between other pathologies that may mimic DPT. In our study, we excluded 16 patients with pleural 
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effusions; six of these patients had small effusions that could have easily been interpreted as pleural 
thickening on the chest radiograph in the absence of contemporaneous CT imaging.  
It is unclear how the arbitrary size based CT definition proposed by Lynch et al. was reached [39], 
however it remains widely cited in leading reviews and texts [138].  In our study, we have refined the 
definition in order to exclude patients with confluent pleural plaques in two ways: first, the 
morphology of pleural thickening was assessed. Tapered margins are a feature of diffuse pleural 
thickening compared to the shouldered margins of pleural plaques [41].  Second, the presence of 
folded lung or pleuroparenchymal bands was assessed confirming that there was fibrosis of the 
visceral pleura rather than thickening of the parietal pleura alone [139].  
The mechanism of breathlessness in DPT remains controversial. The reduction in the lung function 
vital capacity has been attributed to the reduced expansion of the lower thoracic rib cage and reduced 
axial height of the rib cage. [136] If the extent of the pleural thickening is significant, this in itself can 
cause restriction in the movement of the chest wall, a ‘lung en cuirasse’ effect, despite the lack of 
extension over the diaphragm [140]. In our study, we clearly demonstrate a significant difference in 
the predicted FVC and the TLC in those with DPT but no CPA obliteration (Figures 2-5 and 2-6) when 
compared to a matched control group who have evidence of previous asbestos exposure – pleural 
plaques, but no other underlying pleuro-parenchymal pathology. The trend of the lung function 
demonstrates that patients with DPT, but no CPA obliteration sits between the control group and the 
unilateral DPT group.  
The current definitions of DPT based on chest radiography have been a pragmatic choice reflecting 
world-wide availability of a low-radiation, cost-effective technique.  They also reflect the high level of 
inter-observer agreement in defining obliteration of the CPA as opposed to size criteria on chest 
radiography [40, 131]. However, CT is now acknowledged as the gold standard for imaging the pleura. 
The Industrial Injuries Disablement Benefit scheme currently uses the ILO’s classification of 
pneumoconiosis criteria when assessing patients’ eligibility for compensation, which requires 
49 
 
‘obliteration of the CP angle’ [37]. This study highlights that there is a group of patients with DPT who 
do not meet the current definitions laid out by the ILO yet have significant respiratory impairment. 
Our study is not without limitations; firstly, although this is the largest published series of patients 
with diffuse pleural thickening on CT imaging, the numbers of subjects in each subgroup remains small. 
Secondly, although every effort was made to match the groups for age, body mass index and 
cumulative smoking history we were unable to adjust for the extent of emphysema present on CT 
imaging. We did however manage to exclude any patients with a co-existing pleural effusion or 
underlying pulmonary fibrosis.  
Particular care must be taken during the initial assessment of patients with new diffuse pleural 
thickening. Six patients (6/64, 9%) in our study who were referred as benign pleural thickening were 
discovered to have pleural malignancy after initial investigations (5 mesotheliomas and 1 metastatic 
breast cancer). Our standard operative procedure for DPT follow up is a minimum of two years with 
interval CT imaging at 6, 12 and 24 months. This allows us to assess any progression and exclude a 
developing underlying pleural malignancy. Some patients may require a confirmatory pleural biopsy 
to exclude underlying malignancy, particularly in the presence of concerning symptoms such as chest 
wall pain or weight loss at presentation, or in the presence of equivocal CT findings. 
The next chapter explores if an alternative imaging modality such as MRI could be helpful in directing 
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CHAPTER 3       ROLE OF MRI IN CHARACTERISING EQUIVOCAL 




Advanced pleural malignancy is well characterised on thoracic computed tomography (CT), but in early 
disease it may be difficult to detect and differentiate from benign pleural thickening. Usually patients 
under go biopsy or serial CT imaging for confirmation of malignancy. Magnetic resonance imaging 
(MRI) has been suggested as a problem-solving tool to aid imaging diagnosis of pleural malignancy and 
benefits from easy accessibility and low costs relative to PET-CT [141]. Leung et al. described the 
classical features of malignancy on CT as circumferential pleural thickening (PT), PT measuring more 
than 1 cm, nodular pleural thickening, and PT extending to the mediastinum [59]. However, in the 
early stages of pleural malignancy, these features can be subtle and similar to the benign PT that 
accompany diffuse pleural thickening [67].  
Different MRI techniques have been examined in studies assessing pleural thickening suspicious for 
pleural malignancy [65, 69, 142]. These techniques include diffusion weighted imaging (DWI) and 
derived apparent diffusion coefficient (ADC) values [142, 143], simple visual assessment of the pleura 
to identify multiple foci of restricted diffusion appearing as high signal areas on b=1000 images on 
DWI images - also known ‘pleural pointillism’ [72], and dynamic contrast enhanced (DCE) techniques 
investigating contrast uptake and wash out patterns to provide information regarding tissue 
vasculature and likelihood of malignancy [69, 144]. None of these MRI techniques are currently in 
routine use in the diagnostic pathway of MPM.  Often in early pleural malignancy, the radiological 
features described by Leung et al. may be subtle if present, warranting further investigation, 
frequently with pleural biopsy. The potential added value of MRI lies in cases where CT features are 
not diagnostic. Previous studies investigating the role of MRI in pleural disease have investigated 
patients with established pleural malignancy, where the diagnosis is fairly evident on CT [66, 69].   
This pilot study aims to investigate the role of MRI using the techniques mentioned above to 
differentiate between benign and malignant pleural thickening in those with equivocal CT features 
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where there is a suspicion of pleural pathology, but not overtly malignant on the basis of the CT alone. 
In addition, the study explores different MRI assessment techniques to determine which technique 
would be most accurate at discriminating benign from malignant pleural thickening.  
3.2 Methods: 
 
We designed and conducted a prospective single centre pilot study of pleural MRI in patients with 
pleural thickening on CT. Patients were recruited from the North Bristol NHS Trust pleural clinic 
between April 2016 and December 2017. All patients were discussed at a dedicated pleural multi-
disciplinary meeting.  
Patients in whom there was diagnostic uncertainty of pleural malignancy and had one of the following 
features on CT were recruited to the ‘indeterminate’ arm of the study: 
1. Smooth pleural thickening increasing over time but < 10mm in thickness  
2. Subtle pleural thickening extending over the mediastinum but no other suspicious features 
3. Pleural thickening < 10mm with minimal nodularity  
4. CT suspicious for pleural malignancy but previous biopsies were benign  
A control population comprised of both benign diffuse pleural thickening patients and malignant 
pleural disease patients. The benign control group either had biopsy proven benign pleural disease or 
had been under follow-up with no radiological progression of their pleural thickening for > 18 months. 
The malignant control group had biopsy proven mesothelioma.     
All recruited patients had a DWI and DCE MRI scan at the same sitting, with both scans taking just over 
10 minutes (see below for image acquisition details). Following the MRI scan, they continued with 
usual care as per clinician discretion to establish a final diagnosis, with either biopsies or interval 
follow-up scans.  
3.2.1 MRI image acquisition  
 
All images were acquired on a Philips Ingenia 3 Tesla MRI scanner (Philips Healthcare, Best, The 
Netherlands) using the manufacturer’s anterior torso coil and built-in posterior coil, giving a total of 
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32 channels. DW-MRI was performed using a single shot spin-echo echo-planar sequence with 
parameters as described below in Table 3-1. To minimise motion artefact, a navigator pulse was used. 
This uses the position of the right hemi-diaphragm as the physiologic trigger so that image acquisition 
is synchronised to the respiratory cycle. DCE-MRI was performed with a T1-weighted three-
dimensional echo gradient sequence with parameters described in Table 3-1.  Mean examination 
duration for DCE-MRI scans were 3 minutes and 8 seconds. Gadolinium contrast (Gadovist) was 
injected (0.1mmol/kg body weight) after 5 non-contrast images, using a power injector. Scans were 
obtained during continuous shallow breathing.              
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 DWI DCE 
Sequence Spin-echo, echo planar Gradient echo 3D 
Orientation Axial Axial 
Scan duration (min:s) 6:18 3:08 
Repetition time (ms) 7000 4.5 
Echo Time (ms) 71 2.3 
Flip angle 90° 10° 
Field of view (mm) 390 (RL) x 312 (AP) x 220 
(FH) 
390 (RL) x 312 (AP) x 220 
(FH) 
Acquistion matrix  80 x 78 280 x 195 
Reconstructed pixel spacing 
(mm) 
 1.01 x 1.01 0.61 x 0.61 
Parallel imaging:  Sense: factor 2 Sense: factor 2 
b values 0,50,100,750,1000  
Dynamic frame time (s) n/a 9.2  
Bandwidth (kHz/pixel) 3.345 0.687 
Table 3-1:DWI and DCE image acquisition parameters. (DWI – diffusion weighted imaging; DCE – dynamic 




3.2.2 MRI analysis 
 
The MRI scans were clinically reported by a thoracic radiologist with an interest in pleural MRI (with 
13 years of experience in thoracic radiology). Data acquisition for research purposes was performed 
by the same radiologist, as described below.  
3.2.3 MRI data acquisition  
 
The DWI and DCE MRI scans were retrieved from the picture archive and communication system 
(PACS) to a 3D Synapse (FUJIFILM Medical Systems, USA) work station. Within 3D Synapse, the 
respiratory gated DWI images were analysed first. Areas of restricted diffusion were selected on these 
DWI images with b-0 and b-1000 datasets viewed simultaneously (b values are an operator selected 
parameter that defines the strength of the gradient and duration. No optimum value but b-0 to b-
1000 are often used for assessing the pleura and other anatomical regions such as the brain).  Using 
the free hand drawing tool, up to 3 regions of interest (ROI) were drawn around areas of restriction 
on the pleura, for each patient. If no regions of restricted diffusion were detected, the most significant 
area of pleural thickening appreciable on the MRI, was chosen and a ROI was drawn in this area. ADC 
values were automatically generated for the ROIs by built-in software (Fuji Synapse 3D) and saved 
separately as a comma separated value (CSV) file. 
Using 3D Synapse the dynamic imaging scans were analysed next. The location of ROIs was matched 
anatomically with those drawn on the DWI data. The ROI drawn on the DWI scan was identified and a 
corresponding ROI was drawn on the dynamic contrast enhanced (DCE) scan using the free hand 
drawing tool. Fuji Synapse 3Ds built in software allows raw data to be generated for contrast 
enhancement over time for each region of interest. This data is then exported to Microsoft Excel 
(Microsoft Corporation, USA) for further analysis. Three ROIs and contrast uptake graphs are shown 
in Figures 3-1a and 3-1b.  





Figure 3-1a: Axial contrast enhanced fat-suppressed T1 weighted MRI images for patient M2. Images A and B 










Figure 3-1b: Axial contrast enhanced fat-suppressed T1 weighted MRI images for patient M2. Image C 
showing the 3rd region of interest drawn around the pleura with the corresponding time intensity curve. Image 
D shows the region of interest drawn in the aorta which is then used for standardising the raw data (discussed 








3.2.4 MRI data analysis: 
 
3.2.4.1 ADC data acquired from DWI scans  
 
For each ROI a minimum, maximum and a mean ADC value was generated using commercially 
available Fuji Synapse 3D (FUJIFILM Medical Systems, USA) software. The average of the mean ADCs 
for the 3 ROIs was used for analytical purposes from here on. 
3.2.4.2 Pleural pointillism on DWI scans  
 
This novel technique introduced by Coolen et al. in 2015 involves visually examining the pleura to 
identify areas of restricted diffusion based on review of b-0 and b-1000 images.  Restricted diffusion 
appears as focal hyperintensities on b-1000 [72]. Pleural pointillism is present when at least 2 of these 
hyperintense areas are present on b-1000 images. We adopted the same technique for visual 






Figure 3-2: Axial CT image and corresponding DWI T2 weighted axial images on b=0 and b=1000 sequences showing pleural pointillism. Figure A shows benign pleural thickening on the right (arrow), with a 
small pleural effusion and folded lung above the effusion. On the corresponding b=1000 and b=0 images the pleura is seen as a dark band with no areas of hyper-intensity. Note fluid is bright on T2 weighted 
images hence the pleural effusion and spinal canal seen clearly on the middle image but less clearly on the b=1000 image. Figure B shows axial CT image of nodular pleural thickening which is seen as 





3.2.5 DCE data preparation for analysis 
 
An example of the exported raw data for contrast enhancement for 3 ROIs and aorta is shown in 
Table 3-2. The baseline was calculated by averaging the points prior to one frame length before 
enhancement of the curve (Figures 3-1a and 3-1b). The aorta curve was used to identify the start 
of enhancement due to the contrast agent. The example below shows the raw data generated 
from patient M2, the 3 ROIs and aorta (Table 3-2). The corresponding contrast enhancement 
curves over time are shown in Figure 3-3.      
For analysis, 2 parameters were examined from the DCE data; the area under the curve at 60 




Time point (seconds)  
 
ROI1 ROI2 ROI3 Aorta 
10 266.5 158.9 101.8 185.6 
20 266.3 159.3 109.7 189.6 
30 269.1 164.2 111.5 211 
40 266.3 169.7 112.9 196.4 
50 269.8 150.6 109.3 226.9 
60 204.1 177.2 95.7 762.3 
70 244.4 236.1 162.1 613.7 
80 303.2 310.1 216.7 950.3 
90 297.3 312 239.8 968.9 
100 305.8 335 263.4 947.2 
110 283.1 345.2 288.5 1016.1 
120 282.3 361.6 291.8 935.8 
130 306.2 358.2 318.9 886 
140 309.4 375 326.1 932.2 
150 292.8 380.4 336.4 905.8 
160 315.3 376.2 355.1 877 
170 292.2 377.5 361.3 951.6 
180 287.5 399.3 371.7 939.5 
190 299.9 407 379.3 845.1 
200 305.7 399 378.9 900.5 






Figure 3-3: Contrast enhancement graph for patient M2 corresponding to the values in the table above. Aorta curve shown in 
yellow starts to enhance at 50 seconds 
 
The aorta curve, shown in yellow, starts rising when contrast is injected at 50 seconds. Therefore, this was 
chosen as the baseline. The baseline adjusted values for ROI1 are shown below, as per the method 
described earlier: 
Average for the baseline for ROI1 = (266.5 + 266.3 + 269.1 + 266.3)/4 = 267 
Adjusted against aorta for time point 5 = (269.8 – 267)/267 = 0.01 
The adjusted data allows comparison of different sized ROI by giving a normalised fractional increase in 
signal. All time points are corrected using the same formula. Table 3-3 shows the baseline adjusted data 




































Signal intenisty over time - post contrast injection 
ROI1 ROI2 ROI3 AORTA
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Time (in seconds)  ROI1 (au) ROI2 (au) ROI3 (au) 
0 0.010298 -0.07622 0.002982 
10 -0.23572 0.08695 -0.12182 
20 -0.08482 0.448244 0.487497 
30 0.135368 0.902162 0.988529 
40 0.113275 0.913817 1.200505 
50 0.145104 1.0549 1.417068 
60 0.060101 1.117467 1.647396 
70 0.057105 1.218065 1.677678 
80 0.146602 1.197209 1.926359 
90 0.158585 1.300261 1.992429 
100 0.096424 1.333384 2.086947 
110 0.180678 1.307622 2.258546 
120 0.094177 1.315596 2.315439 
130 0.076577 1.449318 2.410874 
140 0.123011 1.49655 2.480615 
150 0.144729 1.447477 2.476944 
Table 3-3: Baseline adjusted values. (ROI- region of interest; au – arbitrary units) 
 
 
Figure 3-4: Contrast uptake corrected to the Aorta for the 3 regions of interest 
 
The corrected values were then used to calculate the area under the curve (AUC) for the first 60 seconds 










































Figure 3-5: Calculation of the area under the curve using Trapezium rule 
 
 
First, the area of the square (area beneath the dotted blue line) is calculated: h1 * X 
Second, the area of the triangle is calculated: (h2-h1)*X / 2  
Total AUC for duration X = (h1*X) + (h2-h1)*X/2 = h1X + ½ h1X – ½ h2X = ½ h1X + ½ h2X  
When using the Trapezium rule we assume the curve to be a straight line for the duration X (as shown by 
the diagonal blue dotted line on the example).   
Calculation of maximum signal intensity gradient (MSIG): 
To calculate the gradient of the curve at each time point: (h2-h1)/X 
The signal gradient is calculated for each 10 second time period for the 3 curves. The largest value 
corresponds to the steepest gradient of the signal intensity curve. The largest value of the 3 curves is used 
for subsequent analysis exploring MSIG.   
Figure 3-6 shows 3 baseline adjusted graphs for a benign control, malignant control and an indeterminate 






Figure 3-6: Contrast enhancement against time for benign and malignant control group patients and indeterminate group 
patient 
  









































































































All statistical analyses were carried out in Stata version 15 (StataCorp, Texas, USA). As the ADC and DCE 
data was not normally distributed the median values with interquartile ranges (IQR) are reported. Mann-
Whitney U test was used to compare the means of non-parametric data. A p value less than 0.05 was 
considered significant, unless otherwise specified in the text. The optimal cut-off for diagnostic tests was 
calculated using the Liu method [145] on Stata. Intra-observer variability was tested using Bland Altman 
method for continuous variables.   
3.3 Results 
 
Twenty-seven patients were recruited to the study. Two were excluded; 1 patient had the scan while the 
MRI protocol was being finalised, therefore the data from his scan was not used for analysis and 1 patient 
declined the study after recruitment. Patient demographics, asbestos exposure history and diagnoses at 
recruitment for the remaining 25 patients are listed in Table 3-4.  
Demographics 
 
n = 25 
Age (mean ± SD) in years 
 
















1 (4 %) 
Diagnosis at recruitment  
Benign (control group) 
Malignant (control group) 






Table 3-4: Baseline characteristics. (SD – standard deviation)  
 
Mean age at recruitment was 72 (±8) years. A majority of the patients were male (92%). Nine patients 
were recruited into the indeterminate group if they met the criteria mentioned previously. Of these 9 
patients, 3 were subsequently confirmed as malignant while 6 were benign. Sixteen patients were 
recruited to the control arm; 13 of these with confirmed benign pleural disease and 3 with confirmed 
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malignant pleural mesothelioma (Figure 3-7). Two thirds of patients admitted to a history of previous 
definite asbestos exposure.    
 
Figure 3-7: Flow chart of patients in each group 
 
Following their MRI scan 7 patients had pleural biopsies (6 CT guided biopsies and 1 ultrasound guided 
biopsy) 3 of these were confirmed as malignant. Of the 2 patients who did not have biopsies 1 patient had 
20 months of follow-up with interval scans with no development of a pleural malignancy. The other 
patient had 12 months of interval CT scan follow-up and died of an unrelated malignancy. A PET-CT scan 





Table 3-5 shows the individual data including CT features for classifying patients as ‘indeterminate’. 
Individual MRI parameters, presence or absence of pleural pointillism sign, and the patients’ final 




























Present or absent Benign/malignant  
2 Progressive pleural 
thickening with benign 
biopsies 
1.32 0.99 1.65 7.99 0.06 Absent Benign pleural disease 
3 PT < 10mm with subtle 
nodularity 
1.15 0.18 2.51 18.62 0.03 Absent Benign pleural disease 
4 High CT and clinical suspicion 
but benign biopsies 
1.48 0.94 2.12 109.93 0.11 Present Epithelioid 
mesothelioma 
7 PT with subtle nodularity and 
benign biopsies 
1.48 1.12 1.78 13.38 0.04 Absent Benign pleural disease 
9 PT < 10 mm with subtle 
nodularity  
1.51 0.92 2.00 28.18 0.04 Present Epithelioid 
Mesothelioma 
13 PT < 10mm with subtle 
pleural nodularity 
1.26 0.79 1.66 76.95 0.09 Present Benign pleural disease   
18 Progressive pleural thickening 
but < 10mm 
2.10 1.55 2.76 85.77 0.14 Present Epithelioid 
Mesothelioma 
19 PT < 10mm with subtle 
pleural nodularity 
2.05 1.4 2.72 77.64 0.11 Absent Benign pleural disease 
23 PT < 10mm with subtle 
pleural nodularity 
1.81 1.09 2.48 25.39 0.17 Absent Benign pleural disease 
Table 3-5: Individual data for the patients in the indeterminate group. (PT – Pleural thickening; DWI – diffusion weighted imaging; DCE – dynamic contrast enhanced; ADC- apparent diffusion 




3.3.1 DWI and DCE data analysis: 
 
For each scan, a minimum, maximum and a mean ADC was reported for each ROI giving a total of 9 
ADC values per scan. The average of the 3 was used for analysis purposes. For DCE data, the mean 
area under the curve at 60 seconds (AUC60) and the maximum signal intensity gradient (MSIG) were 
used for analyses.  
Using our control population, we derived an optimum cut-off for both DWI and DCE data to 
discriminate between benign and malignant pleural thickening. Diagnostic performance indices such 
as sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and overall 
area under the receiver operating curve (AUROC) were also derived and are shown in the Table 3-6 























(1.5 – 1.86) 
1.11 
(0.95 – 1.24) 
2.25 
(2.03 – 2.5) 
7.25 






(1.65 – 1.80) 
1.24 
(1.17 – 1.26) 
2.32 
(2.10 – 2.52) 
44.04 
(16.75 – 73.61) 
0.08 
(0.06-0.11) 
Optimal cut-off 1.68 1.17 2.23 23.01 0.06 
Sensitivity 67% 100% 67% 67% 100% 
Specificity 54% 46% 38% 77% 77% 
PPV 25% 30% 20% 40% 50% 
NPV 87% 100% 83% 91% 100% 
AUROC 60% 80% 53% 72% 88% 
Cut-off values tested in the indeterminate group (n=9) 
Sensitivity 33% 33% 33% 67% 67% 
Specificity 67% 83% 50% 67% 33% 
PPV 33% 50% 25% 50% 33% 
NPV 67% 71% 60% 80% 67% 
AUROC 50% 58% 42% 67% 50% 
Table 3-6: Derivation of cut-offs for diffusion weighted and dynamic contrast values. Using the control 
population an optimal cut-off was derived for the control group. Diagnostic performance at this cut-off is shown 
first followed by the diagnostic performance when using these cut-offs in the indeterminate group. (ADC- 
apparent diffusion coefficient; AUC - area under curve; MSIG - maximum signal intensity gradient; PPV – positive 







3.3.2 Pleural pointillism: 
 
For our indeterminate group, MRI visual assessment using pleural pointillism alone had a sensitivity 
of 100%, specificity of 83%, PPV 75% and NPV of 100% with AUROC 91% (Table 3-7).   
 Pointillism present 
 
Pointillism absent Total 
Malignant 
 
3 0 3 
Benign 
 
1 5 6 
Total  
 
4 5 9 
Table 3-7: Diagnostic performance of pleural pointillism in the indeterminate cohort 
 
When considering all benign and malignant diagnoses in our cohort of patients (control and 
indeterminate group together), there was no difference in the median ADC values. The benign group 
had a median ADC value of 1.62 mm2/sec (IQR 1.46 – 1.83 mm2/sec) while the malignant group had a 









Median mean ADC 
(mm2/sec) (IQR) 
1.62 
(1.46 – 1.83) 
1.66 
(1.51 – 1.80) 
p = 0.51 
Median min ADC 
(mm2/sec) (IQR) 
1.08 
(0.87 – 1.24) 
1.21 
(0.94 – 1.26) 
p = 0.44 
Median max ADC 
(mm2/sec) (IQR) 
2.25 
(1.87 – 2.51) 
2.22 
(2.10 – 2.52) 





(4.91 – 30.30) 
58.82 
(23.01 - 77.4) 





(0.02 – 0.09) 
0.09 
(0.06 – 0.11) 
p = 0.07 
Table 3-8: Diffusion weighted, and dynamic contrast enhanced data separated by disease cohort. (ADC - 







Figure 3-8 is a Box-and-Whisker plot of the mean ADC values for the benign and malignant groups. 
The central line of the box denotes the median ADC for each group. As shown by the outliers, the 






Figure 3-8: Box-and-whisker distribution of the median values for the mead ADCs in the benign and malignant 
groups. The horizontal line in the centre of the box depicts the median, the upper and lower margins of the 
box shows the 75th and 25th quartiles. The horizontal lines of the whiskers show the range, highest to lowest 
values. Note 2 outliers shown separately for the benign group as 2 solid circles.   
 
Coolen et al., have previously published data proposing an ADC value of 1.52 mm2/sec to be an 
optimum cut-off for discriminating benign from malignant pleural thickening [70]. Applying this cut-
off in our cohort we obtained a sensitivity of 83%, specificity of 37%, PPV of 29%, NPV 87.5% and 
accuracy of 48% for our study population. 
3.3.3 Intra-observer variability 
 
To check for intra-observer variability the same method described above was used to draw ROIs on 3 
patients, 1 each from the benign control, malignant control and indeterminate groups. The overall 
correlation between ROIs was moderate at r = 0.65. Interestingly, the correlation between the benign 
and malignant patients was r =0.974 and r=0.855, respectively. For the patient in the indeterminate 
group this dropped to r=0.122.   
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3.4   Discussion 
 
This is the first MRI pilot study to incorporate functional MRI assessment methods in equivocal pleural 
thickening on CT. Our results suggest that visual assessment using pleural pointillism is the most robust 
method for assessing early malignant pleural disease on MRI. Our study is pragmatic and was 
specifically aimed at identifying those with equivocal signs on CT rather than established malignant 
pleural thickening, as this is the group that usually presents a clinical conundrum. Patients may go on 
to have unnecessary biopsies or multiple interval CT scans until a definitive diagnosis is made.     
MRI as an imaging modality has certain advantages over CT and PET scans. It is free of ionising 
radiation, relatively easily accessible and well tolerated. MRI is also significantly superior at soft tissue 
delineation and spatial resolution [65, 146]. For these reasons MRI has been under investigation for 
over 2 decades by researchers with an interest in pleural disease [147]. Various quantitative and non-
quantitative methods have been investigated as discussed earlier.  
Using the DWI data in our control population, we determined an optimal cut-off for the mean ADC at 
1.68 mm2/sec for differentiating benign from malignant pleural thickening in our cohort.   This was 
then validated in our indeterminate group. With a sensitivity of 33%, specificity of 67%, PPV of 25% 
and NPV of 87.5% this derived cut-off value did not perform well in the indeterminate group. Exploring 
the minimum and maximum ADC values using derived cut-offs in the indeterminate cohort, which 
again did not prove to be useful. Similar results were observed in a study by Inan et al with 34 patients 
where the overlap in the ADC values between benign and malignant groups prevented them from 
identifying a discriminative cut-off [142].   
Studies investigating DWI techniques have reported mean ADC values ranging from 0.99 to 2.0, as 
potential cut-offs for discriminating benign from malignant pleural thickening [66, 70] however, these 
absolute numbers are unlikely to be transferable between studies due to inter scanner and software 
variability. As discussed in the introduction chapter, the ADC is derived from the signal loss associated 
with thermal motion of water molecules with the switching of the magnetic field [148]. The diffusivity 
of water molecules is dependent on the cellularity of the tissue and the integrity of the cell membrane. 
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MPM is a heterogenous malignancy, therefore the cut-off values may vary from study to study 
depending on the cohort under investigation.  In the study by Gill et al [66] they found a mean ADC 
value of 1.31 mm2/sec for their epithelioid patients and 0.99 mm2/sec for the sarcomatoid patients. 
In the current cohort the median ADC value for all epithelioid patients (n=5) was 1.64 mm2/sec while 
the only sarcomatoid patient had an ADC of 1.80 mm2/sec. Our sample size was too small to confirm 
or refute findings from previous literature reporting lower ADC values for sarcomatoid and biphasic 
sub-types (1 sarcomatoid and no biphasic patients) in the current study. Coolen et al., reported a mean 
ADC value of 1.52 mm2/sec to be an optimum cut-off for discriminating malignant pleural thickening, 
with a 71% sensitivity and 100% specificity [70]. Using this cut-off, we were able to demonstrate a 
better sensitivity than they reported at 83%, but worse specificity at 37% and an overall accuracy of 
only 48%.  
Our DCE data performed better than DWI data in keeping with previously published literature [70, 
144]. Using the derived cut-off 23.01au, patients with malignancy in the indeterminate group were 
identified with a 67% sensitivity and specificity, 50% PPV and 80% NPV. Furthermore, when exploring 
the full cohort separated by disease status, benign or malignant, there was a statistically significant 
difference in the mean AUC60 between the 2 groups; 9.64au versus 58.82au (p=0.008), respectively. 
The higher AUC60 and MSIG are in keeping with what would be expected in malignant tissue; 
increased neovascularisation leading to rapid contrast uptake in tumour tissue. Other studies using 
DCE-MRI report similar results for early contrast enhancement. Tsim et al., recently published a study 
with 58 patients undergoing DCE-MRI looking at early contrast enhancement, signal intensity peaking 
at or before 4.5 minutes as a marker of malignancy [144]. They reported an 83% sensitivity and 
specificity using this method alone. When combined with MRI morphology the sensitivity increased to 
92% while the specificity dropped slightly to 78%. In the Tsim et al. study 15 ROIs were specified on 
each scan, increasing the accuracy of the data obtained. In the current study only 3 ROIs were specified 
on each scan and this may have been a limitation leading to false negative results. The higher the 
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number of ROIs the more accurate the data derived is likely to be. However, this is a very laborious 
task and unlikely to be practical in routine clinical use.  
The Tsim et al. study used scan duration of 4.5 minutes as the cut-off following their pilot 
investigations and confirmation that malignant patients would reach a peak signal intensity post-
gadolinium contrast injection, at or before this time point. Mean total scan duration in their study was 
8 minutes while the mean scan duration for our patients was 3 minutes and 8 seconds. Tsim et al also 
showed correlation between micro vessel density in histopathological samples and MSIG in their 
study, in keeping with the hypothesis that the increased vasculature leads to early contrast 
enhancement [144]. Similar to our data there was significant variation in the contrast enhancement 
curves between ROIs (Table 1-2 difference between ROI1 and ROI3).   
The most striking results in our study is the simple yet accurate visual assessment of the pleura using 
pleural pointillism on MRI. In our indeterminate cohort pleural pointillism had a sensitivity of 100%, 
specificity of 83%, positive and negative predictive values of 75% and 100%, respectively. However, 
larger prospective studies are required for validation before this technique can be recommended in 
the routine diagnostic pathway of patients with suspicious pleural thickening and equivocal CT 
findings.  
Practicality, patient tolerability, efficiency and cost are some of the key factors to consider when 
adopting an imaging modality for routine clinical use. Although a number of small studies have shown 
encouraging results with the use of functional DCE-MRI, adopting this in routine clinical practise may 
not be very feasible. Drawing regions of interest around subtle areas of pleural thickening is time 
consuming with potential to inter and intra observer variability [143]. Justification of a contrast 
enhanced scan is difficult, when the non-contrast pleural pointillism on DWI is superior to DCE-MRI, 
as shown here. However, with advancing technology/software, improved algorithms/magnetic fields 
and artificial intelligence there maybe scope for improvement of this technique in the future. 
Furthermore, when comparing to other imaging modalities such as PET-CT which has been extensively 
investigated for diagnosing pleural malignancy [76], DWI-MRI certainly has several advantages. A DWI-
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MRI scan takes just over 3 minutes, as opposed to a PET scan that can take up to 20 minutes (after a 
60-minute sedentary wait following the injection of the 18-FDG). With PET scans patients should fast 
for at least 6 hours prior to the scan and those with diabetes should have good glycaemic control. 
Furthermore, with low volume tumour (early pleural malignancy) and tumours with low proliferative 
indices such as early epithelioid mesothelioma, the false negative rate tends to be higher with PET-CT 
[76].   
Our study has a number of limitations. Our study population was small, particularly the number in the 
indeterminate cohort. However, this is a reflection of the incidence of such cases. They are rare, but 
when present, diagnosing these patients can be challenging. Our control population of confirmed 
benign (n=13) and malignant (n=3) which served as the discovery cohort was also small. A larger 
discovery population is likely to give more accurate cut-off data, particularly considering the 
heterogeneity of MPM. By opening more sites, we could have increased our population, but this would 
have weakened the strength of the study due to using different scanners. Competing diagnostic 
studies such as the TARGET trial (next chapter) meant a very small number of patients were 
preferentially entered to TARGET, which is unfortunately another weakness of the study as not all 
consecutive patients were entered.  
One of the weaknesses of the study is the number of ROIs drawn on the scans. For practicality and 
eventually ease of clinical utility, only 3 ROI were drawn where restricted diffusion was evident on the 
DWI MRI scan. Due to the heterogeneity of the disease these areas of restricted diffusion were quite 
subtle and subject to significant intra-observer variability that could have led to false negative results.  
If the number ROI were higher as in the Tsim et al. study, maybe a stronger signal would have emerged. 
However, as mentioned earlier drawing ROIs and transposing these to the DCE scans is not practical 
in routine clinical application. Hence a more acceptable compromise of 3 ROIs was used in this study. 
Furthermore, the ROIs were drawn in conjunction by a radiologist and me, a non-radiologist.  Perhaps 
the accuracy of ROI would have been higher had 2 thoracic radiologists with experience in MRI, 
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performed this task. Ideally, all ROI should have been drawn twice independently by the investigators 
and assessed for inter and intra observer variability to strengthen the findings. 
Another limitation of our study is the duration of the DCE scan. The DCE scan was only 3 minutes in 
duration, this was mainly for patient tolerability. However, this meant we did not obtain any wash-out 
data for the dynamic studies which may have given additional information that could be useful. 
 Despite these limitations, we have demonstrated that whilst there may be a slight advantage to using 
functional MRI for assessment of early suspicious pleural thickening, overall, visual assessment using 
pleural pointillism may be superior, without the need for a time-consuming process to quantify DCE 
data. Pleural pointillism using DWI MRI may have a role in supporting a diagnosis of pleural 
malignancy, but on its own it cannot be used as confirmatory investigations without further validation 
in larger prospective trials. The role of MRI in pleural disease may lie with assessment of soft tissue 
invasion (such as through diaphragm and chest wall) [149] if this is likely to have an impact on 
management, for example upstaging T stage of MPM which would preclude a patient from having 
surgery [150]. However, in its current state functional MRI does not have an additional role in the 
diagnostic pathway of patients with equivocal pleural thickening on CT.  
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CHAPTER 4       A RANDOMISED CONTROLLED TRIAL TO 
COMPARE THE DIAGNOSTIC YIELD OF POSITRON EMISSION 
TOMOGRAPHY COMPUTED TOMOGRAPHY (PET-CT) TARGETED 
PLEURAL BIOPSY VERSUS CT-GUIDED PLEURAL BIOPSY IN 
SUSPECTED PLEURAL MALIGNANCY. (TARGET TRIAL) 
 
4.1 Introduction  
 
Patients with high a clinico-radiological suspicion of pleural malignancy usually proceed to a pleural 
biopsy, either radiologically or thoracoscopically. In a proportion of patients these biopsies maybe 
non-diagnostic, requiring a further biopsy to confirm underlying malignancy. The yield of repeated CT 
guided biopsies is low; local audit data from our trust indicated that only 3 out of 15 (20%) repeat 
pleural biopsies for suspected pleural malignancy (all later confirmed to be cancer) were positive. This 
compares to a yield of 4 of 6 patients (66%) in the arm that underwent PET-CT with the pleural biopsy 
targeting the area of highest metabolic activity on the scan. This highlights a potential role for PET-CT 
in this group of patients, which warrants further investigation. 
 
The TARGET trial was designed to investigate this role of PET-CT in pleural malignancy, for patients 
with a non-diagnostic first biopsy. The study idea was conceived by Professor Nick Maskell and was 
later refined by me in the process of applying for funding. Several funding options were explored for 
the proposed multicentre randomised controlled trial (RCT). Two grant applications were submitted 
to the British Lung Foundation (BLF) and the National Institute for Health Research (NIHR) research 
for patient benefit (RfPB) funding streams, simultaneously. A condensed version of the NIHR grant 
application can be found in Appendix I. 
Much work was undertaken to ensure appropriate support was in place to design and conduct this 
trial. Potential recruitment centres from across the UK were contacted at an early stage to ensure 
their willingness to participate in the trial. In addition, the local research & innovation (R&I) 
department, research design service (RDS) and the clinical trials & evaluation unit (CTEU) in Bristol 
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were involved from the early design stages of the trial. The Bristol CTEU provided statistical, database 
and administrative support for the duration of the trial. The proposed study plan was presented to a 
mesothelioma focus group for their input from a patient and public perspective. This proved very 
useful and their feedback had an impact on the final design of the final study.  
Both grant applications were successful but BLF later withdrew their grant (of £50,000) as NIHR was 
able to support the trial fully with £344,811.  
The trial protocol and other trial related documents necessary for the running of the trial, such as the 
patient information leaflet (PIL), consent forms, and case record forms (CRF) were developed by me. 
The clinical input necessary for setting-up and running the trial was provided by me, in the role of the 
trial coordinator. In addition, the necessary regulatory approvals such as research ethics committee 
(REC) review and administration of radioactive substances advisory committee (ARSAC) certification 
were all applied for by myself and subsequently presented along with Professor Maskell, to the South 
West Research Ethics Committee (REC) in Exeter. Following a few minor amendments REC approval 
was granted on the 15th of July 2015. A CTEU appointed trial manager took charge of the day-to-day 







4.2.1 Study objective 
 
The TARGET trial is a UK based multicentre parallel group randomised controlled trial, aiming to 
evaluate whether a PET-CT targeted CT guided biopsy is superior to a standard CT guided biopsy in 
patients with suspected pleural malignancy who have undergone one non-diagnostic biopsy.   
4.2.2 Study outcomes 
 
The primary outcome of the study is ‘pleural malignancy correctly identified on the second biopsy’.  
The primary aim of the study was to determine the sensitivity and specificity of the PET-CT targeted 
second biopsy as a part of the trial. Patients were followed up for 12 months or to the end of the trial 
- if recruited in the last 6 months of the recruitment period. Patients with a non-diagnostic biopsy in 
the trial may have had further biopsies during this time via other means, which may confirm the 
diagnosis. Some patients may be given a clinico-radiological diagnosis of pleural malignancy due to 
characteristic progressive features on subsequent radiology. All suspected cancer diagnoses were 
discussed in a mesothelioma or lung cancer multi-disciplinary team (MDT) meeting and members were 
in consensus of the diagnosis, prior to classifying the disease as malignancy.   
The secondary outcomes of the study were as below: 
• Total number of invasive procedures (video-assisted thoracic surgery –VATS- or radiology 
guided biopsies) undertaken following randomisation to confirm the diagnosis 
• Time from randomisation to cancer diagnosis (those not diagnosed with cancer to be censored 
at last follow-up) 
• Time from randomisation to death (survivors to be censored at last follow-up) 
• Total number of hospital attendances following randomisation to confirm the diagnosis 
• Procedure related adverse events 




• Serum mesothelin levels measured at baseline, 6 and 12-month follow-up visits for those 
followed up for 12 months 
• PET scan parameters - Total Glycolytic Volume (TGV), maximum and mean standard uptake 
value (SUV) (PET-CT group only) 
• Estimated costs associated with health-related resource use from randomisation to diagnosis 
  
At the conclusion of the study, biopsies and radiology results are to be reviewed by an independent 
adjudication committee.  The committee will be blinded to the results. 
 
4.2.3 Participant identification  
 
Patients were identified via the local lung cancer and mesothelioma MDTs. Patients suspected of 
pleural malignancy usually have a biopsy and are discussed at the MDT meeting. Therefore, patients 
with a non-diagnostic biopsy would be identified and screened through the MDT.   
4.2.4 Pre-screening, screening and recruitment  
 
Eligible potential patients were given a patient information leaflet. Provided they were happy to 
participate in the trial, they were asked to consent to the trial and recruited. Following a baseline 
assessment gathering data on their demographics, investigations to date, they were randomised 
either to the standard arm of the trial, or a PET-CT scan followed by a CT guided biopsy to an area 
identified on the PET-CT scan.  
4.2.5 Eligibility criteria 
 
4.2.5.1 Inclusion criteria: 
 
Patients were eligible if they met all the criteria below:   
• Pleural thickening on CT suspicious for pleural malignancy 
• Have had any form of pleural biopsy in the last 12 months (either by thoracoscopy or under 
radiological guidance) which was non-diagnostic for cancer  
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• Lung Cancer/mesothelioma MDT decision to perform a further CT-guided biopsy to pursue a 
diagnosis 
4.2.5.2 Exclusion criteria 
 
Patients did not enter the study if they met any of the criteria below: 
• Unsuitable for a CT guided biopsy – inability to co-operate, lie still for the duration of the 
biopsy, uncorrectable coagulopathy, inability to tolerate a pneumothorax, severe underlying lung 
disease (patients with an FEV1 < 35% assessed using simple spirometry) 
• Unable to give written informed consent 
• Pregnancy or lactation 
• Age <18 years 
• Pleural thickening not amenable to a radiologically guided biopsy 
• Talc pleurodesis in the previous 6 months 
4.2.6 Randomisation and blinding procedures: 
 
Patients were allocated on a 1:1 basis to either the intervention (PET-CT prior to CT guided biopsy) or 
comparator (CT guided biopsy only) arm.  The allocation was blocked using varying block sizes and 
stratified according to enrolling centre.  Only authorised personnel were given access to randomise 
patients and access was password protected. 
Concealed randomisation ensured selection bias excluded. The sequence of random allocations were 
generated by computer and was concealed from all clinical and research personnel until a participant 
was recruited. 
Due to the nature of the investigations performed, neither participants nor investigators were blinded 
to allocation.  
4.2.7 Research Procedures: 
 
All patients had a baseline assessment at the time of their recruitment to the trial. Patients also had 
blood tests which included a full blood count, urea and electrolytes a clotting screen and a trial specific 
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blood test Mesothelin at their baseline assessment. All Mesothelin blood tests were analysed at the 
lead centre NBT. Other centres were asked to send their samples securely to the NBT laboratory.  
Patients had simple spirometry at their baseline assessment to ensure they were able to tolerate a 
pneumothorax in the unlikely event this was a complication of the CT guided biopsy. Patients were 
randomised at the end of their baseline assessment.  
Those randomised to the PET-CT arm had the PET-CT scan followed by a CT guided biopsy, within a 2-
week period from randomisation. Patients in the standard arm went straight to a CT guided biopsy 





Figure 4-1: Trial flow chart 
 
 
Patients with suspected pleural malignancy and 
a non-diagnostic first biopsy identified from 
local lung cancer and mesothelioma MDTs   
Eligible patients screened and consented  
  
Baseline assessment 




Using web based software 
Stratification by centre 
Intervention group 
PET-CT scan performed and reported 
highlighting potential areas for biopsy. 
CT guided biopsy 
Control group 
CT guided biopsy of safe and accessible area 
as per standard operating procedure 
Post biopsy  
All patients to be discussed at loco-regional 
lung or mesothelioma MDTs 
Post-biopsy follow-up after MDT  
Follow-up 
3, 6 and 12 month follow-up face-to-face or 
by telephone. 
Follow-up CT scans at 4-6 months and 10-12  
Patients recruited from September 2017 will 
only have 6 months follow-up 
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The Mesothelin blood test was a trial specific blood test, and was performed at baseline, 6 and 12-
month follow-up visits on patients who were able to attend these follow-up visits. 
Patients also had a CT scan between 4-6 months and another at 10-12 months. This is of particular 
importance for those with a non-diagnostic biopsy as a part of the trial, as the expectation was an 
underlying malignancy that was yet to be diagnosed would become apparent during this follow-up 
period.  
4.2.8 Follow-up visits 
 
The first follow-up visit was scheduled for when participants attended clinic for their biopsy results. 
This was usually 1-2 weeks after their biopsy. Adverse events relating to the PET-CT scan and CT guided 
biopsy were captured at this visit. In addition, information pertaining to their final diagnosis and any 
further interventions undergone were also captured.  
Three further follow-up visits occurred at 3, 6 and 12 months from randomisation (Figure 4-1). Patients 
recruited in the last 6 months of recruitment only had 6 months of follow-up. At each follow-up visit, 
information regarding any further intervention patients had undergone, adverse events they had 
experienced, and treatment received were captured.  
4.3 Statistical analysis 
 
An intention to treat analysis is planned which will include all randomised participants unless consent 
to use data is withdrawn. Study protocol adherence and reasons for deviation will be described. 
Recruitment and participant flow will be described using a Consolidated Standards of Reporting Trials 
(CONSORT) flow diagram.  If the number of withdrawals differ by group, the sensitivity of the findings 
to this attrition bias will be explored. 
The number of positive biopsies will be compared, as a proportion of the participants recruited and as 
a proportion of those with a confirmed diagnosis of mesothelioma on second biopsy using logistic 
regression. Other binary outcomes will be analysed similarly. Time-to-event outcomes (e.g. time to a 
confirmed diagnosis of mesothelioma) will be compared using survival methods.  
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Differences between groups will be quantified and reported with 95% confidence intervals. If the data 
is sufficient to allow parameter estimation, we will adjust for centre as a random effect.  
The ability of the serum mesothelin levels to predict a positive diagnosis (sensitivity, specificity, 
positive and negative predictive values, area under curve) will be assessed for the study cohort as a 
whole. Similar analyses of the value of the PET parameters to predict a positive diagnosis will be 
restricted to participants in the PET-CT group. 
4.4 Safety reporting 
 
Standard definitions and clinical judgement was used when reporting any adverse events (AE) relating 
to the trial. As the only research intervention in this trial was a PET-CT scan, significant events were 
not expected. A list of expected adverse events relating to the PET-CT scan and CT guided biopsy were 
listed in the protocol.    
   
4.5 Study overview 
 
The trial was funded by NIHR Research for patient benefit funding stream (Ref: PB-PG-0214-33095). 
The necessary ethical and regulatory approvals were obtained from the South West – Exeter research 
ethics committee in May 2015 (15/SW/0156). The trial was registered with the International Standard 
Randomised Controlled Trials Number (ISRCTN ref: 14024829) registry and adopted by the NIHR 
clinical research network portfolio, as an NIHR funded study. The lead centre for the trial was North 
Bristol NHS Trust (NBT) and the study was sponsored by the research and innovation department at 
NBT.   
The first trial steering committee (TSC) meeting was held on the 13th of July 2015. The meeting was 
chaired by an independent member of the TSC. The background of the trial, design of the trial and trial 
related procedures were presented to the TSC by me, as the trial coordinator.  
4.6 Set-up and recruitment 




The site-initiation visit for the lead centre North Bristol Trust (NBT) took place on the 04th of September 
2015 shortly after which the trial opened to recruitment at NBT.  
4.6.2 Set-up and opening of other sites 
 
Due to unforeseen circumstances, significant delays incurred prior to opening the other sites as listed 
below:  
- withdrawal of some of the centres who originally agreed to participate in the trial  
- identifying and assessing capability of new centres to participate in the trial 
- changes to the clinical diagnostic pathway leading to some centres being unable to deliver the 
trial protocol 
- changes to the Health Research Authority (HRA) system 
- ARSAC certification delays for each centre 
In the 18-month period from initial agreement to participating in the trial (February 2014), to 
approaching the sites again for setting up the trial (Aug 2015), there were changes in circumstances 
at some of the centres restricting them from participating in the trial. These circumstances varied from 
changes in personnel who were able to deliver the trial, ie reduced capacity or change of PI who 
initially agreed to the trial, to changes in the diagnostic pathway. For example, at the concept of this 
study most centres would repeat a non-diagnostic biopsy, using CT guidance, but with better access 
to surgical pathways and establishment of mesothelioma MDTs more patients were being referred for 
surgical biopsies. Therefore, some centres felt they would be unable to deliver the study protocol of 
a second CT guided biopsy.  
Remedial measures were taken to identify other suitable sites: 
• The trial was published in the BTS monthly newsletter informing the wider respiratory 
community about the trial and inviting centres interested to contact the lead centre 




• Poster presentation of the trial at 2 international conferences for more exposure - the British 
thoracic oncology group meeting in Dublin 2016 which was attended by thoracic and oncology 
physicians, and the iMig meeting in May 2016, attended by a large network of mesothelioma 
specialists.  
• Publicising the trial in the Mesothelioma UK newsletter – this newsletter reaches most 
clinicians and specialist nurses managing mesothelioma 
• The trial was presented at the National pleural research meetings from 2015 to 2017 to raise 
awareness and recruit centres that maybe interested. 




Recruitment was slower than expected. Due to the niche population under consideration in this study, 
low patient numbers were expected, however the recruitment rate was much lower than anticipated. 
Therefore, the following remedial measures were taken in an attempt to boost recruitment.  
• Increasing the number of recruiting centres from 6 to 10 
• Relaxing the eligibility criteria so more patients would be eligible for the trial, without 
compromising the trial results 
• Extending the recruitment period by 12 months. 
Table 4-1 shows recruitment centres with respective PIs and recruitment to date.  
Figure 4-2 is a recruitment graph with predicted recruitment against adjusted recruitment target 
(taking into consideration the extension), and actual recruitment.   














Site Name of principal 
investigator 
Date opened to 
recruitment 
Number of patients 
screened 
Number of patients 
randomised 
North Bristol NHS Trust Prof Nick Maskell (CI) 04/09/2015 32 27 
Gloucestershire Hospitals NHS Foundation Trust  Dr Henry Steer  27/04/2016 2 2 
Glasgow Royal Infirmary Dr Kevin Blyth 04/05/2016 10 5 
Oxford University Hospitals Dr Najib Rahman 18/05/2016 9 8 
University Hospitals of North Midlands Dr Shahul Khan 16/08/2016 3 3 
Norfolk and Norwich University Hospitals NHSFT Dr Eleanor Mishra 21/02/2017 3 0 
Sheffield Teaching Hospitals NHSFT Dr Leon Lewis 17/03/2017 9 4 
Portsmouth Hospitals NHS Trust Dr Hitasha Rupani 03/04/2017 0 0 
Aneurin Bevan University Health Board Dr Alina Ionescu 19/07/2017 3 3 
Blackpool Teaching Hospitals NHSFT Dr Tarek Saba 15/11/2017 0 0 
TOTAL   71 52 








Figure 4-3:CONSORT diagram for TARGET trial 
 
Assessed for eligibility (n=71) 
32 Bristol, 2 Gloucester, 10 Glasgow, 9 Oxford, 3 Stoke,3 Norfolk, 9 Sheffield, 3 Newport 
Allocated to procedure A (n=26) 
 
Withdrawals pre-intervention (n=1) 
 
Deaths pre-intervention (n=0) 
Allocated to procedure B (n=26) 
 
Withdrawals pre-intervention (n=1) 
 
Deaths pre-intervention (n=0) 




27 Bristol, 2 Gloucester, 5 Glasgow, 8 Oxford, 2 Stoke, 4 Sheffield and 3 Newport 
Follow-up visit 1; 1-2 weeks post biopsy 
(n=16) 
 
Follow-up visit 2; 3 months post 
randomisation (n=14) 
 
Follow-up visit 3; 6 months post 
randomisation (n=10) 
 
Underwent procedure (n=22) 
 
 
Follow-up visit 1; 1-2 weeks post biopsy 
(n=18) 
 
Follow-up visit 2; 3 months post 
randomisation (n=13) 
 
Follow-up visit 3; 6 months post 
randomisation (n=11) 
 
Follow-up visit 4; 12 months post 
randomisation (n=7) 
 
Follow-up visit 4; 12 months post 
randomisation (n=6) 
 
Patients excluded (n=19)  
Ineligible (n=9): 
Not approached (n=5): 
Did not consent (n=5): 
Death post-intervention (n=1) 
Death post-intervention (n=1) 
Death post-intervention (n=1) 
Death post-intervention (n=1) 
Death post-intervention (n=1) 
Death post-intervention (n=1) Death post-intervention (n=1) 
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4.6.4 Trial Status 
 
The 10 centres continued to recruit patients until September 2018. A 6-month follow-up period will 
then conclude trial related patient activity in March 2019. Following data cleaning and validation the 
database will be locked, and the data will be analysed according to the pre-published statistical 
analysis plan.  
4.6.5 Ethics Amendments  
 
Since original REC approval the trial protocol and some of the PILs underwent several amendments. 
Two of the amendments were major amendments relating to changes to eligibility criteria in an 
attempt to boost recruitment as stated below: 
• Exclusion criteria changed from ‘pleural thickening not amenable to ‘Tru-cut biopsy’ to ‘pleural 
thickening not amenable to radiologically guided biopsy’. As Tru-cut refers to a specific type 
of biopsy method, this was replaced with ‘radiologically’ to encompass standard biopsy 
methods.  
• Inclusion criterion ‘any form of pleural biopsy in the previous 6 months’ was changed to ‘any 
form of pleural biopsy in the previous 12 months’ to include more patients who would 
otherwise be ineligible.  
• Exclusion criterion ‘prior Talc pleurodesis’ was changed to ‘Talc pleurodesis in the previous 6 
months’ due to emergence of new evidence suggesting no increased Fluorodeoxyglucose 
(FDG) uptake on PET 6 months post talc pleurodesis [119]. 
Several minor amendments relating to addition of new sites and extensions to trial recruitment period 




4.7  Discussion 
 
Pleural malignancy, particularly MPM can be a challenging disease to diagnose. The heterogeneity of 
the disease and the tumour itself, the difficulty of establishing the diagnosis on pathology and its slow 
indolent presentation are some reasons why MPM can be a diagnostic challenge. A lack of diagnosis 
can disadvantage the patient by delays in oncological treatment or stopping them from entry into 
clinical trials. 
The role of PET-CT in MPM is still not firmly established although the literature does suggest a 
potential purpose in staging the disease when patients are considered for surgery, a PET-CT scan can 
be useful to exclude distant metastases [149]. As PET-CT scans can reliably highlight areas of increased 
metabolic activity this would be a useful method of targeting biopsies to confirm the diagnosis of 
pleural malignancy.  
If the trial confirms superiority of PET-CT targeted biopsies, this could potentially minimise the number 
of invasive investigations patients are currently subjected to. In addition to the obvious patient 
benefits it is also likely to have a health economic benefit. 
The Target Trial enabled me to learn about the processes involved in designing and conducting a 
multicentre clinical trial. I was able to design a study, including all the trial related processes from a 
preconceived hypothesis by Professor Maskell. I learnt the importance of a fool-proof trial design at 
the point of applying for funding.  Coming from a non-academic background of clinical work, this was  
new to me. Having had no experience of applying for funding, setting up or conducting a clinical trial, 
I embarked on applying for funding which involved exploring various funding opportunities, attending 
grant applications work-shops and identifying the necessary personnel to help me with the 
development of a grant application. I learnt the importance of collaborating with the research design 
service, local research and development teams including financial officers who helped me in costing 
the application appropriately. Having not been aware of the importance of patients and public 
involvement in setting up clinical trials, I was soon organising a focus group of patients and relatives, 
with mesothelioma and presenting my study design to them. Having never applied for any funding for 
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a clinical trial, yet being successful in obtaining both grants applied for, is proof what a steep learning 
curve this has been.  
 Following on from the successes of obtaining funding and ethical approval, we were then faced with 
a series of obstacles when attempting to set up other sites. One of the biggest obstacles here, was the 
change in the diagnostic pathway of patients with suspected pleural malignancy. At the inception of 
the study idea, most patients had repeated percutaneously guided biopsies to confirm pleural 
malignancy. With the adoption of regional mesothelioma multi-disciplinary team meetings and the 
presence of thoracic surgeons in a large number of these, most patients are now being offered surgery 
as the next choice of biopsy. Hence, a number of centres who originally agreed to participate could 
not take part in the trial due to a change in their diagnostic pathway. Therefore, new sites needed to 
be identified. Urgent action was taken to publicise the trial via newsletters that would reach the 
specific target audience such as the British Thoracic Society newsletter, Mesothelioma UK newsletter 
and also raising awareness of the trial with the local clinical research networks (CRNs). The annual 
pleural research update meeting was a good platform to introduce the trial and attract researchers 
who were already taking part in national pleural trials. The trial was also presented in poster form at 
2 international conferences where clinicians managing mesothelioma would congregate; the British 
Thoracic Oncology Group meeting and the International mesothelioma interest group meeting. 
Despite reaching a large audience, I soon realised only a small number of centres could take part due 
to variances in their diagnostic pathways. By this point I had learnt how an initial feasibility assessment 
could have saved significant time and resource down the line and act as a method of excluding some 
centres quite early on. Therefore, we started feasibility assessments for all interested sites at a very 
early stage. Since the advent of the HRA, feasibility and capabilities assessments have now become 
routine for all new sites under consideration for joining a clinical trial.  
Another challenge was that the PET-CT scan, which is the crucial investigation under scrutiny here, 
was not funded as a research cost. PET-CT scans are expensive and considering this as an excess 
treatment cost meant the sites having to pay for the scans themselves. The financial implications of 
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this was cited as a reason by several sites not taking part. This is an important lesson I will bear in mind 
when designing and costing future research trials.  
Having successfully enrolled 10 sites for recruitment we then faced the challenge of slow recruitment 
or non-recruitment from some sites. We expected the target population to be niche and recruitment 
was expected to be slow, however recruitment numbers were much lower than we had anticipated. 
As mentioned previously several, remedial measures were taken after discussion in the TSC meetings. 
Careful thought was needed to ensure the quality of the trial was not compromised when remedial 
measures were taken; for example, relaxing the recruitment criteria such as length of time since 
previous biopsy. Even with the measures undertaken, it was clear we were not going to reach our 
target within the previously specified time frame of 2 years of recruitment. A time extension was 
therefore sought and granted by the funder. Simultaneous measures to boost recruitment included 
regular contact with investigators to ensure the trial remained on the forefront of the investigators’ 
minds, ensuring no potential patients were missed. Regular contact included quarterly Target Trial 
newsletters, frequent reminder emails and over the phone discussion with PIs at centres that were 
particularly slow to recruit.  
From applying for funding to setting up and conducting the trial, this trial has taught me some valuable 
lessons which will undoubtedly help me in the future when designing and conducting clinical trials. 
TARGET is attempting to answer an important clinical question regarding the role of PET-CT in this 
cohort of difficult to diagnose pleural malignancies. The role of PET-CT in suspected pleural malignancy 
is poorly studied with mixed results. In addition to directly assessing the pleural characteristics, other 
benefits will also be explored, such as the overall value of PET-CT in identifying distant metastases 
which may have an impact on the management of patients and identifying alternative sites for biopsy.       
Analysis of FDG uptake indices on PET-CT such as TGV and SUV may provide further information to 
negate the suspicion of pleural malignancy in certain cases, thereby preventing patients from 
undergoing unnecessary investigation. Furthermore, identification of distant metastases would 
98 
 
provide prognostic information and suitability for certain treatment options. These are some of the 
secondary benefits of PET-CT scans we would explore as a part of the trial.  
Finally, the biomarker serum mesothelin in this cohort may be diagnostically useful in some of the 
patients in conjunction with the biopsy ± cytology result. Change in Mesothelin levels over the follow 
up period may also be of benefit to the treating physician with their further management of the 





The TARGET protocol is published in the BMJ Open Respiratory Research electronic journal.  
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CHAPTER 5       ZOLEDRONIC ACID IN THE MANAGEMENT OF 




The poor survival associated with a diagnosis of MPM, even with active treatment was discussed 
earlier in the introduction chapter. Phase I to III clinical trials investigating chemotherapy, 
immunotherapy and surgery are actively recruiting patients in a bid to discover treatment options 
with better outcomes in MPM [98, 151]. The projected peak of mesothelioma is between 2015 and 
2025 [50], and although the Western world is likely to see a decline in the incidence after the next 
decade, this may not be the case in other parts of the world.  
Drug repurposing is  a very relevant research area in MPM [152]. ‘Drug repurposing’ refers to finding 
new indications for approved drugs and is ideal for a disease like MPM, which is rarer than other 
thoracic malignancies, therefore recruitment to phase I to III trials may prove challenging, in a disease 
where there is an urgent need for better treatments [153]. By the time the current phase I treatments 
are approved, the Western world that can afford these treatments may be seeing a decline in the 
incidence. Although the disease will continue to rise in developing countries, the novel treatments 
more than likely would be beyond their reach due to cost implications. Several well-known drugs for 
non-malignant indications have been studied for their potential anti-cancer activity in MPM; 
Valproate, thalidomide and zoledronic acid to name a few [152].     
Zoledronic acid in Mesothelioma 
 
Bisphosphonates are synthetic analogues of naturally occurring pyrophosphate [113]. 
Bisphosphonates are commonly used in the treatment of osteoporosis and other bone disorders such 
as Paget’s disease, due to their action on inhibiting osteoclast mediated bone resorption [154]. 
Nitrogen containing bisphosphonates (n-bisphosphonates) have been shown to inhibit various 
epithelial cancer cells in vitro, by inhibiting the mevalonate pathway [155]. Potential anti-tumour 
activity of bisphosphonates includes reduced tumour angiogenesis, reduced tumour cell proliferation, 
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migration, invasion and adhesion, increased tumour cell apoptosis and increased cytotoxicity of 
gamma-delta T cells, which subsequently lead to reduced tumour vascularization[112, 156]. 
Studies using n-bisphosphonates, particularly Zoledronic acid (ZA) have shown a survival benefit in 
patients with breast cancer [157, 158]. In vivo studies on mice inoculated with mesothelioma cells, 
treated with bisphosphonates have shown a significant survival advantage [114], supporting the direct 
anti-cancer properties of bisphosphonates in MPM. Similar results were seen in other in vivo studies 
of murine models inoculated with small cell and non-small cell lung cancer, both showing a reduction 
in tumour burden and increased survival in mice treated with n-bisphosphonates [159, 160] 
Zoledronic acid (ZA) is a potent nitrogen containing bisphosphonate which has bone independent anti-
tumour activity [155]. In addition, when combined with certain chemotherapy agents such as 
Paclitaxel, Etoposide, Cisplatin and Irinotecan in lung cancers, it has an even greater synergistic effect 
in induction of apoptosis in vitro [159]. 
The role of ZA in MPM is unclear. Anecdotal accounts of ZA given for MPM have been described in the 
literature without any clinical trial evidence to substantiate its effect [161].  A study by Jamil et al[115] 
recently investigated the role of single agent ZA in a small cohort of patients with advanced MPM, 
who had either completed chemotherapy or were too frail to receive chemotherapy. They 
demonstrated some benefit with ZA, where there was a 37.5% rate of clinical benefit (progression free 
survival + stable disease). Clive et al from our research group conducted a proof of principle RCT 
investigating the role of ZA in malignant pleural effusions (MPE) [162]. Although, they were unable to 
demonstrate any clinical or radiological significance in their MPE cohort treated with ZA, 2 patients 
with MPM who received ZA showed a reduction in tumour bulk on radiology [162].  
When used in isolation in advanced MPM there was no improvement in overall survival [115]. There 
are no human studies investigating the synergistic effect between ZA and chemotherapy. A double 
blind multi-centre RCT would be best placed to investigate the hypothesis that treatment with the n-
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bisphosphonate ZA, in addition to the standard chemotherapy (pemetrexed and cisplatin) confers a 
survival benefit to patients with MPM compared to chemotherapy alone. We designed a feasibility 
study to capture the data needed to inform a definitive phase III trial. In the Zol-A trial we aimed to 
randomise 50 patients to receive either ZA or placebo alongside chemotherapy, over a 12-month 
period across 3 centres.  
A qualitative sub-study was designed to help understand patient experience and acceptability of trial 
related procedures and explore reasons behind their decisions to accept/decline chemotherapy or 
participating in a trial.  
5.2 Obtaining funding for the trial 
 
With the above study design in mind, I applied for funding via a mesothelioma themed NIHR Research 
for Patient Benefit (RfPB) funding stream in January 2015 (condensed version of the grant application 
can be found in Appendix III). During the grant application development, I worked closely with the 
Research Design Service (RDS) and the local Research and Innovation (R&I) teams. As before with the 
TARGET trial, I met with a mesothelioma focus group, comprising mesothelioma patients and carers, 
to discuss the study and ask for their opinion on the study design and trial related procedures. This 
meeting was very helpful in that they identified a weakness which led to a change in the study design. 
They made a pragmatic argument that, if patients did not want to receive chemotherapy, but were 
keen to consider the trial treatment this was not an option in our study design. Audit data from North 
Bristol has since been published showing up to 40% of patients who are fit and eligible for 
chemotherapy may decline chemotherapy [163]. This was an important group of patients that we had 
not taken into consideration prior to the focus group meeting. As a result, we altered the study design 
to include an open-label ZA arm for those who were eligible but declined chemotherapy but were 
keen to consider open-label ZA.  
I was successful in obtaining the NIHR RfPB grant for the value of £ 287, 465.  
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5.3 Ethics approval and opening of sites 
 
In the capacity of the trial manager I developed the trial related documents such as the trial protocol, 
patient information leaflet (PIL), consent forms and case record forms (CRFs). The trial was then 
presented to the East of England, Cambridge East Research Ethics Committee (REC). Following minor 
amendments, we were granted a favourable opinion on the 04/05/2016 (ref: 16/EE/0105). As a clinical 
trial of an investigational medical product (CTIMP), regulatory authority for administering ZA in 
mesothelioma was sought through the medicines and healthcare products regulatory agency (MHRA). 
As a multicentre RCT sponsored by the National Health Service (NHS), the study was registered with 
the Health Research Authority (HRA) prior to setting up other sites. The first trial steering committee 
meeting was held on the 10/05/2016.  
As we stipulated a definitive recruitment period of 12 months to achieve our feasibility outcomes, we 
were keen to open the 3 recruiting sites, North Bristol NHS Trust (NBT), Bristol Royal Infirmary (BRI) 
and Royal United Hospital (RUH) Bath, simultaneously. With the involvement of different departments 
such as pharmacy, oncology and radiology there were delays and hurdles, prior to finally opening the 
trial across the 3 sites on 04/10/2016.   
The trial was registered with ISRCTN, trial registration number 45536692 and was sponsored by North 
Bristol NHS Trust (R&I ref: 3638). The trial was also registered with the European Union Drug 
Regulations Authorities clinical trials (EudraCT ref: 2015-004433-26) database.  
 
5.4 Methods: 
5.4.1 Feasibility outcomes: 
 
Our primary feasibility outcome was to randomise 50 patients over a 12-month period, however the 
trial was extended by 1 month (discussed later in this chapter) therefore extending the recruitment 
period to 13 months. In addition, we had a number of secondary feasibility outcomes largely exploring 
the acceptability of trial related procedures as stated below: 
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• Acceptability of recruitment procedures, consent and randomisation, and data collection 
methods. 
• Acceptability of ZA in MPM patients, and the optimal timing and location for ZA 
administration. 
• Qualitative assessment (QA) in a subgroup of up to 10 patients (from both the randomised 
and non-randomised groups) to evaluate patients experience in the randomisation and 
recruitment process. Qualitative analysis of the group of patients who declined participation 
in the trial.  
• Quantification of drop-out and data completeness rates 
• Estimates of outcome event rates e.g. survival times, measures of mean response and 
outcome variance (continuous variables such as quality of life) and confidence intervals 
around estimates of proportions, categorical variables such as recruitment rates) to use for 
calculating full trial size and number of sites.  
 
5.4.2 Participant identification  
 
Potential participants were identified by the principal investigators (PI) across the three sites, primarily 
from the local lung cancer/mesothelioma multi-disciplinary team (MDT) meetings. In addition, the 
regional mesothelioma MDT meeting is held at the lead centre NBT and is led by the chief investigator 
for the study, Professor Nick Maskell. All new cases of MPM from across the region (including the 
three hospitals taking part in the trial) are discussed at this meeting. Patients who met the eligibility 
criteria for Zol-A were identified as potential participants, and the relevant PIs were informed. 
5.4.3 Pre-screening, screening and recruitment  
 
All patients with a new diagnosis of mesothelioma between 04/10/2016 and 04/11/2017 were pre-
screened for the trial. Eligible patients were approached for a discussion about the trial and if 
interested were invited to take part in the trial, after reading the PIL. The trial was discussed again 
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when they returned to consult the specialist mesothelioma nurses, prior to seeing the oncology 
specialists. If patients were agreeable to taking part in the trial, they were invited to consent at this 
point.  
5.4.4 Eligibility criteria 
 
Inclusion criteria  
If the participants met all the following criteria, they were eligible for the study: 
• Histo-cytologically confirmed diagnosis of MPM  
• World Health Organisation (WHO) performance status (PS) 0-1  
• Eligible for first line chemotherapy  
• Ability to give informed consent 
 
Exclusion criteria 
If the participants met any of the criteria below, they were not eligible for the study: 
• Not fit for chemotherapy due to PS or other comorbidities,  
• Previous chemotherapy for MPM  
• IV bisphosphonate therapy in the preceding 3 months 
• Significant renal disease defined as an eGFR < 30ml/min within the preceding 4 weeks  
• Current hypocalcaemia receiving treatment or evidence of hypocalcaemia within the 
preceding 6 weeks   
• Age < 18 years  
• Severe untreated dental caries  
• Concomitant participation in another drug trial for MPM  
• Allergy to 18-fluorodeoxyglucose used for PET scans  
• Women of child bearing potential (defined as fertile or following menarche and until 
becoming post-menopausal unless permanently sterilised). 
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5.4.5 Randomisation and blinding procedures: 
 
Patients were allocated on a 1:1 basis to either the intervention (ZA) or placebo. Allocation was 
blocked using varying block sizes and stratified according to histological subtype (epithelioid or 
cytological versus non-epithelioid) using web-based software provided by Sealed Envelope Ltd.  
Participants and investigators were blinded to the treatment received. The ZA or placebo was provided 
in identically matched 100ml 0.9% saline bags by pharmacy. The infusion bag contained the participant 
trial ID and randomisation kit number. The allocation of treatment pertaining to the relevant 
randomisation kit number remained within the pharmacies preparing the IMP/placebo.   
5.5 Trial interventions 
5.5.1 Baseline assessment  
 
A baseline assessment at the point of recruitment captured demographic data, medical history, 
current treatment, and investigations undergone for the diagnosis of MPM. Baseline blood tests 
performed at this visit included a full blood count (FBC), electrolyte levels (including adjusted Calcium 
level, Magnesium and Phosphate), liver function tests and C reactive protein (CRP) level. A research 
specific blood test, serum Mesothelin was also checked at the baseline assessment.  Those receiving 
ZA/placebo alongside chemotherapy were then randomised.   
All participants were started on calcium supplementation if they were not already on them, to prevent 
hypocalcaemia whilst undergoing treatment.   
5.5.2 Scans 
 
The initial CT scan at presentation, which was used for establishing the diagnosis was used as the 
baseline scan. A baseline PET-CT scan was performed following recruitment and prior to receiving their 
first cycle of ZA/placebo. A further CT and PET-CT scan was performed after 3 cycles of treatment 
(Figure 5-1). A final CT scan was performed at 6 months from enrolment. CT scans were performed as 
standard chest and abdomen scans at patient’s local hospital. All PET-CT scans for patients taking part 
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in the trial were performed at the Cobalt Imaging Centre in Cheltenham using a standardised imaging 
protocol.   
5.5.3 Follow-up assessments 
 
All participants had follow-up appointments 2-3 weeks after their previous cycle of treatment. For 
patients in the randomised arm this often coincided with their pre-chemotherapy oncology 
assessment visits. Data on any adverse effects and new symptoms were captured at these follow-up 
appointments. If the blood tests identified any electrolyte disturbances, additional supplementation 
was prescribed as necessary.  





Figure 5-1: Trial flowchart for patients receiving treatment in the Zol-A trial (Randomised patients in the blue arm non-





5.5.4 Mesothelin tests 
 
Patients had a serum mesothelin at baseline and every follow-up visit. A final mesothelin test was 
performed at the 6-month follow-up visit. All mesothelin samples were analysed using the commercial 
MesomarkTM ELISA (Fujirebio) according to the manufacturer’s recommended methods for sample 
processing (sample processing is discussed in detail in Chapter 6 section 6.2.2). 
5.5.5 IMP/placebo schedule and administration  
 
Patients in both the randomised and non-randomised arms received up to a maximum of 6 cycles of 
ZA/placebo, at 3 weekly intervals. (Figure 5-1)  
Zoledronic acid was given in 100ml of 0.9% saline over a 15-minute period. The exact dose of the ZA 











Table 5-1: Dose of Zoledronic acid according to renal function. (eGFR: estimated glomerular 
filtration rate; ZA – zoledronic acid; mg – milligrams; ml – millilitres; min - minute) 
 
5.5.6 Semi structured interviews 
 
As a feasibility study potentially paving the way to a larger phase III trial we were keen to explore 
patients’ decisions behind their chosen treatment option, acceptability of trial related procedures and 
their overall experience of participating in the Zol-A trial. Therefore, we designed a qualitative 
component to this study centred around semi-structured interviews for up to 10 patients. 
A purposive maximum variation sample of 7 patients took part in the semi-structured interviews. 
Patients who had varied experiences in the study were purposely sought and approached in order to 
obtain a wealth of different information from patients’ perspective. The decisions on who to approach 
were decided upon informal feedback received from both NBT and RUH patients.  
Renal Function Dose of ZA (mg) 
eGFR  60 ml/min 4.0 
eGFR 50-59 ml/min 3.5 
eGFR 40-49 ml/min 3.3 
eGFR 30-39 ml/min 3.0 
eGFR < 30ml/min 0.0 
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Patients were approached at their end-of-treatment follow-up appointment. If they were interested, 
a PIL relating specifically to the qualitative sub-study was given. This was followed up with a telephone 
call to ascertain interest in participating. If interested, an appointment was scheduled for the interview 
either at their home or at the Clinical Research Centre (CRC) at NBT. All patients were interviewed by 
Mrs Anna Morley (registered nurse), who has experience and an interest in qualitative research.  
The interviews were structured across a number of themes relating to the diagnosis of MPM, and 
patients’ participation in the trial. The full list of themes is available in Appendix IV.      
A total of 7 interviews took place between 26th of April 2017 and 24th of May 2018. Six of the 
interviewed patients were randomised whilst one patient was in the open label arm. Three interviews 
took place at patient’s own homes and 4 interviews took place in the CRC at NBT. The interviews 
ranged from 27 minutes to 42 minutes. All interviews were recorded and subsequently transcribed 
verbatim by me and checked by the interviewer (AM). The transcriptions were analysed by me using 
a semantic and deductive thematic analysis.      
5.6   Radiology reporting 
 
5.6.1 CT scan reporting   
 
CT scans at baseline, post 3-cycles of treatment and at 6 months from randomisation were analysed 
in conjunction by 2 radiologists with expertise in thoracic radiology and pleural disease. The baseline 
scan was reported as per the International Association for the Study of Lung Cancer (IASLC) 
mesothelioma staging project’s 8th edition of the Tumour Node Metastases (TNM) classification 
system for MPM [19]. All scans were also reported using the recently updated mRECIST version 1.1 
guidelines to assess tumour response after 3 cycles of treatment and at 6 months [164]. As per the 
most recent literature, the minimum measurable tumour thickness was taken as 7mm, with pleural 
thickening measuring < 7mm classified as non-measurable disease [164, 165]. To calculate an mRECIST 
score the pleural tumour (if >7mm) is measured on 2 regions at 3 separate anatomical levels on the 
CT scan. The sum of the 6 measurements gives a final mRECIST score for each tumour. In addition, if 
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lymph nodes measuring > 15mm on short axis were present, these were also included in the final sum. 
(A detailed diagrammatic explanation of mRECIST calculation is shown in the Chapter 6 section 6.2.1)    
Using mRECIST tumour response is classified into 4 categories. Complete response (CR) denotes 
disappearance of all pleural and non-pleural disease. A partial response (PR) is when the summed 
measurement is reduced by at least 30% from the baseline scan. A sustained response on 2 scans 4 
weeks apart is required for confirmation of above. Progressive disease (PD) is when the summed 
measurement is increased by > 20% or if any new pleural or extra-pleural lesions are detected. To 
classify as stable disease (SD), the summed measurements should not meet criteria as PR or PD, as 
described above [164].    
5.6.2 PET-CT scan reporting 
 
Two nuclear medicine experts independently reported the PET-CT scan SUV parameters for the 
baseline and post cycle-3 PET-CT scans. For reporting purposes, three anatomical levels were defined 
on the thorax as upper – above the arch of the aorta; middle – between the arch of the aorta and the 
carina; lower - below the level of the carina. A 15mm spherical region of interest (ROI) was drawn in 
the most intense area of FDG activity within each of these anatomical regions. SUV values were 
generated for each ROI using commercially available software, Syngo.via (Molecular Imaging, Siemens 
Healthcare). The average of the readings from the 2 reporters were used for subsequent analyses.      
Using previously published data on tumour response grading for PET-CT criteria [121], a complete 
metabolic response (CMR) is defined as a complete resolution of FDG SUV uptake in tumour volume 
so that it is indistinguishable from surrounding tissue. A partial metabolic response (PMR) is when 
there is a > 25% reduction in FDG SUV after 1 treatment cycle, whereas progressive metabolic disease 
(PMD) is when there is an increase of > 25% FDG SUV uptake compared to baseline scan. Stable 
metabolic disease (SMD) is when the increase in the FDG SUV uptake is < 25% or the reduction of 




5.7 Analysis plan  
 
The statistical analysis is as per the feasibility objectives detailed above. The information obtained 
from this study would hopefully allow us to calculate numbers needed to treat in a full phase III trial. 
Assuming a 40% response rate for chemotherapy alone, the difference in the number of patients with 
a disease response between the IMP group and the placebo group will be used to calculate the sample 
size for the full trial. The quantifiable feasibility outcome such as screening and recruitment 
information, treatment up take, drop-out rates and radiology findings are reported here with. Inter-
observer agreement for PET-CT reporting was tested using the kappa coefficient. The Mann-Whitney-
U test was used for comparison of non-parametric data. Simple linear regression was used to examine 
the relationship between normally distributed variables. The full statistical analysis plan designed with 
the help of Bristol Clinical Trials and Evaluation Unit (CTEU) can be found in Appendix V.   
A framework analysis which consisted of several stages of familiarization of the data (including 
transcribing the recorded interviews), theme recognition, coding and finally interpretation of the data 
was used for the qualitative analysis. Interpretation of the data was planned along deductive theme 
however due to unexpected emergence of certain themes, a combination of deductive and semantic 
analyses were used.     
5.8 Safety reporting 
 
Standard definitions and clinical judgement was used when reporting any adverse events (AE) relating 
to the trial. Given the nature of the disease and the chemotherapy treatment patients were receiving 
certain adverse reactions were to be expected as detailed below.  
Expected adverse events relating to zoledronic acid  
- Poor appetite 
- Sore eyes 
- Redness and soreness around drip site 




Expected adverse events relating to chemotherapy  
- Flu-like symptoms 
- Tiredness/lethargy  
- Nausea and vomiting 
- Gastrointestinal upset (diarrhoea) 
- Skin reaction 
- Peripheral neuropathy 
- Pancytopaenia 
- Neutropaenic sepsis 
- Low Folate levels 
   
Expected SAEs relating to ZA and chemotherapy    
- Electrolyte disturbances requiring hospital admission for replacement of electrolytes 
- Neutropaenic sepsis requiring hospital admission 
5.9 Data collection: 
 
All patients who were approached about the trial and given a PIL, were captured on a screening log. 
Consent, baseline information and blood results were recorded on the specific worksheets and 
subsequently entered onto an electronic database, locally at the relevant sites. At each pre-
chemotherapy visit the patients had an assessment covering any AEs/SAEs secondary to treatment 
and had repeat blood tests. The results of these and a quality of life measure was documented in the 
specific worksheets and subsequently entered on to the database.  All CT and PET-CT scans were 
imported to the local centre for assessment.  
The trial team involved with conducting the trial at the lead centre and the statistician will have access 
to the final trial dataset once the database has been locked down.  
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5.10 Trial management: 
 
A trial steering committee (TSC) comprising of the key members of the trial and a patient 
representative met before the start of the trial and twice since at regular intervals. An independent 
data monitoring committee met at the start of the trial. After 10 patients were randomised they 






The results reported in this chapter were prior to unblinding the patients as we were unable to lock 
the database due to ongoing data cleaning and awaiting finalising of the statistical analysis plan. 
Despite not unblinding we have been able to report on most of the feasibility outcomes as discussed 
below.   
5.11.1 Screening and recruitment  
 
Between October 2016 and November 2017, 47 patients were screened across the 3 sites and 22 
patients were recruited. Fifteen of the recruited patients were randomised while 7 were enrolled into 
the open label arm of the study. Figure 5-2 is a CONSORT diagram with recruitment and follow-up data 
for the Zol-A trial.  Table 5-3 summarises the screening data by centre.  
Of the 15 potential participants who did not meet the eligibility criteria 13 patients failed based on 
their WHO performance status. Two patients were ineligible due to only having a clinico radiological 
diagnosis of MPM rather than a histo-cytological diagnosis.  
Of the other 10 patients who did not take part in the trial, 3 patients declined chemotherapy and 
hence failed inclusion into the randomised arm of the trial. Three patients declined to participate in 
the trial without giving a reason, while 1 patient declined the trial on the basis the trial schedule was 
too demanding for them. Two patients fell just outside the trial treatment period and 1 patient 
delayed their chemotherapy and hence fell outside the trial recruitment period.  
Patient demographics and baseline characteristics for the recruited patients are shown in Table 5-4, 





Assessed for eligibility 
 
(n = 47)  
Figure 5-3: Consort diagram of 
Recruited to trial  
(n = 22)  
Randomised (n = 15) Open label arm (n = 7)   
Follow-up data available 
(n = 11)     
Withdrawn (n = 1)  
Follow-up data available 
(n = 3)  
Excluded (n= 25) 
-Ineligible (n= 15) 
-Declined chemotherapy (n= 3) 
-Not interested in trial (n=4) 
-Other (n = 3) 
 
Completed 6 cycles of 
treatment (n = 6) 
Completed 6 cycles (n = 3) 
Post cycle-3 scans  
CT (n = 14) 
PET-CT (n = 13) 
Post cycle-3 scans 
CT (n = 5) 
PET-CT (n = 4)   
Analysed  
(n = 15) 
Analysed  
(n = 6) 
Table 5-2: Consort diagram of patient recruitment in the Zol-A trial Figure 5-2: ONSORT diagram of patient recruitment in the Zol-A trial 
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Site Screened EXCLUDED FROM STUDY Recruited 
(% of screened 
patients) 
Randomised 
(% of screened 
patients) Ineligible Declined 
chemotherapy and 
trial 
Not interested in trial 
(had chemotherapy) 
Other 
NBT 31 9 1 2 3 16 (52%) 9 (29%) 
RUH 13 6 2 2 0 3 (23%) 3 (23%) 
UHB 3 0 0 0 0 3 (100%) 3 (100%) 
Table 5-3: Screening, recruitment and randomisation by centre
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Age (years ± SD) 72.2 (±5.6) 82.3 (±5.2) 
Sex (M:F) 14:1 6:1 
BMI 25.1 (± 2.8) 22.8 (±2.4) 


















































PET-CT parameters    
Upper SUV max (median; IQR) 
Mid SUV max (median; IQR)  
Lower SUV max (median; IQR) 
6.1 (4.3 – 12.3) 
6.1 (4.6 – 10.3) 
6.0 (5.2 – 9.7) 
6.6 (5.8 – 11) 
10.9 (6.7 – 11.5) 
10.2 (5.8 – 11.2) 
Blood markers   







140 (127 – 148) 
 
4.64 (3.57 – 7.78) 
 
2.4 (2.32 – 2.46) 
 
38 (9 – 80) 
130 (121 – 132) 
 
6.26 (2.97 – 10.41) 
 
2.46 (2.41 – 2.48) 
 
33 (9.2 – 49) 
   
Mesothelin level 5.7 (1.9 – 8.3) 4.7 (2.6 – 6.3) 
   
Baseline EQ5D VAS score  80 (75 – 89) 70 (40 – 75) 
   
Number of treatment cycles received (median; 
IQR) 
5 (4 – 6) 5.5 (3 - 6) 
Table 5-4: Baseline characteristics, blood results and radiology findings. (BMI – body mass index; SD – 
standard deviation; SUV – standard uptake value; IQR – interquartile range; NLR – neutrophil lymphocyte ratio; 




The mean age of the randomised participants was 72.2 (±5.6) years. A majority, 20/22 (91%) of the 
patients were male. Epithelioid was the predominant histological subtype with 72% and 73% in the 
randomised versus open label groups respectively. Overall, when taking into consideration age, stage 
of disease, WHO performance status and PET parameters, the patients in the open label cohort were 
older with more advanced disease. However, as the purpose of this group was not for direct 
comparison with the randomised group, inter group comparisons were not performed.    
5.11.2 Treatment uptake and adherence  
 
In the randomised cohort 7/15 (47%) patients received the total complement of 6 or 4 cycles of 
chemotherapy + ZA/placebo treatment. Four (27%) patients stopped treatment after 5 cycles of 
treatment; 3 due to drug side effects and 1 due to general deterioration in health condition. One (7%) 
patients stopped after 4 cycles of treatment due to side effects of chemotherapy. Of the remaining 3 
patients 1 stopped after 3 cycles due to progression of disease; 1 after 2 cycles due to general 
deterioration in overall health and 1 after 1 cycle due to treatment side effects (severe toxicity from 
chemotherapy). Trial treatment/placebo was given or stopped in conjunction with chemotherapy, no 
patients stopped one treatment or the other separately. 
Of the 7 patients in the open label group 3 (43%) patients completed 6 cycles of open label ZA. Of the 
other 4 patients, 1 patient stopped after 5 cycles of treatment, by choice; 1 patient stopped after 3 
cycles due to progression of disease; 1 stopped after 2 cycles due to general deterioration in health 
and 1 patients was withdrawn by the principal investigator after 2 cycles of treatment due to 
significant deterioration in health.  
5.11.3 Drop out and data completeness rates 
 
Of the 22 patients 3 patients were lost to follow-up and one patient withdrew. Three patients died 
prior to their 6-month follow-up appointment.   
Although a number of patients (53%) did not complete the full 4 or 6 cycles of treatment they were 
not classed as ‘drop outs’ from the trial. Their treatment was stopped early, either by patient or 
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investigative team due to reasons mentioned above. These patients continued to participate in the 
trial and went on to have the necessary trial related scans and follow-up. 
5.11.4 Withdrawals 
 
One patient in the open label arm was withdrawn from the trial as per the principal investigators 
decision. Patient’s general health deteriorated significantly making attendance to hospital too 
cumbersome. Therefore, a decision was made to withdraw this patient.  
No patients withdrew from the randomised arm.  
5.11.5 Protocol deviations 
 
Two protocol deviations were reported for 2 patients in the randomised arm of the trial. One patient 
was given open label ZA from stock by a staff nurse at the chemotherapy suite in error, unaware that 
the patient was in the Zol-A trial. This was despite a specific trial prescription being available for Zol-
A/placebo as per randomisation. The second deviation was a failure to record clinical observations 
post administration of the Zol-A/placebo infusion.   
5.11.6 Outcome events 
 
We did not feel the trial follow-up of 6 months was sufficiently long to collect survival data on overall 
survival or progression free survival. Therefore, survival was not included in our feasibility outcomes. 
Quantifiable outcome data on radiology such as mRECIST scores and changes in PET parameters were 
collected instead. The individual CT and PET-CT data is shown in Table 5-5 for the open label group 
and Table 5-6 for the randomised patients. Figure 5-3 shows the pre and post PET images for RUH405. 
There was good inter-observer agreement for overall response using PET-CT SUV values with a kappa 

























NBT003 1A 0 0 0 SD 0 0 SD 15.4 15.3 -0.7 SMD 
NBT004 1A 0 0 0 SD 35 High PD 25.8 34.4 33.1 PMD 
NBT006 3B 53 74 39.4 PD 136 156.6 PD 35.3 21.7 -38.4 PMR 
NBT012 1A 20 CT not 
done 
0 NA CT not done  NA NA 38.1 Not done NA NA 
NBT014 1A 0 CT not 
done 
0 NA CT not done NA NA 15.5 Not done NA NA 
NBT016 3B 56 103 83.9 PD CT not done NA NA 25.7 33.8 31.3 SMD 
NBT029 1A 0 64 High PD CT not done NA NA 28.2 Not done NA NA 
Table 5-5: Radiology outcomes for the open label patients. (CT - computed tomography; mRECIST - modified response criteria in solid tumours; SD - stable disease; PR - 








































NBT005 1B 60 7 -88.3 PR 0 -100 CR 16.1 4.8 -69.8 PMR 
NBT015 2 0 92 High PD 16 High SD 7.2 6.3 -12.5 SMD 
NBT021 3B 106 111 4.7 PD 67 -36.8 PR 44.2 28.3 -35.9 PMR 
NBT022 1A 0 0 0 SD 0 0 SD 17.1 7.4 -56.9 PMR 
NBT023 4 72 0 -100 CR 0 -100 CR 19.4 7.5 -61.4 PMR 
NBT024 3B 94 95 1.06 SD 90 -4.3 SD 22.1 21.7 -1.8 SMD 
NBT025 1A 0 24 High PD 50 High PD 20.0 15.3 -23.3 SMD 
NBT026 1A 0 51 High PD 61 High PD 25.0 12.5 -49.9 PMR 
NBT030 1B 13 15 15.4 SD 32 146.1 PD 19.5 13.8 -29.2 PMR 
RUH405 2 83 0 -100 CR 0 -100 CR 42.8 10.8 -74.9 PMR 
RUH410 4 117 38 -67.5 PR 88 -24.8 PD 20.7 13.9 -32.6 PMR 
RUH413 1A 0 76 High PD CT not done NA NA 34.1 Not done NA NA 
UHB201 2 21 0 -100 CR CT not done NA NA 9.9 Not done NA NA 
UHB202 0 0 67 0 PD 119 High PD 15.1 16.4 8.6 SMD 
UHB203 1B 0 CT not 
done 
NA NA CT not done NA NA 19.0 16.6 -12.6 SMD 
Table 5-6: Radiology outcomes for the randomised patients (CT - computed tomography; mRECIST - modified response criteria in solid tumours; SD - stable disease; PR - 






Figure 5-4: Pre and post-3 cycles of treatment PET-CT scans for RUH405 in the randomised arm of the trial. Images A and 
B showing high uptake on PET scan with the entire pleura displaying avid FDG uptake (bright yellow area on image A and 















The median baseline mesothelin value across the entire cohort was 5.2 (IQR: 2.1 – 6.7) nmol/L. 
Excluding the 1 patient with histological subtype Mesothelioma NOS, patients with epithelioid 
histology had a median baseline mesothelin of 6.05 (IQR: 2.4 – 7.5) nmol/L, while for non-epithelioid 
patients it was 2.1 (1.3 – 4.3) nmol/L, a significant difference between the 2 groups (p<0.05).  
Mesothelin levels after 3 cycles of treatment and CT data for the same time point were available for 
comparison for 14 patients. Percentage change in mesothelin tracked CT response fairly accurately 




Radiological response Median percentage change in mesothelin 
compared to baseline 
Complete Response (n=2) 82 % reduction (SD± 13%) 
Partial Response (n=2) 63 % reduction (SD± 6%) 
Stable Disease (n=5) 23% reduction (SD ± 33%) 
Progressive Disease (n=5) 21% Increase (SD ± 88%) 
Table 5-7: Mesothelin performance against CT findings 
 
The waterfall plot in Figure 5-5 shows the percentage change in mesothelin for individual patients at 
3 cycles post-treatment. The colours of the bars depict the response shown on CT as per mRECIST 




Figure 5-5: Percentage change in mesothelin after 3 cycles of treatment for patients in the randomised group. The colour of the bar shows their response on CT as per mRECIST. Table at the bottom shows 




5.11.8 Safety data 
 
One hundred and nineteen adverse events (AEs) were reported for the duration of the trial. 31/119 
(26%) were expected AEs as stipulated in the protocol. See table 5-8. Eighty-eight other adverse events 
were reported ranging from constipation to breathlessness.  
Averse Event  Frequency (%) 
  
Flu-like symptoms 2 (1.68) 
Nausea 7 (5.88) 
Poor appetite 3 (2.52) 
Vomiting 4 (3.36) 
Gastro-intestinal upset (diarrhoea) 1 (0.84) 
Tiredness 8 (6.72) 
Skin Reaction 4 (3.36) 











Table 5-8: Adverse events reported and the reported frequency  
 
Sixteen SAEs were reported for 11 of the patients (Table 5-9). Only 1 of these SAEs were considered 
to be ‘possibly related’ to the trial drug. Twelve out of the 16 SAEs were due to hospital admission or 
prolongation mainly due to side effects of chemotherapy or progression of MPM. None of these were 
thought to be related to the trial drug. 
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Patient ID  Serious adverse event  Reason Relatedness 
NBT012 Required Hospitalisation / Prolongation General deterioration Not related 
NBT014 Required Hospitalisation / Prolongation Lower respiratory tract requiring IV antibiotics Not related 
NBT014 Resulted in Death Progression of mesothelioma Not related  
NBT015 Required Hospitalisation / Prolongation Collapse – pulmonary emboli Unlikely to be related 
NBT021 Required Hospitalisation / Prolongation Diarrhoea and vomiting Unlikely to be related 
NBT022 Required Hospitalisation / Prolongation Sepsis and derange bloods  Possibly related 
NBT029 Resulted in Death Progression of mesothelioma Not related 
NBT030 Required Hospitalisation / Prolongation Increased pleural effusion Unlikely to be related 
NBT030 Required Hospitalisation / Prolongation Pneumonia Unlikely to be related 
RUH410 Required Hospitalisation / Prolongation Neutropaenic sepsis Unlikely to be related 
RUH410 Required Hospitalisation / Prolongation Lower respiratory tract infection Unlikely to be related 
RUH413 Required Hospitalisation / Prolongation Opioid toxicity Not related 
RUH413 Required Hospitalisation / Prolongation Lower respiratory tract infection Not related 
UHB201 Life-threatening Neutropaenic sepsis Not related 
UHB203 Required Hospitalisation / Prolongation Rash to Co-amoxiclav Not related 
UHB203 Life-threatening Rash to Amoxicillin Not related 
Table 5-9: Serious adverse events, reasons for reporting and relatedness to investigational medicinal product 
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5.12 Results of the qualitative sub-study 
 
The findings of the qualitative sub-study are reported along deductive themes generated by the 
questions posed to the patients and any other interesting themes that emerged which were 
considered useful.       
 
Initial thoughts on the diagnosis of mesothelioma   
All patients interviewed expressed either ‘shock’ or ‘surprise’ at the diagnosis of mesothelioma. 4/7 
patients talked about diagnostic delays and being treated for other conditions such as heart conditions 
for a number of months before a definitive diagnosis of mesothelioma was made. The opening 
question asked about the patients understanding of mesothelioma, and most patients answered the 
question by referring to the diagnostic delay. This suggests an element of anxiety/concern around the 
diagnostic delay. No direct reference was made to advanced stage of disease with delay in diagnosis, 
but a perceived late stage of disease could be one of the concerns. Two patients also voiced their 
feelings that they had never smoked in their life yet, developed a cancer associated with the lung.    
 
“Well I was quite surprised to hear the diagnosis, you know, originally…….. Considering that the GPs 
didn’t have any clue as to what it was……” [NBT015] 
“It was big shock. I’ve never been involved with anything to do with asbestos in my life and therefore 
something totally out of the blue.” [RUH410] 
 
MPM and its relatedness to asbestos  
Although most of the patients interviewed had an awareness of asbestos, and related health 
problems, their diagnosis was as a consequence of previous asbestos exposure was surprising to all of 
them. 5/7 patients were disappointed that they were exposed during previous occupations, and that 
health and safety regulations were not in place to protect them. Despite the initial disappointment of 
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the occupationally related malignancy, patients appeared to have come to terms with the cause and 
effect, seemingly accepting the diagnosis.  
“…..but asbestos has been known to cause this [mesothelioma] since early 1900s……..They have known, 
the people in charge have known this is a killer! Asbestos is a killer since the early 1900s. I mean turn 
of the century. And still used it……”[RUH410]  
 “……I was working on building sites. Back then there was no health and safety as regards to asbestos 
dust, general thing it was there. You worked around it………” [RUH405] 
  
Thoughts on a terminal disease with a lack of effective treatment  
The terminal nature of the diagnosis and the lack of curative treatment rendered them powerless and 
out of control. Taking part in the trial was seen as one way of taking control back and not letting the 
disease take over their lives.  
“……it was a shock when I first thought about it obviously. Nobody likes being told that they are that 
close to dying in the end……….” [NBT005] 
 “I mean we try to continue as if this wasn’t this mesothelioma wasn’t there to a certain extent” 
[NBT030] 
 
Symptoms and disability secondary to MPM  
There were mixed opinions about the symptom burden and associated disability. Some had a clear 
expectation that they should be more ill than they were, for a malignancy with such a poor prognosis. 
Whereas others did not want to class themselves as ill, which was almost felt as giving into the disease.  
 “we’ve gone from really doing what we want when we want, to… hang on… we can’t do that today. 
I’m not very well, I don’t feel like doing it” [NBT030] 
 
One patient discussed the pleural effusion and MPM as 2 separate entities altogether saying: 
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“The worse thing about is this, was the cancer never made me ill. The fluid, that my body made to fight 
the cancer, was what was making me ill” [RUH410]        
 
Information regarding mesothelioma 
Patients were asked about information received at the time of diagnosis. Patients were satisfied with 
information regarding diagnosis and available treatments, or lack of it. However, 5/7 admitted they 
or their spouses wanted to find more information by searching the internet. This could be driven by a 
sense of hopelessness at the lack of treatment options, wanting to be in control of their disease, 
wanting to understand more about the disease and what it entails. All patients preferred written 
information as opposed to verbal information as they thought a leaflet could be taken away to study 
at a later time, keep it as a resource they could refer back to in the future in case they forgot verbal 
information.  
“…. I generally don’t. [Names husband] used the internet and had a look at a little bit”  [RUH410] 
 “When I was first diagnosed [wife named] was on the internet all the time. Reading all about 
it”[NBT015] 
 
Thoughts about taking part and understanding of the trial  
We explored participants’ decisions behind taking part in a research trial. Altruism was the main 
reason for participation in a majority of cases. In 5 out of the 7 cases patients wanted to help find a 
treatment to cure mesothelioma. In 2 cases patients were driven more by desperation of wanting 
better treatment and the addition of another drug to the chemotherapy was perceived as a better 
option than chemotherapy in isolation. A sense of desperation for better treatments was apparent in 
all 7 interviews. A willingness to try ‘anything’ if it would help. Two of the participants were very 
grateful a trial was available for them to consider. 
“……we’ve got to try and find a cure if we could. But if nobody wants to take part in these trials, you’re 
never going to know, are you? They might strike lucky one day!” [NBT005] 
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 “….… if it didn’t help me it might help others in the future. So… it’s worth you know trying…..” [NBT015] 
“…..I saw nothing really other than a benefit of going down the trial because I had a 50% chance of 
getting something that may help me personally of…. Of…. Treating…. Or going some way towards 
treating this cancer………..” [RUH410]      
“……all I knew was I’m like a guinea pig in that respect, and whatever comes out it’ll benefit somebody 
else. And at the end of the day I have nothing to lose. So, had to be done. Amazing that……. There’s 
nothing to lose is there?” [NBT003] 
  
Other perceived benefits  
All patients felt they would have more contact and support from the research team and health care 
professionals by taking part in a trial. More contact with trial teams, research nurses and doctors were 
reassuring for the patients. 1 patient felt taking part in a trial would allow quicker access to treatment. 
Patients also felt PET scans would offer additional information and was reassured by the extra scans 
offered as a part of the trial.  
“Positive thing is having so many extra people looking after you…. Basically, if you’ve got any problems, 
you are on the end of a phone. It doesn’t matter which one of you that we spoke to, you were all 
brilliant.” [NBT015] 
 “…. it was wonderful to have all the support of the research team….”[NBT003] 
 
Receiving chemotherapy and IMP/placebo at the same time 
Chemotherapy administration usually takes a number of hours at each sitting. Addition of the trial 
drug extended this duration. We asked patients about their thoughts on receiving both chemotherapy 
and the trial drug on the same day. All randomised patients agreed it was better to have all the 
treatments in 1 sitting rather than have another day trip for the trial drug. They accepted it was a long 
day, yet one less trip to hospital if all treatments can be delivered in the same sitting.  
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“So um…. It possibly made it a little longer day but I was having a long day anyway, so I wouldn’t have 
wanted to have to go back and do it at a different day” [RUH410] 
 
Trial related scans   
All interviewed patients felt PET-CT scans to be a positive addition. The trial scans were performed at 
the Cobalt centre in Cheltenham for all participants. Patients did not find travelling to be much of an 
issue. They were happy to be offered a scan that may potentially provide the medical professionals 
with additional information than the usual clinical CT scans.  
“And then you know as it progressed further, I’m being sent to Cheltenham for the PET-CT scans, which 
we wouldn’t have had if we weren’t part of the trial” [NBT015]   
Interviewer: The extra PET scans, how did you find those? 
“Not a problem at all. It was excellent. They ordered a taxi. It was a day out.” [NBT003] 
 
Chemotherapy and trial drug/placebo administration for NBT patients 
NBT patients usually have chemotherapy at Bristol Haematology and Oncology Centre (BHOC). 
Therefore, they received the trial drug alongside chemotherapy at BHOC with each cycle. Significant 
delays were incurred which was informally fed back to us via patients, but the same issues were 
highlighted by the patients as shown below. 
 “The only problem I got or had was…. It [trial drug] not being available when I turned up like. You 
know. I was given obviously dates and times when I should be there. But sometimes I was sat there for 
2 hours coz they never had the drug” [NBT005] 
“Not with the actual drug…. But when we went to oncology sometimes the drug wasn’t ready or you 





All patients had a degree of understanding about randomisation, including the one patient who was 
not randomised. However, only 1 person had a clear understanding about the full benefits of 
randomisation in clinical trials. None of the randomised participants had strong feelings about 
whether they received ZA or placebo, but all hoped they received the trial drug. One participant was 
firm in his belief he did not receive the drug as he did not experience any of the side effects mentioned 
in the patient information leaflet. The lack of side effects was perceived as not receiving the treatment. 
All participants had a good understanding of the double-blind nature of the trial; that the investigators 
were also blinded to which treatment they were allocated to.  
 “Well really….a bit of  a lucky dip really. As they explain the placebo, you might be getting it. Never 
really talked about it sort of ……. No one was in the know as such. No one could tell me I didn’t ask” 
[RUH405]  
  “Well I’m presuming that… that…. It’s absolutely random as to whether you get the zoledronic acid 
or you get a placebo. So you don’t know which one you are getting, so you can’t make up symptoms 






Other interesting themes 
Being in control of the disease 
One of the recurring themes throughout all interviews was a need to be in control of their situation. 
Participants’ desperate need to know disease activity with treatment. A majority of patients felt having 
more scans would be reassuring. They wanted more information from the clinicians with each cycle 
of treatment. The PET-CT scans were considered a positive aspect of participating in the trial by 2 of 
the patients.   
“…….I need to know like… “is it getting better” is it not like, you know…. Have they stabilised it……?” 
“……I would’ve had a scan every time I had a chemo sessions really……” [NBT005] 
 
Progression of disease in the future 
Patients expressed wishes for more information regarding disease progression and the future after 
completion of chemotherapy. A definite uncertainty about the future and an ‘in-limbo’ feeling was 
apparent amongst all patients interviewed. This may be due to participants responding well to 
treatment which is in contrast to the information given at the time of diagnosis. There was an 
expectation of a sudden deterioration and patients had almost stopped living their life waiting for the 
end.   
“……the only worry really is… no one seems to know what will happen in the future to me…… Even 
[names consultant] says ‘no one’s had ‘you’ here before’. So we don’t know what’s going to happen. 
So that’s only problem…. How long I’m going to live….or… or what…..” [NBT005] 
 
Information sharing between clinicians and patients   
Two of the patients had strong feelings about the lack of information being communicated through to 
the patients. They believed the clinicians were aware of their prognosis but did not wish to upset them 
by discussing a poor prognosis. A definite sense of helplessness was evident in these 2 participants.  
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“…..I’m sure they [doctors] know, or they can estimate, but perhaps they are unwilling to upset you…. 
Or I don’t’ know……….” [NBT003] 
“…….perhaps there isn’t nothing else to know about it. You know. Doc… [names consultant] and all 
those people up here they don’t talk at your level anyway do they? So they are like ‘ohhh you got it” 
you got it….” [NBT005] 
Although the themes were deductive from the questions posed to the patients some unrelated 
themes did surface. Hence a semantic analysis was carried out as above to appreciate and recognise 




5.13  Discussion 
 
The Zol-A multicentre feasibility RCT is the first trial to explore recruitment, patient acceptability and 
tolerability of Zoledronic acid or placebo concurrently with first line chemotherapy, for patients with 
MPM. It is also the first study to investigate Zoledronic acid in isolation for patients with MPM, who 
are relatively fit and well, and are eligible for chemotherapy. Whilst we failed to achieve our ambitious 
primary feasibility outcome of randomising 50 patients over a 13-month period across 3 sites, we 
obtained useful data regarding the overall feasibility of a full phase III trial.  
As mentioned previously the data discussed here is blinded data. Therefore, the final results regarding 
effect sizes or sample size for a full phase III study could not be reported herein.  
We obtained good screening data from 2 of the centres participating in the study (NBT and RUH), the 
screening data from the third centre only included three randomised patients. All screening logs were 
available for review. Of the 47 patients screened, 13 were ineligible due to their WHO performance 
status, and 2 due to a clinico-radiological diagnosis only. Therefore, the primary reason for ineligibility 
was patients being frail and old, assuming the 2 patients who were unable to have biopsies were 
probably too frail for further investigation. It is also interesting to note that the open label group, 
which comprised of patients who were fit, yet declined chemo, were older (mean age 72.2 years for 
the randomised group versus 82.3 years for the open label group). Older patients maybe disinclined 
to accept the toxic side effects of chemotherapy yet would be willing to accept non-chemotherapy 
trials, if they were available [163]. In total 10/32 (31%) patients declined chemotherapy despite being 
eligible for first line treatment (7 patients in the open label group and 3 patients who declined 
chemotherapy and the trial). The response rate with first-line chemotherapy in MPM is moderate with 
only a 3-month additional survival benefit, and only 40% of patients responding to the treatment 
[109]. The trade-off between 3 months of extended survival for a potentially worse quality of life may 
deter some patients from taking up 1st line treatment. With more effective treatments this trend may 
change in the future. 
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Mesothelioma is a relatively rare thoracic malignancy and clinical trials in MPM struggle to recruit 
patients. A number of MPM treatment trials have prematurely terminated due to poor recruitment 
(NCT00597116; NCT00003508). However, patients who are fit, and likely to take-up treatment are 
keen to participate in first line clinical trials. First line treatment trials are sparse in MPM at present 
and most other treatment trials stipulate completion of first line chemotherapy as an eligibility 
criterion. Therefore, patient choices are limited, they are obliged to have a poorly effective treatment 
in order to be eligible for clinical trials further along. A trial such as Zol-A will be well placed for those 
interested in a first line clinical trial alongside chemotherapy.      
It became apparent that an eligibility criterion specifying ‘measurable’ disease according to mRECIST 
criteria (i.e. a tumour thickness>10mm) was inappropriate as some patients have early disease and 
the tumour thickness would not meet this criterion. Relaxing the eligibility criteria was considered 
when recruitment in the trial was slow to start with. Measurable disease was removed from our 
eligibility criteria at this point. The results from the CT scans do not suffer as a consequence of 
removing this criterion. In fact, 6 of the recruited patients did not have measurable disease at 
recruitment, as shown in Table 5-6. A full list of amendments since original REC approval is listed in 
table 5-10 at the end of the discussion section.       
Attrition is a common issue with MPM trials due to the rapid deterioration and death of patients. In 
the current study 3/22 (14%) patients were lost to follow-up and 3/22 (14%) patients died during the 
relatively short 6-month trial period. Two of the 3 patients who were lost to follow-up were from 
peripheral hospitals, having to travel further to receive treatment at the regional oncology 
department. This is an important factor to take into consideration when designing a future trial. 
Patients may have to travel to different sites, at times different cities, for chemotherapy treatment as 
chemotherapy administration is only at sites with oncological support. Alternative forms of trial 
follow-up such as telephone follow-up and locally performed CTs and blood tests need to be 
incorporated to reduce loss to follow-up.  The 3 deaths in the short trial period reflects the 
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unpredictability and rapidity of progression of mesothelioma, even in cases where patients were fit 
and well at the start. When designing a full trial these numbers should to be taken into consideration.  
It is unsurprising that a number of patients (8/15; 53%) stopped treatment early due to the side effects 
(27%) or lack of effectiveness (13%). Identifying those who are unlikely to respond or those with a 
poor prognosis is useful for both patients and researchers. The Brims decisions tree analysis model is 
one method of risk stratifying MPM patients, however at the time of designing this trial, the Brims 
model had not been published [166]. This model can be incorporated in future mesothelioma studies, 
so an informative discussion can be held with the patients about their prognosis and positive/negative 
impact of chemotherapy.  
Tumour response in mesothelioma is difficult to measure objectively. MPM does not grow spherically 
like other solid tumours, instead like a ‘rind’ following the contours of the pleura. Response to 
treatment may not be uniform throughout the tumour. The modified RECIST criteria allows an 
objective assessment of tumour response and to date this is the best available tool for measuring 
MPM response in clinical trials [116]. Using the most recently published mRECIST version 1.1 criteria 
for assessing tumour response, we were still unable to measure the tumour in 21/56 (38%) available 
scans in the study as the minimum tumour measurement did not meet the >7mm cut-off criteria [164]. 
But until another imaging modality or biomarker is proven better, CT will continue to be used despite 
its deficiencies. Therefore, it is reassuring to know that the patients had no concerns about the number 
of CT scans offered as a part of the trial and were happy to undergo regular scans.  
In addition to the CT scans we explored PET-CT as a more reliable alternative for tumour response in 
MPM.  At the time of writing this chapter we only had the standard uptake value (SUV) data from PET-
CT scans available for comparison, not the TGV data which can probably give a more accurate 
reflection of global tumour response. Thirteen patients had both a baseline and a mid-cycle PET-CT 
scan. Of these, 8/13 (62%) had a partial metabolic response (PMR) and 5/13 (38%) had stable 
metabolic disease (SMD). The mean reduction in the SUVmax for PMR was 51.3% (range 29.2% – 
74.9%). In the SMD group, the mean change in the SUVmax was a reduction of 8.3% (range 8.6% to - 
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23.3%). Without longer term survival or CT data it is difficult to comment on the significance of the 
large reduction in SUVmax, and the number of responders by PET-CT criteria. None of the patients in 
the randomised group had disease progression by PET-CT SUV criteria, despite 5 patients showing 
disease progression on CT by mRECIST criteria. This variability between CT and PET-CT response was 
seen across all categories of response. For example, 3 out of the 5 patients who had SMD on PET-CT 
had progressive disease by mRECIST on CT. Similarly, of the 8 patients who had a PMR on PET-CT, 2 
patients each had CR, PR, SD and PD by mRECIST criteria. It is therefore difficult to comment on the 
accuracy of the PET-CT findings without longer term survival data. The significant reduction in the FDG 
uptake can partly be explained by the tumour stunning effect that has been previously reported with 
malignant tumours receiving chemotherapy [119]. A pseudo-response effect is seen depending on 
timing of the PET-CT scan and treatment cycle. We may be in a position to explore the PET-CT 
characteristics further when the TGV data is available. The investigators were concerned about the 
PET-CT scans being an extra burden to patients, particularly with the extra travel to Cheltenham. 
Contrary to the investigators concerns, patients felt the extra-scans were reassuring as they may 
provide additional information that may not be available on routine standard care (CT scans).     
Mesothelin is a less invasive method of monitoring response in MPM and probably the most reliable 
biomarker investigated in MPM for this purpose [93]. In this study we monitored levels of mesothelin 
in parallel with each cycle of chemotherapy. Patients who had a baseline serum Mesothelin level > 
2.5nmol tracked the disease well (p=0.008). Those who had a partial/complete response showed a 
significant reduction in their mesothelin compared to the baseline values. As would be expected, those 
with progressive disease had an increase in the mesothelin levels, compared to baseline. Mesothelin 
levels are related to tumour volume [96]. Therefore, if patients were classified as responders by 
mRECIST criteria due to a reduction in tumour volume, the mesothelin level is also expected to reduce. 
This is confirmed in our study. There were a number of missing data points with Mesothelin. The main 
issue around this being some patients not returning to hospital to have their pre-chemotherapy 
bloods. For some patients attending the GP practice was more convenient for the pre-chemotherapy 
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bloods. Unfortunately, as the Mesothelin test was a research blood test, they were unable to have 
their mesothelin test performed at GPs. The missed mesothelin tests were not reported as protocol 
deviations, a pragmatic decision was made at the start to allow the patients to have their blood tests 
at GPs where needed but every effort was made to repeat the mesothelin at their next visit to hospital. 
One way of overcoming the hurdle of missing mesothelin levels maybe to perform the mesothelin 
blood test on the day of their chemotherapy at the time of iv access.          
There were no safety concerns regarding administering ZA at the same time as chemotherapy. No 
immediate complications of extravasation, flushing or low BP was recorded for any of the patients 
after receiving the infusion. In total 119 AEs and 16 SAEs were reported for the duration of the trial. 
All expected AEs and SAEs stipulated in the protocol were captured and reported. The commonest 
reported AE was constipation 11/119 (9%), the IMP was thought to be related in 4 of these cases, in 6 
cases the IMP was not thought to be related and data was missing for 1 case. Electrolyte disturbance 
was reported twice, for the same patient where Magnesium supplementation was prescribed. As 
shown in Table 1-8 the SAEs were largely expected, and predominantly due to the side effects of 
chemotherapy. One patient had deranged electrolytes on a background of sepsis and diarrhoea. And 
a low magnesium on this context was considered ‘possibly related’ to ZA. 
Two protocol deviations were reported, one of which was a significant deviation where a patient 
received ‘stock’ held ZA in error. This was the first patient to be randomised in the trial and the first 
to receive treatment at the chemotherapy suite. Due to unfamiliarity of the trial, and familiarity of a 
stock drug that is administered to cancer patients regularly, ZA was administered open label on this 
occasion despite the prescription clearly stating ZA or placebo. Immediate measures were taken to 
prevent any future recurrences. This highlights the importance of communication and raising 
awareness of new trials when setting up sites.  
The information obtained from the semi-structured interviews suggest that the trial related 
procedures were broadly acceptable to patients. A repeated complaint was the time delay associated 
with administering the drug, on the day of their chemotherapy. This issue was primarily with one site 
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and when identified measures were taken to expedite the prescription completion and delivery 
process which had a significant impact on lessening the time delays. Despite a long chemotherapy day 
made even longer by administration of a trial drug, patients preferred to have all treatment in one 
sitting rather than at two visits. Patients were also happy with the structure of the trial follow-up being 
embedded with oncology clinical visits.   
Overall, the SSIs gave some insight into patients’ reasons for taking part in a clinical trial. Altruism was 
cited as one of the main reasons while the need to take back control and find a cure for MPM was 
cited as another. Most patients had a good understanding of what randomisation entailed and the 
need for randomisation in clinical treatment trials.  
Uncertainty regarding the future was another recurrent theme that emerged from the SSIs.  Whether 
this was with regards to progression of disease, leaving loved ones behind, or simply not knowing what 
to expect next, after chemotherapy had finished. These themes are important not only from a trial 
perspective but from the point of managing such patients in the future. Follow-up and long-term care 
of MPM is not well described and the information gleaned here suggests that the patients may be 
suffering as a result. Not just from a clinical trial perspective but as a clinician caring for MPM patients 
we should aim for a more structured long-term follow-up arrangement for patients with MPM, 
whether this is with respiratory, oncology or their own GP. There is also a role for exploring whether 
this follow-up should be in combination with imaging or biomarker tests (discussed in the next 
chapter).  
Other interesting themes unrelated to the questions posed to the patients, also emerged. Patients 
perceived the clinicians to have more knowledge of their disease process than they were informed. 
The withholding of information on occasions was thought to protect them from further 
disappointment. The thirst for information and the urge to be in control could be due to the need for 
control in a battle they felt they had lost.  
In summary, although I am unable to report the full results of the Zol-A study, valuable feasibility data 
was obtained from the Zol-A study as discussed here.  Whilst we were unable to meet the primary 
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feasibility outcome, important data regarding safety, tolerability and overall acceptability of the trial 
is available. When patients have been unblinded to treatment, the full results will be published in a 




5.14 Trial protocol amendments 
 
The substantial amendment 1 (SA01) was undertaken to allow more independence to the research 
nurses to allow randomisation. We also made a change to our inclusion criteria. We had previously 
stipulated that patients should have measurable pleural disease as per modified response evaluation 
criteria in solid tumours (mRECIST) criteria for them to be eligible for the study. However, a large 
proportion of our patients do not have measurable disease at presentation. Therefore, the eligibility 
criteria were amended slightly from mRECIST criteria to ‘measurable disease on CT’. This inclusion 
criterion was removed altogether after the trial has been open for 3 months as it was preventing 
patients from participating in the trial. SA04 was another important amendment. We noted a number 
of patients declined chemotherapy and declined participating in the trial altogether. This is a well-
known phenomenon in MPM as well as other oncology trials, some terminating prematurely due to 
poor accrual (NCT00597116; NCT00003508). In an attempt to explore patients’ reasons behind their 
decisions not to take part in a clinical trial we sought REC approval to interview patients who declined 
the trial. All amendments since the original REC approval in May 2016 are summarised in Table 5-10.     
 
   
List of 
amendments  
Summary of change 
SA01 
14/09/2016 
Personnel randomizing to the trial has changed from pharmacy to research members as 
the randomization software allows randomization whilst protecting the blind. 




Change to eligibility criteria - remove ‘measurable disease on CT (tumour thickness > 
5mm)’ 
Dr Steve Walker added as sub-investigator 
Radiological data collection is further explained in section 5.13 
Plan of analysis (Section 6.1) details how the radiological information will be used to 
calculate the sample size for the full study 
SA03 
26/04/2017 





Request to interview patients who decline participation in the trial 
Clarify number of patients for semi-structured interview (up to data saturation rather than 
the previously stated 10) 
NSA01 
20/09/2017 
Extend recruitment period by 1 month, to November 2017 




I would like to thank the following oncologists for their support with recruitment to the trial; Doctors 
Alfredo Addeo and Charlie Commins for recruitment at NBT and UHB; Drs Ashley Cox and Matt 
Sephton at RUH; Dr Adam Dangoor at UHB. I would also like to thank the research and pharmacy 
teams at UHB and RUH for their help with day to day conduct of the trial. Finally, thank you to Mr Rob 
Thompson, our patient representative who tirelessly attended all except one TSC meeting, despite 
slowly progressive mesothelioma.     
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CHAPTER 6       A PROSPECTIVE STUDY OF SERIAL SERUM 




Monitoring disease activity post chemotherapy is important in mesothelioma.  The previous chapters 
have demonstrated potential roles for PET-CT and CT, however these modalities subject patients to 
high doses of radiation, are time consuming and expensive. Hence a less invasive, easily accessible and 
cheaper method of monitoring disease progression would be welcomed both by clinicians and 
patients. Specifically, for those in a remission stage under regular observation prior to second or third 
line treatments, a simple blood test performed at regular intervals as opposed to 3 or 6 monthly CT 
scans offers an appealing alternative to identify disease progression.    
As a diagnostic biomarker Mesothelin has the most robust evidence compared to a number of other 
biomarkers investigated in mesothelioma [93]. No studies have assessed the utility of Mesothelin in 
monitoring of patients not receiving chemotherapy or other forms of active treatment. In this 
prospective cohort study, we aim to assess the ability of serum Mesothelin to monitor disease in 
patients who have completed chemotherapy or those receiving best supportive care (BSC). 
I designed the study with Professor Maskell. At its inception we presented the study concept to the 
local oncologists treating mesothelioma at NBT, for their suggestions and support for the study. We 
planned to recruit all patients with a diagnosis of mesothelioma who were under active monitoring, 
having completed prior chemotherapy or receiving best supportive care. Ethical approval was granted 
for an amendment appended to the existing pleural investigation trial (South West REC Ref: 
08/H0102/11).   
145 
 
6.2  Methods 
 
From February 2014 to October 2016 consecutive patients were prospectively recruited to the study 
alongside normal clinical care.  Patients were invited to participate if they had a histocytologically 
confirmed diagnosis of malignant pleural mesothelioma (MPM) and were under active monitoring for 
the disease, aged over 18 years and had an expected life expectancy greater than 3 months. Patients 
who were receiving chemotherapy were not included, until they had completed their treatment. All 
patients gave written informed consent. At baseline, patient demographics, method of diagnosis of 
MPM and WHO performance status were recorded.  Blood samples were taken at baseline and a full 
staging CT scan was performed. This study had no impact on the treatments received by the patient, 
but prior treatment information was recorded. 
 
6.2.1 CT imaging and reporting 
 
All patients had a baseline full staging CT scan. Patients who had just completed chemotherapy had 
CT scans every 3 months. Those on best supportive care had CT scans every 6 months. CT scans were 
reported by two methods.  Firstly, they were all reported in a standard reporting fashion for clinical 
purposes by a consultant thoracic radiologist who classified the scans into radiological progression, 
stability or partial response but did not use formal reporting criteria (herein described as the ‘clinically 
reported CT’). Secondly, another independent radiologist and I assessed the same CT scans using 
the modified RECIST criteria (herein described as the ‘mRECIST CT’) [118].  
Assessment of pleural tumour by mRECIST criteria involves measuring 2 sites of tumour at 3 different 
anatomical levels, where the tumour thickness is measured perpendicular to the chest wall or 
mediastinum. The thickness of the tumour measured should be at least 1cm, lesions less than 1cm are 
considered non-measurable [118]. The resultant 6 pleural thickness measurements are then summed 





Figure 6-1: Measurement of tumour thickness for calculation of mRECIST. Tumour thickness measured perpendicular to 
the mediastinum. Measurement of 2 sites at 2 levels shown here. Images a and c are from the baseline scan. Images b and 
d from a subsequent scan 6 months later, showing significant progression of disease. 
 
 
The mRECIST criteria define a complete response (CR) as the disappearance of all target lesions with 
no visible tumour elsewhere and partial response (PR) as at least a 30% reduction in cumulative 
tumour measurement. Progressive disease (PD) is defined as an increase of 20% in cumulative tumour 
measurement or emergence of new lesions. Stable disease (SD) is defined as not fulfilling the criteria 
for PR of PD. All reporting physicians were blinded to mesothelin results.  
 






mRECIST score percentage change = (mRECIST score on scan 2 – mRECIST score on scan 1) *  100 
                 mRECIST score on scan 1  
 
(where scan 2 is a subsequent scan to scan 1 usually 3 or 6 months after scan 1 in our study)  
 
6.2.2 Mesothelin sample processing 
 
Serum samples for Mesothelin testing were collected at respiratory or oncology clinic appointments. 
They were routinely analysed using the commercial MesomarkTM ELISA (Fujirebio) according to the 
manufacturer’s recommended methods for sample processing, by investigators unware of the 
patients clinical or radiological characteristics. Mesothelin samples were processed using a manual 
enzyme linked immunosorbent assay (ELISA). Samples were batch processed with 12-14 samples at a 
time with calibration samples and controls analysed in parallel. Spun down whole blood was stored at 
-20 degrees Celsius until they were ready for processing. Two separate monoclonal antibodies are 
used in routine mesothelin sample testing, one to capture the mesothelin peptide and the second for 
the detection of it. Diluted patient serum (10µL per sample) is added to antibody coated wells which 
were then incubated on a 700rpm plate shaker for 60 minutes. This was followed by a rinse-cycle to 
remove any residue. Next the conjugate monoclonal antibody (100µL) was added and incubated on a 
700rpm plate shaker for another hour. Once this was rinsed through a substrate was added which 
binds to the conjugate antibody allowing detection of serum mesothelin related peptide (SMRP also 
called Mesothelin) by ELISA. The optical density of ELISA is directly proportional to amount of SMRP 
present. Using the calibrators and controls the samples can then be interpreted to give a value in 
nanomolar. All samples were processed in duplicates and the mean of the 2 samples was counted as 
the final value. For calibrators, controls and samples the coefficient of variation should be ≤ 15%.            




6.2.3 Statistical analysis 
 
Mesothelin levels were not normally distributed, therefore results were presented as medians with 
interquartile ranges (IQR). Comparison of baseline mesothelin levels between groups was performed 
using the Mann Whitney U test, with a p value less than 0.05 considered statistically significant.  The 
non-parametric Mantel-Cox log-rank test was used to assess survival differences between groups. The 
Cox proportional hazards model was used to investigate independent and combined multivariable 
relationships between age, histological sub-types, treatment status and baseline mesothelin. Data 
imputation was not used for missing values. 
The ability of serum mesothelin to predict radiological progression was assessed using timepoint 
analysis. A mesothelin measurement with a paired CT scan (defined as performed within a maximum 
of 31 days of each other) was called a ‘timepoint’. These timepoints were grouped depending on the 
time from baseline into 3 monthly intervals. Two timepoints in the same patient allowed for a 
‘comparison’ between the percentage change in mesothelin level and the radiological report (both 
clinically reported and mRECIST CTs). Patients were grouped into whether their CT scan showed 
progression of disease or stable disease/partial response.  The ‘baseline’ for treatment naïve patients 
was when they were enrolled into the study. For patients who had received chemotherapy, the post-
chemotherapy mesothelin and CT scan was considered the new point of reference, or baseline.   
 
For the timepoint analysis a change in mesothelin was defined as a relative change from the previous 
mesothelin level, either ‘falling’ or ‘rising’, with separate analyses performed using 10%, 15% and 25% 
cut-offs. The thresholds were calculated by the following method; 
 
% change in mesothelin = (Later timepoint mesothelin – Earlier timepoint mesothelin)  * 100 




The ability of mesothelin to predict radiological progression was assessed using sensitivity, specificity, 
predictive values and accuracy. Exploratory subgroup analysis was carried out based on baseline 
mesothelin level and histological type. 
 
To further assess the ability of changes in mesothelin to track disease, independent of radiological 
assessments, the impact of a rising level on survival was calculated and compared to stable mesothelin 







In total, 41 patients with malignant pleural mesothelioma were recruited to this study and had a 
mesothelin taken at baseline alongside usual care (see Table 6-1). The majority were males (35 males 
vs 6 females) and the cohort had a median age of 72 (range 58-83). Twenty-three patients had received 
prior chemotherapy in the form of Pemetrexed and Cisplatin, with no patients being referred for 
surgical intervention. Eighteen patients received no chemotherapy either due to choice (n=8), poor 
performance status (n=6), or intention for delayed chemotherapy by the physician (n=4). Patients in 
the non-chemotherapy group were older on average (75 vs 69) but had a similar distribution of 
histological subtypes. Overall, 25 (61%) were epithelioid histological sub-type, while 9 (22%) were 
sarcomatoid, 4 (10%) biphasic and 3 (7%) were cytological diagnoses only therefore the exact subtype 
was not known.  
 
6.3.2 Baseline mesothelin 
 
All 41 patients had a serum mesothelin performed at baseline, with a median of 2.3nmol/L (IQR 1.2-
6.6) across the entire cohort. Baseline mesothelin was significantly higher in the epithelioid (3.1 
nmol/L IQR 1.25-13.6) compared to non-epithelioid (1.3 nmol/L IQR 0.75-2.95) histological subtypes 
(p=0.04). Survival of the entire cohort was 15 months (IQR 10-23). When analysed as a bivariate 
variable (dichotomizing the cohort at a mesothelin level of 2nmol/) there was no difference in survival 
between those with a low (<2 nmol/L) or high (≥2 nmol/L) baseline mesothelin with median survival 
times of 11 (IQR 7.5 to 20) months and 15 (IQR 10 to 26) months, respectively (p=0.191). Additionally, 
baseline mesothelin did not impact on survival when analysed as a continuous variable (p=0.193). 
There was no significant difference on baseline mesothelin or change in mesothelin levels depending 








Median age (range) 69 (58-77) 75 (67-83) 
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Table 6-1: Baseline characteristics, mesothelin and survival. 
6.3.3 Change in mesothelin and radiological progression 
 
At baseline, all 41 patients had a CT scan within 31 days of a serum mesothelin measurement for 
comparison to later timepoints. The numbers of patients with data recorded at subsequent timepoints 
were: 2 at 3 months, 20 at 6 months, 3 at 9 months, 13 at 12 months, and 5 at later timepoints. This 
allowed for 43 time-point comparisons, with 25 time-points in the post-chemo group and 18 time-
points in the non-chemotherapy group. The median time between mesothelin measurement and CT 
was 13 days (range 0 to 31 days).  
When all comparisons were amalgamated across the cohort there was no change in median 
mesothelin levels in patients who had not progressed on the clinically reported CT (0.0 nmol/l (IQR -
0.6 – 0.4)). This compared to a rise of 1.8 nmol/l (IQR 0.7 – 1.8) in patients with radiological progression 
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Accuracy 86.0%  83.7%  81%  




Results from Table 6-2 demonstrated the ability of a rising mesothelin to predict radiological 
progression on both clinically reported and mRECIST CT in individual patients. Due to non-measurable 
disease (pleural thickening < 1cm) only 25 of the scans could be reported according to mRECIST 
criteria. A variety of pre-defined mesothelin cut-offs were tested. Regardless of cut-off used, 
mesothelin tracked the clinically reported CT results with greater accuracy than mRECIST CT reports. 
Resultantly, the clinically reported CT has been used for ongoing analyses. Figure 6-2 is a waterfall plot 
of the absolute changes of mesothelin divided by clinically reported CT report (SD and PR versus PD). 
It demonstrated that the vast majority of patients with radiologically progressive disease had a rising 
mesothelin (with only 1 patient having a small fall in level).  
Further subgroup analysis was performed depending on baseline mesothelin or histological subtype, 
see Table 6-3. Serial changes in mesothelin predicted radiological progression with 100% sensitivity in 
patients with a high baseline mesothelin (defined as >2nmol/l). There was a fall in sensitivity and 
specificity in patients with low baseline mesothelin or sarcomatoid disease, although sensitivity 










6.3.4 Change in mesothelin and overall survival 
 
At 6 months, patients with a rising mesothelin (using a 10% cut-off) had a shorter median 
survival (from the date of sampling) compared to those with a falling or stable level 
(p=0.003). Those with a rising mesothelin had median survival of 175 days (IQR 80–211) 
compared to 448 days (IQR 321 to 554). Patients with radiologically progressive disease 
at 6 months (n=9) on clinically reported CT had a median survival of 170 days (IQR 72 - 
223) from the date of CT scan compared to 433 days (IQR 255 to 581) in those with stable 
disease or partial response (n=11) (p=0.001). The majority of CT scans (10/21) performed 
at a 6-month time point were non-measurable using mRECIST criteria so these results 
were not analyzable.  
In a multivariate cox regression analysis including age (≥70 vs <70), histological subtype 
(epithelioid vs non-epithelioid) and treatment modality neither change in mesothelin or 










Progression on CT 
(Y/N) 
13/6 11/13 5/4 
Sensitivity  100 (75.3-100) 90.9 (58.7-99.7) 80.0 (28.4-99.5) 
Specificity 83.3 (35.9- 99.6) 69.2 (38.5- 90.9) 75.0 (19.4- 99.4) 
PPV 92.7 (68.4-98.7) 71.4 (51.9- 85.2) 80.0 (40.9-95.9) 
NPV 100 90.0 (57.3-98.4) 75.0 (32.2-94.9) 
Table 6-3: Subgroup analysis of ability of mesothelin to predict progression. (CT – computed tomography; 





This study assessed the ability of serum mesothelin to detect progression of MPM in 
patients not currently receiving active chemotherapy treatment. To our knowledge this is 
the first study to evaluate the role of mesothelin in disease monitoring in mesothelioma 
as opposed to mesothelin’s role as a marker of treatment response during chemotherapy 
or surgery. No specific evidence exists on the optimal monitoring strategy for patients 
with MPM following first line chemotherapy. Based on expert opinion rather than 
published data, recent UK guidelines have suggested that following patients up every 3-4 
month is good practice although what this follow up should involve was not specified 
[107].   
 
There is considerable variation in UK practice [57], for two main reasons. Firstly, until 
recently many oncologists felt there was no data to support the role of second line 
chemotherapy in this setting [167] and there was limited access to clinical trials after first 
line treatment. There was, therefore, no perceived benefit from monitoring patients post 
first line chemotherapy or in those having BSC. However, given promising results from 
second line chemotherapy trials[110], as well as non-chemotherapeutic options [103] this 
perception is changing. Secondly, no radiological marker has shown the ability to 
accurately monitor disease progression [118]. A serum biomarker that could identify 
disease progression would be very useful to oncologists and physicians, with the 
additional benefit of reducing patient burden and healthcare costs.  
 
Mesothelin is the most studied serum biomarker for mesothelioma with the majority of 
literature assessing its diagnostic potential. Although a raised level is fairly specific for 
MPM, many patients with non-epithelioid disease will have unrecordable levels even at 
an advanced stage. This has limited its utility as a diagnostic test, although recent studies 
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have attempted to combine it with more novel markers [168, 169]. The role of biomarkers 
in other malignancies has often begun as a putative diagnostic marker before becoming a 
marker of treatment response or recurrence (CA125, Prostate Specific Antigen) [170, 
171].   
Previous literature has shown that mesothelin can be used as a marker of treatment 
response when measured serially. The first example from Grigoriu and colleagues [126] 
took patients with a positive (>1nM/L) mesothelin at baseline receiving chemotherapy 
and immunotherapy (n= 40). They found that in patients with a 10% or greater rise in 
mesothelin there was a 75% chance of radiological progression using mRECIST as well 
significantly worse overall survival. The largest study of its type [96] correlated both CT 
scans (mRECIST) and PET (TGV and tumour volume) with change in mesothelin levels after 
treatment (using a 25% cut-off). In the chemotherapy group (n=55) the change in 
mesothelin significantly correlated with radiological response on CT (p= 0.023). Although 
only a minority of the cohort (n= 28) could be reassessed using PET imaging, due to prior 
pleurodesis or surgery, the change in both metabolic activity (TGV) and tumour bulk 
strongly correlated with change in mesothelin levels (p<0.001). Survival analysis 
demonstrated that the trend of mesothelin correlated with survival in a multivariate 
model that included age, sex, histology and treatment. Interestingly, this was not true 
when tumour volume on PET was added to the model, indicating that mesothelin was 
probably acting as a proxy for tumour bulk.  
Across the literature we found several different thresholds for defining a clinically 
significant change in mesothelin level, including 10% [126], 15% [172] and 25% [96]. 
Wheatley-Price and colleagues [125] performed a post-hoc analysis of mesothelin values 
from a cohort of 42 patients using absolute (5mmol) and relative (10%) changes and their 
correlation with survival, finding that relative changes were more accurate. This current 
study assessed a variety of cut-offs, finding that a 10% cut-off reduced the specificity of a 
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rising mesothelin level but had a sensitivity of 96%. Given our aim was to assess the ability 
of mesothelin to detect disease progression we felt this reduction in specificity was 
justified with a false positive rate of 28% but a false negative rate of only 4%.  
We demonstrated that disease progression could be detected using change in mesothelin 
of >10% with an accuracy of 86% and NPV of 94%. Unlike some previous literature [125, 
126] this analysis did not exclude patients from the analysis with low baseline mesothelin 
or non-epithelioid disease. There has been uncertainty about the utility of serially 
measuring mesothelin in these patients. In this study, 44% (8/19) of patients with a 
mesothelin of less than 2mmol/L at baseline had an increased level (range 2.1-20.4) at 
later timepoints. Additionally, when the analysis was limited to patients with a baseline 
mesothelin of <2mmol there was only a limited reduction in sensitivity to predict 
progression. Given the small subgroup, no firm recommendations can be made regarding 
the utility of retesting mesothelin when the baseline is negative (<2nmol/l). This needs 
further assessment in other prospective studies.  
 
This study has several limitations that could impact on the conclusions drawn. The cohort 
of patients was small, which has an impact on the conclusions of the multivariate analyses, 
but comparable to other studies of its type. This was an observational study alongside 
normal clinical practice and there were instances where a mesothelin was collected but 
the patient did not receive a scan within the pre-allocated 1-month period. Additionally, 
given the aggressive nature of MPM very few comparisons of timepoints over 12 months 
were available, but this is likely to be a pragmatic assessment of following up these 
patients in clinical practice. As previously mentioned other studies have monitored the 
change in mesothelin levels in response to systemic therapy. As a result, these studies had 
a proportion of patients where mesothelin levels fell considerably, which was correlated 
with radiological ‘partial response’. Worsening renal function has been shown to falsely 
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elevate mesothelin levels [173]. Although there was no difference in mesothelin 
sensitivity between patients with normal and abnormal renal function at baseline, there 
was no ongoing assessment during follow up. Given this study focused on patients not 
receiving treatment there were few instances of falling mesothelin. Finally, the difficulty 
with studies of this type is that the current ‘gold standard’ of monitoring (mRECIST CT) 
which mesothelin trends are compared to has been shown to be insensitive at detecting 
early progression. This analysis found that mesothelin correlated better with the clinically 
reported CT scan compared to mRECIST reporting, a finding of other similar studies [125]. 
Additionally, over half (25/43) of the CT scans used in the timepoint analysis were non-
measurable by mRECIST criteria with a short axis diameter of less than 1 cm. This is 
another shortcoming of the mRECIST criteria that limits its sensitivity and applicability in 
clinical practice. It is for this reason that we assessed the impact of a changing mesothelin 
levels on survival as a means of validation, finding that a rising mesothelin at 6 months 
was a poor prognostic indicator. As with other cancer biomarkers [174] the reason for 
several ‘false-positive’ results (where a rising mesothelin occurred in the context of 
radiologically stable disease) could be because changes in mesothelin preceded 
radiological change. 
In conclusion, we have demonstrated that a rising serum mesothelin is a sensitive marker 
of progression in the follow up of patients with MPM. Given the emergence of effective 
non-chemotherapeutic treatments and second-line agents, accurate disease monitoring 
is becoming increasingly important. This study has demonstrated that regular mesothelins 
could be used as a cost effective adjunct or alternative to serial CT scanning.  
 
Footnote: 
This chapter has been peer reviewed and published in the BioMed Central (BMC) Cancer 
online journal (February 2018). The mRECIST criteria used in this chapter are from version 
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1.0 as version 1.1 was not published at the time of CT reporting in this study. Hence the 
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CHAPTER 7       FUTURE DIRECTIONS  
 
Despite clinical guidelines with recommendations on the best management of pleural 
disease a number of issues remain unresolved. Asbestos related pleural disease is one 
such poorly researched area with low level evidence to inform guidelines.  The diagnosis 
and management of malignant pleural mesothelioma (MPM) can be particularly 
challenging. This thesis explored the diagnostic conundrums and challenges of benign 
versus malignant pleural thickening. In addition, it examined aspects of treatment and 
monitoring of MPM.  
7.1 Future directions: 
 
• The DPT study confirmed patients without costo-phrenic angle obliteration could 
still have significant restrictive defect in their lung function. The IIDB now 
appreciates the limitations of relying solely on CXR appearances and have recently 
published a revised statement removing ‘the costo-phrenic angle obliteration’ 
requirement in order to be eligible for compensation and have recognised CT to 
be more sensitive for assessing DPT. The findings from this study will be included 
in any future iterations of their guidelines.     
• Pleural pointillism is a promising simple visual assessment technique for 
differentiating benign from malignant pleural thickening on DWI MRI with high 
sensitivity and specificity. Currently only one study is published in the literature 
demonstrating its effectiveness. The study reported here is expected to be 
published in a peer reviewed journal in the near future. A large prospective multi-
centre study with robust inclusion criteria is now needed to further assess its role, 
and the current study will be useful in providing the information required for the 
power calculation, for the grant application. 
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• A project is currently being designed by the radiology researchers at Oxford with 
plans to collaborate with all UK centres performing DCE-MRI scans to assess 
pleural thickening, in order to develop software that may be able to analyse these 
scans using artificial intelligence (AI). The MRI data obtained from the current 
study will be shared with Oxford to help with their AI project.  
• The results of the TARGET study are awaited with much interest. The full results 
of the study will be available by mid-2019, after completion of the 6-month 
follow-up period. The results are expected to be published in a peer reviewed 
scientific journal. Hopefully, the findings will point in the direction of whether or 
not PET-CT targeted pleural biopsies are justified in a difficult to diagnose cohort 
of patients with suspected pleural malignancy.  
• The Zol-A unblinding is planned for late July 2018. The final unblinded results are 
awaited with anticipation, to determine if there was any effect in delivering ZA 
alongside chemotherapy. If the overall findings are positive, funding to be applied 
for a full phase III trial. The results will be published in a peer reviewed scientific 
journal.  
• The association between MPM and mesothelin is very encouraging. Further large 
prospective studies are needed to validate our findings. Following on from the 
current study, mesothelin has been included in a prospective longitudinal cohort 
study conducted by the Academic Respiratory Unit at North Bristol Trust – the 
Assess-Meso study. This trial is currently recruiting mesothelioma patients from 
3 centres across the UK and hope to open 12 more over the next 12 months. As a 
longitudinal cohort study, it will recruit and monitor mesothelioma patients over 
a 10-year period. The study protocol specifies 3 monthly follow-up appointments 
with serum mesothelin levels and CT scans, well placed to answer the question 
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whether CT scans could be replaced by a simple blood test in mesothelioma 
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Randomised controlled trial to compare the diagnostic yield of Positron 
Emission Tomography Computerised Tomography (PET-CT) guided 
pleural biopsy versus CT-guided pleural biopsy in suspected pleural 























Many patients with a history of asbestos exposure can develop irregular 
thickening of the lung lining (the pleura). Although in many cases the 
pleural thickening is not serious a small proportion of patients can develop 
cancer of the lung lining (mesothelioma). Chest X-rays and CT (computed 
tomography) scans of these patients can indicate a suspicion of 
mesothelioma but the only way to confirm the diagnosis is by obtaining a 





Unfortunately, in a subgroup of patients, it can take a considerable time to 
confirm the diagnosis of mesothelioma with a tissue sample. This is due to 
the difficulty of obtaining a sample containing cancerous cells in some 
patients. These patients will often require repeated samples to be taken until 
a definitive diagnosis can be made. A rapid diagnosis is important as, 
although mesothelioma is incurable, life-extending treatments started early 
can be effective and diagnosis allows patients with confirmed mesothelioma 





Currently, pleural tissue samples are taken with guidance from a CT scan of 
the lungs. We believe that another type of scan (Positron Emission 
Tomography 'PET scan' is a whole body scan where radio-labelled glucose 
is taken up more avidly by cancerous cells) may be better at identifying the 
location of the cancerous tissue allowing a more targeted biopsy to occur, 
thus improving the diagnostic accuracy. PET scanners are expensive and 
in high demand so good evidence is required before they can be used 





This study aims to determine how effective PET-scan targeted tissue 
sampling is compared to the conventional CT targeted sampling in patients 
requiring a second biopsy. We intend to conduct a clinical study comparing 





 one or the other method. 
Total Research Cost 344,811.00 
 
 
The Department of Health, National Institute for Health Research (DH NIHR) is the Data Controller under the Data 
Protection Act 1998 (‘the Act’). Applicants for funding should be aware that information contained in this 
application might be shared with other DH NIHR bodies for the purposes of statistical analysis and other DH NIHR 
management purposes, including targeted communications with selected groups of researchers. Applicants may 
be assured that DH NIHR is committed to protecting privacy and to processing all personal information in a 
manner that meets the requirements of the Act 
 
 




In this section it is important that you describe, in as much detail as possible, how patients and the public 







Were patient and the public actively involved in either identifying the research topic/prioritising 





If Yes, please tick the appropriate boxes below 
 
Involved in identifying the research topic/prioritising the research questions, Involved in preparing the Application 
 
 
Please further describe how patient and public involvement has informed and/or influenced the development 
of the application and how patients and the public have been actively involved 
 
Our research question and study protocol was put forward to a mesothelioma focus group made up of 
patients with the disease and their relatives/carers. We have redesigned our protocol and methodology as 
below, following the groups' feedback. 
 
The research question was thought to be important and relevant as pleural malignancy (predominantly 
mesothelioma) can be difficult to diagnose. Patients undergoing investigations for mesothelioma would want a 
speedy diagnosis. Repeated investigations can be distressing. Negative results and further investigations can 
be frustrating to patients as well as leading to a delay in diagnosis. Therefore, PET scanning can be utilised as 
a quicker and more efficient way of diagnosing in a small group of patients where the diagnosis can be 
challenging. 
 
There was concern regarding the extra travel costs for patients randomised to the PET arm. We have 
now costed in their travel expenses into the research costs. 
 
The focus group highlighted an additional scan could incur a delay. In response to this we are now developing 
a standard operating policy (SOP) which would be adhered to across the sites, to ensure the PET-scan is done 
in the 2 week window while patients would normally be waiting to have the CT-guided biopsy. 
 
We had originally planned a sub-study involving magnetic resonance imaging (MRI) in addition to PET 
scanning for those who would be randomised to the PET arm. The focus group was in the opinion that 3 scans 
would be too many for patients and that could deter them from entering the study. Therefore, MRI component 
has now been removed from the study. 
 
Members of the focus group reviewed the lay summary on this application and advised to change some of 





The Avon Mesothelioma Foundation is a charity made up of patients with mesothelioma and their relatives. 
They have supported our study as an important study which would help patients to get to their diagnosis 
quickly. 
 
The original focus group and the North Bristol NHS Trust Research lay panel will be reviewing our 
patient information sheets to ensure they are easily understandable. 
 
 
Please indicate the ways in which the public will be actively involved in the proposed research, by ticking 
all relevant boxes 
 
Design of the research, Management of the research (e.g. steering/advisory group), Developing 







Please give more details, including how patient and public involvement will benefit the research, the reasons 
for taking this approach and arrangements for training and support 
 
 
As mentioned above we have taken on board patients’ and their relatives' views on the design of the study. 
Throughout the trial we will consult with the patient focus group on any changes made to the protocol and in 
preparation of the patients information sheet. This group together with the Research & Innovation Lay panel at 
North Bristol NHS Trust will be reviewing our patient information sheets. The opinions of patients and lay people 
are important as they may highlight issue that are not necessarily picked up by clinicians. 
We would like to have had a patient representative on our trial steering committee but unfortunately due to the 
nature of the disease (poor survival) it would be difficult to have a patient sitting on the trial committee. However 
partners of patients with mesothelioma are keen to support our research, therefore we have approached Anne 
Craig (a patient’s partner) who has agreed to sit on our trial steering committee. 
We shall use one of the members from our focus group to help with the final write up of the research paper. 
Our research findings will be presented locally at an Avon Mesothelioma Foundation study day. These meetings 
are usually attended by patients with mesothelioma, their relatives and relatives of patients who have died of 
mesothelioma. 
At a national level we would apply to present our findings at a MesoUK study day. 
Members of the focus group we have used above will be informed of the end result in a final group meeting. 
The original focus group and the North Bristol NHS Trust Research lay panel will be reviewing our patient 






8. Case for Support - Part 1 
 
 
Aims and objectives 
 
Describe the overarching aims of the research, outlining the research question which the work will address 
 
Patients with suspected cancer of the lung lining (pleura) often have a biopsy of the pleura to confirm or refute 
the diagnosis of malignancy. Usually the biopsy is performed using radiological guidance (Computed 
Tomography or Ultrasound) or during thoracoscopy (a camera into the chest cavity through a small incision on 
the chest wall, which allows visualisation of the pleura and biopsy) . If the original biopsy does not give a 
definitive answer they would go on to have a second biopsy and this is usually under CT (Computed 
tomography) guidance. 
Those patients who have already had one non-diagnostic biopsy, tend to have a low overall diagnostic rate for 
second and subsequent biopsies. Identifying an area where a high yield of cancerous cells is likely to be 
obtained at biopsy can be difficult from CT imaging alone. Positron Emission Tomography (PET) scanning can 
identify areas with high metabolic activity that occurs with malignancy. If patients have a PET scan first to identify 
areas of high metabolic activity then target the CT guided biopsy to these areas, the yield is much higher than 
just CT guided biopsy. 
The overall aim of this study is to compare the effectiveness of PET targeted biopsy over CT guided biopsy in a 
population of patients with suspected pleural cancer, who have had one negative pleural biopsy. 
Patients will be randomised to either have a PET scan followed by a targeted CT guided biopsy. Or a CT guided 
biopsy alone. 
Our primary outcome measure is the number of pleural malignancies correctly diagnosed by PET-CT guided 
biopsy versus CT guided biopsy. All patients will be followed up for a year, during which time those patients who 
have cancer but have negative biopsies will become clinically and radiologically apparent, as their disease 
progresses. 
As a secondary outcome measure we would like to look at the benefits of using PET-scan targeted biopsy in 
terms of improving diagnostic delays, number of hospital attendances for patients, number of invasive pleural 
procedures, survival and reduction in costs associated with health related resource use. 
 
Mesothelin is a biomarker that can be raised in patients with cancer of the lung lining (Mesothelioma). At present 
the role of Mesothelin is unclear in the diagnostic pathway of mesothelioma. We would like to investigate the role 
of Mesothelin in patients with suspected mesothelioma by testing their levels at enrolment and at subsequent 
follow-up to evaluate its potential role in the diagnostic pathway for pleural malignancy. 
 
 
Plain English Summary 
 
Please summarise your proposed research in plain English 
 
Many patients with a history of asbestos exposure can develop irregular thickening of the lung lining (the pleura). 
Although in many cases the pleural thickening is not serious a small proportion of patients can develop cancer of 
the lung lining (mesothelioma). Chest X-rays and CT (computed tomography) scans of these patients can indicate 
a suspicion of mesothelioma but the only way to confirm the diagnosis is by obtaining a sample of the lung lining 
and examining the cells. 
 
Unfortunately, in a subgroup of patients, it can take a considerable time to confirm the diagnosis of mesothelioma 
with a tissue sample. This is due to the difficulty of obtaining a sample containing cancerous cells in some patients. 
These patients will often require repeated samples to be taken until a definitive diagnosis can be made. A rapid 
diagnosis is important as, although mesothelioma is incurable, life-extending treatments started early can be 
effective and diagnosis allows patients with confirmed mesothelioma to apply for compensation. 
 
Currently, pleural tissue samples are taken with guidance from a CT scan of the lungs. We believe that another 
type of scan (Positron Emission Tomography 'PET scan' is a whole body scan where radio-labelled glucose is 
taken up more avidly by cancerous cells) may be better at identifying the location of the cancerous tissue 
allowing a more targeted biopsy to occur, thus improving the diagnostic accuracy. PET scanners are expensive 
and in high demand so good evidence is required before they can be used routinely for this purpose. 
 
This study aims to determine how effective PET-scan targeted tissue sampling is compared to the conventional 
CT targeted sampling in patients requiring a second biopsy. We intend to conduct a clinical study comparing the 





Scientific abstract of research 
 
Please provide a structured summary which outlines the background to the research, the aims of the work, 
including the question to be addressed by this research, the plan of investigation and a summary of the potential 
benefits to patients and the NHS 
 
Background 
Asbestos was a commonly used material in the building industry in the 1950s. Due to the unknown deleterious 
effects to humans from asbestos exposure, it was used without any health and safety protection at the time. 
There was an increasing emergence of lung disease that was later found to be attributable to asbestos exposure. 
 
Malignant pleural mesothelioma is cancer of the lung lining occurring as a consequence of asbestos exposure. It 
is an aggressive and fatal tumour that is still on the increase in many parts of the world. Due to its long latency 
period from exposure, patients may not develop mesothelioma up to 30 to 40 years from exposure. Unfortunately, 




Diagnosis of mesothelioma can be challenging in the absence of pleural fluid (fluid in the chest cavity), to 
perform a thoracoscopy for direct visualisation and biopsy of the pleura. Computed Tomography (CT) or 
Ultrasound (US) guided biopsy of the pleura are two of the commonest techniques used in this situation but the 
diagnostic rate is low. 
 
 
Diagnostic imaging in pleural malignancy remains a significant challenge. PET scanning has proved itself a useful 
tool in diagnosing and staging lung cancer. It identifies areas of high metabolic activity, which is a feature of 
malignant disease, by highlighting areas of uptake of the radio labelled glucose analogue Fluorodeoxyglucose 
(FDG). 
 




This study will assess whether a PET-CT guided biopsy is superior to a standard CT guided biopsy when 
obtaining pleural tissue in suspected pleural malignancy, in patients who have already undergone one non- 
diagnostic pleural biopsy. 
 
At present there are no studies comparing the two approaches. Pilot data from our institution has shown a 66% 
sensitivity with PET for repeat biopsies as opposed to 20% sensitivity with a repeat CT guided biopsy. 
 
Plan of investigation 
This multi-centre randomised controlled study will recruit patients from 6 respiratory departments over a 24 
month period or until 78 patients have been recruited. Patients will be randomised either to receive a PET 
targeted biopsy or a standard CT guided biopsy using an online randomisation tool provided by the Bristol 
Clinical Trial Evaluation Unit (CTEU). The experimental group will undergo a PET scan which will be reviewed by a 
local radiologist to identify the most suitable area for biopsy, then a CT guided biopsy targeted to the afore 
highlighted area. The standard CT group will have a repeat CT and a biopsy from a site identified as per the local 
radiologist. Standard Operating Procedures (SOP) will be in place to minimise variation. 
The diagnostic yield for the two biopsy methods in identifying malignancy will be compared using the chi-squared 
test for proportions. 
Final analysis will occur once all recruited patients have undergone a second pleural biopsy and a tissue 
diagnosis confirmed or 12 months follow-up occurred. 
 
Potential impact 
If this superiority study is proven successful, it would shorten the patient’s cancer journey and reduce the number 
of invasive investigations they undergo. 
An early diagnosis may allow more patients to have life prolonging chemotherapy that they may not be able to 
have at a later stage in disease if they are too unwell. 
Mesothelioma patients have a very poor survival and often some of this time may be spent in hospital. An early 
diagnosis would allow patients more time to enjoy the financial benefits of the compensations they receive 





Background and rationale 
 
What is the problem being addressed? 
 
Describe the background to the research, describing the limitations identified in the evidence base that the 
research is trying to address 
 
Asbestos was a commonly used material in the manufacturing and building industry since the late 19th century for 
its high tensile strength, heat resistance and affordability1. Due to the unknown deleterious effects to humans from 
asbestos exposure, it was used without any health and safety protection at the time. There has been an increase 
in emergence of lung disease that was later found to be attributable to asbestos exposure2. 
 
Patients who have been exposed to asbestos can develop thickening of the lung lining (pleura). Although in most 
cases the pleural thickening is benign in nature, a small proportion of patients can go on to develop cancer of the 
lung lining (malignant pleural mesothelioma) secondary to the asbestos exposure. 
 
Malignant pleural mesothelioma is an aggressive and universally fatal tumour, the incidence of which is 
increasing in many parts of the world and currently kills one person every 4 hours in the UK3. Despite 
accounting for 1% of malignant disease in this country, it remains under researched and is currently incurable. 
 
The vast majority of patients require a pleural biopsy in order to confirm the diagnosis. When lack of pleural fluid 
makes thoracoscopy difficult or when pleural thickening is the only abnormality on CT, pleural tissue is usually 
obtained using CT guided pleural biopsy with a Tru-cut needle4 or with ultrasound guidance. However, the yield 
remains low (70-75%) as only one small area of the pleural thickening is biopsied, leading to occasional false 
negative biopsy results.  This means patients often undergo multiple diagnostic procedures in order to establish a 
histological diagnosis. 
 
Diagnostic imaging in pleural malignancy remains a significant challenge and a topic of international debate5. 
Tumour growth is unlike that of solid tumours due to its circumferential expansion and hence tumour may 
conceal itself within areas of pleural thickening. This, along with secondary pleural effusion and atelectasis make 
precise delineation of the tumour volume and radiological staging difficult.  In addition, the appearances of 
benign pleural thickening and pleural malignancy on CT may be similar and hence other imaging modalities have 
been evaluated in order to improve the diagnostic pathway for patients. 
 
Positron Emission Tomography (PET) scanning has proved itself as a useful tool in the diagnosis and staging of 
lung malignancy. It identifies areas of tissue with the highest metabolic turnover by highlighting areas of uptake of 
the radio-labelled glucose analogue - Fluorodeoxyglucose (FDG). Initial results in pleural malignancy have been 
encouraging6, but no study has yet looked at using this modality to target biopsies. 
 
We hypothesise that targeting the CT guided biopsy to the ‘hot’ areas on PET may improve the diagnostic yield. 
This would reduce the number of biopsies required to make a diagnosis (with their associated risks and costs). 
 
Audit data in our institution recorded that only 3 out of 15 (20%) repeat pleural biopsies for suspected pleural 
malignancy (all later confirmed to be mesothelioma) were positive. This compares to 6 patients for whom special 
funding was obtained to undergo a PET-CT guided pleural biopsy targeting the area of highest metabolic activity 
instead of a repeat CT guided biopsy. A positive histological diagnosis was made in 4 of the 6 patients (66%). All 
6 were eventually confirmed as having malignancy. This data reflects PET-CT scanning and biopsy is far 
superior to CT guided biopsy alone. 
 
This has highlighted a potentially significant role for PET scanning in this group of patients, which warrants 
further investigation. 
 
In this study we will also compare the use of the different PET-CT interpretation methods, Standardized Uptake 
Value (SUV) and Total Glycolytic Volume (TGV), different methods of interpretation of PET-CT findings, to 
evaluate their role as non-invasive methods of predicting a subsequent diagnosis of malignant disease. 
 
Identification of a potential biomarker for mesothelioma is also a subject of current research. Mesothelin levels 
have been shown to be elevated in 80% of patients with mesothelioma at presentation but its role is yet to be 
firmly established in routine clinical practice7. 
 
A literature review using PubMed and the keywords malignant mesothelioma, fluorodeoxyglucose-positron 
emission tomography biopsy and computed tomography biopsy did not identify any randomised controlled trials 





mesothelioma. Published literature has identified PET scanning as a highly sensitive imaging method to 
diagnose and stage mesothelioma8 but histological confirmation is still required with a biopsy of the pleura for the 
final diagnosis. 
 
This trial will be the first to address targeted biopsies in patients with suspected pleural malignancy using PET 
scanning and to evaluate the role of these other novel tests in the diagnostic pathway. 
 
If this proves successful, it could alter the investigation pathway for patients with this condition and help to 
expedite a diagnosis. By doing so, we would expect fewer repeat procedures required to make a diagnosis and 
hence a reduction in associated risks and costs.  In addition, by expediting the diagnosis, more patients may be 
fit enough to receive chemotherapy, which has been shown to have a survival advantage9. 
 
 
Why is this research important in terms of improving the health of the public and/or patients and the NHS? 
 
If our study proves that PET scanning and targeted biopsies are superior to current standard care of CT guided 
biopsy, for patients who have already had one non-diagnostic biopsy, then PET scanning can be incorporated 
into the diagnostic pathway of suspected mesothelioma patients. At present, although PET-scanning is widely 
used in cancer diagnosis and staging, it has a very limited role in mesothelioma. 
 
Literature suggests PET-scanning as a method of identifying areas of high metabolic activity that is invariably seen 
with mesothelioma. Therefore utilising this technique to target areas for biopsy would increase the chances of a 
positive biopsy. 
 
There are several reasons for trying to obtain an early diagnosis for patients with suspected mesothelioma: 
 
1.   Mesothelioma is an incurable disease and patients have a median life expectancy of 6 months9 from 
diagnosis, without palliative treatment such as chemotherapy. Chemotherapy can prolong life to 8 to 14 months.10 
Patients cannot have chemotherapy without histological confirmation of mesothelioma. Therefore it is vital to 
confirm the diagnosis by biopsy if patients are to have chemotherapy. 
2.   The longer patients wait for a diagnosis the higher the chances their disease could progress and can 
become ‘unfit’ for chemotherapy due to general deterioration in health. Therefore, an early diagnosis could 
lead to more patients being suitable for palliative treatment and prolongation of life. 
3.  Patients diagnosed of mesothelioma are eligible for compensation. If at the time of diagnosis 
patients are fit and healthy they are able to enjoy these financial benefits more, compared to a later stage of 
diagnosis where they are likely to be unwell from the disease. 
4.   More chances of a positive diagnosis with PET-scanning means patients are less likely to under go repeated 
invasive investigations. Fewer hospital trips and more likely to avoid surgery for a biopsy which would require an 




A reduction in the number of investigations and saved bed days would be favourable for the NHS from a health 
economic point of view. 
 
 
Novel bio-markers play an important role in monitoring disease activity. Mesothelin is one such marker that is 
elevated in mesothelioma. We would like to investigate the role of mesothelin in the diagnostic and monitoring 
pathway of mesothelioma, whether mesothelin can be used to as a surrogate marker of disease response to 














Describe the proposed research plan, providing descriptions of the overall research design and a strong 
justification of sampling strategies, methods of data collection and analysis. 
 
It is vital to add as much detail as possible on design and methodology, including justification of sample size, 
power calculations and sample selection and exclusion criteria where applicable. 
 
Study design: A multi-centre parallel group randomised controlled trial (RCT) to compare PET-CT guided pleural 
biopsy versus standard CT guided biopsy for the diagnosis of mesothelioma. 
 
Population: Patients with suspected pleural malignancy 
 
Setting: Respiratory departments in 6 hospitals in the UK. 
The lead centre will be North Bristol NHS Trust. The other centres that have agreed to recruit patients to the 
study are: Oxford Centre for Respiratory Medicine, Oxford; Kings Mill Hospital, Mansfield; Great Western 
Hospital, Swindon; Royal United Hospitals, Bath and Musgrove Park Hospital, Taunton 
 
Inclusion Criteria: Patients eligible for the trial must meet all of the following criteria at randomisation 
 
• Undiagnosed pleural thickening on CT suspicious of pleural malignancy 
• Have had a pleural biopsy (either by thoracoscopy or under radiological guidance) which was non- 
diagnostic for cancer 
• Lung Cancer Multi-disciplinary team (MDT) meeting decision to perform further CT-guided biopsy to 




Exclusion Criteria: Patients will not be eligible if any of the following apply: 
 
• Unfit for a radiological biopsy (coagulopathy, severe underlying lung disease) 
• Expected survival of less than 1 month 
• Unable to give written informed consent 
• Pregnancy or lactation 
• Age <18 years 




Interventions: Eligible patients who consent to participate will be randomised in equal proportions to receive a 
second biopsy, either with PET scanning and targeted CT biopsy or a standard CT guided biopsy. 
 
Image acquisiton will be standardized as much as practically able, across the sites. All sites are members of the 
PET/CT research network, which undertakes regular quality assurance measures (under the supervision of the 
NCRI PET core lab based at St. Thomas' Hospital in London) to ensure the PET centres have standards to 
deliver high quality PET data for multicentre trials. 
 
Participants allocated to the PET group will first undergo a PET-scan. This will take place at the recruiting centre 
where these facilities are available locally, or at the regional PET centre. 
 
The pleural biopsy will then be performed with CT guidance but targeted to areas highlighted on the PET-scan. 
The PET scan is to take place within the 2 week window period while patients are awaiting the CT guided biopsy. 
 
The other group will have a standard CT guided biopsy. 
 
If the results of this second biopsy (whether PET targeted or standard CT) are also negative for cancer the 






All patients regardless of which arm they are randomised to, will have serum Mesothelin levels performed at 
baseline and at each follow up visit (1, 3, 6 monthly and at 12 months from recruitment). 
 
Primary outcome: A definitive diagnosis of cancer on the second biopsy. 
Secondary outcomes: Secondary outcomes will include 
• Total number of invasive procedures (video-assisted thoracic surgery [108] or radiology guided 
biopsies) undertaken following randomisation to confirm the diagnosis 
• Time from randomisation to cancer diagnosis (those not diagnosed with cancer will be censored at last 
follow-up) 
• Time from randomisation to death (survivors will be censored at last follow-up) 
• Total number of hospital attendances following randomisation to confirm the diagnosis 
• Procedure related adverse events 
• Fitness for chemotherapy following a positive diagnosis (assessed using objective published criteria) 
• Uptake of chemotherapy following a positive diagnosis, in the 12 months following recruitment 
• Health status as measured using EQ-5D 
• Estimated costs associated with health-related resource use from randomisation to diagnosis 
• Serum Mesothelin levels measured at baseline and 6 months 
• PET scan parameters (TGV, maximum and mean SUV) (PET-CT group only) 
 
 
Participant follow-up: Participants will have clinical follow-up at 1, 3, 6 and 12 months. At each follow-up 
appointment participants will have a chest X-ray and a clinical examination of the chest as a minimum. They will 
also have serum mesothelin levels repeated at each follow-up visit. Active participation in the trial will end at 12 
months after randomisation or death, whichever is sooner. Unidentified underlying malignancies will become 
apparent during follow-up year, due to radiological and clinical deterioration. 
 
Sample size: The study size has been set at 78 participants, 39 allocated to the CT guided biopsy group and 39 to 
the PET-CT guided biopsy group. A study of this size will have 80% power (5% statistical significance) to detect a 
difference of 30% in the proportion of participants with a positive cancer diagnosis after the second biopsy (20% in 
CT group vs. 50% in PET-CT group). This difference represents a large effect size, but is consistent with our audit 
data, and would be sufficiently compelling to lead to a change in practice. A study of this size will also have 80% 
power to detect a doubling of the “hazard” (hazard ratio of 2) for time to diagnosis or survival, assuming 5% 
dropout. 
 
Recruitment rate: Recruitment will take place over a 24 month period across 6 institutions (average 6 to 7 
patients per year per site). Our audit data suggest these numbers are achievable. 
 
Recruitment: Potential study patients will be identified by principal investigators (PIs) at each site at the local lung 
cancer multi-disciplinary team meetings (MDTs). A member of the local research team (trial investigator or 
research nurse) will send study information to eligible patients, before meeting them at their next hospital visit, 
when they will discuss the trial and answer any questions. Patients willing to take part will then be asked to 
provide written informed consent. Detailed screening logs of all referrals, including reasons for ineligibility, non- 
approach and non-consent, will be kept. 
 
Randomisation: Randomisation, via a secure internet based randomisation system ensuring allocation 
concealment will occur after consent and collection of baseline data. Allocations in a 1:1 ratio to CT or PET-CT 
guided biopsy will be computer generated with varying block sizes, and stratified by centre. 
 
Evaluation of PET scans:  The PET scans will be reported by local radiologists using a standard protocol.  The 
Standard Uptake Value (SUV) and Total Glycolytic Volume (TGV) will be calculated using validated software in 
routine research use, in the participating centres. According to SUV and TGV values areas will be highlighted for 
biopsy when patient returns for their subsequent CT-guided biopsy. 
 
Evaluation of CT scans: All CT components of the scans will be reported using a volumetric assessment. The 
modified RECIST criteria are the standard radiological criteria currently in use to stage mesothelioma11. These 
criteria will be used for reporting and staging patients with mesothelioma in our study. 
 
Pleural biopsies: All pleural biopsies will be performed by one radiologist at each recruiting centre to minimise 
operator variability.  All radiologists will follow a standard protocol to ensure similar biopsy site selection. The 
radiologist will not be blinded to the treatment group for safety reasons.  Audit data suggests that the radiologists 





To minimise variability further for participants in the PET-CT guided group, the area selected for biopsy will be 
the area with the maximum SUV, taking into account possible changes due to previous biopsy and regions of 
pleura that are safely accessible to percutaneous biopsy. If no area of increased SUV is identified the most 
accessible and suspicious area on the CT will be biopsied. 
For participants in the CT-only guided group the radiologist will select an accessible area with suspicious 
malignant features.  Biopsy results will be captured in the study database and discussed in the MDT. 
 
Evaluation of biopsy specimens: The histopathologists interpreting the biopsy specimens will be blinded to the 
treatment group and clinical details. 
 
Blood sampling: Participants will have blood tests at recruitment and at each follow up visit at 1 month, 3 months, 
6 months and at 12 months from recruitment the biomarker mesothelin. 
 
Data collection: Data collected for the study will be entered into a purpose-designed database, developed by the 
clinical trials unit collaborating on this trial. The database will be hosted in the NHS and accessed via the NHS 
clinical portal (password controlled). It will include facilities to upload PET, CT and biopsy reports directly into the 
database. The database will include real-time data queries for missing or erroneous data, to ensure data quality. 
 
Statistical analysis:  The analyses will be by intention to treat. All randomised participants will be included, unless 
consent is withdrawn. The number of positive biopsies will be compared, as a proportion of the participants 
recruited and as a proportion of those with a confirmed diagnosis of mesothelioma in the 12 months following 
randomisation using logistic regression. Other binary outcomes will be analysed similarly. Time-to-event 
outcomes will be compared using survival methods. Quality of life data will be analysed using mixed regression, 
accounting for the correlation between repeated measures on one individual and will be modelled jointly with 
survival. Differences between groups will be quantified and reported with 95% confidence intervals. If the data 
are sufficient to allow parameter estimation, we will adjust for centre as a random effect. The ability of the serum 
Mesothelin levels to predict a positive diagnosis (sensitivity, specificity, positive and negative predictive values, 
area under Receiver Operating Curve) will be assess for the study cohort as a whole. Similar analyses of the 
value of the PET scan parameters to predict a positive diagnosis will be restricted to participants in the PET-CT 
group. The analyses will take place at the end of the study after all queries have been resolved and the database 



















Please describe your plans for disseminating the findings of this research 
 
We hope to publish the results of this study in a high impact respiratory journal such as Thorax or Lancet where 
respiratory and general physicians who are managing pleural malignancies have access to. To simplify the 
diagnostic process of mesothelioma we propose a  ‘mesothelioma diagnostic pathway’ be incorporated into the 
publication with emphasis on where PET- guided biopsy sits on this pathway. We hope the study results will help 
inform the next BTS pleural disease guidelines. 
 
Presentation at international research conferences such as British Thoracic Society (BTS) Winter meeting and 
European Respiratory Society (ERS) annual meeting, again with emphasis on the pathway to simplify the 
diagnostic process. 
Our mesothelioma focus group who assisted us with the design and feedback during the initial preparation of this 
application will be informed either in writing and at a group meeting. 
A lay summary of the results will be presented at an Avon Mesothelioma group meeting and at a 









Please describe how the outcomes of this research could be translated into the NHS and wider healthcare 
community to provide improvements in service delivery, patient health and/or wellbeing 
 
Findings from this study would be made easily accessible to respiratory specialists who are at the forefront of 
decision making regarding initial investigations. We aim to publish the results in a high impact journal such as the 
Lancet. 
We hope to collaborate with British Thoracic Society (BTS)/National Institute of Clinical Excellence (NICE) to 
introduce the mesothelioma diagnostic pathway for patients with suspected pleural malignancy, which would 
simplify and ensure uniformity across diagnostic investigations across the country. 
Principal investigators from each of the sites will be informed of the results along with the proposed 
mesothelioma diagnostic pathway as above. 
 
If PET-CT is proven to be superior in this study, it is an easily implemented investigation as PET-scanners widely 
available with the increasing use of this modality in cancer investigations. Our patient population is clearly 
defined and the number of patients who would be going down pathway are small. Therefore implementing this 
investigation as a routine for the clearly defined population is inexpensive. Furthermore in the longer term due to 
the fewer investigations these patients are having, likely to be more cost-effective than the traditional method of 
repeated CT guided biopsies. 
If this study is positive, future patients would gain the benefits of less invasive pleural investigations in total with 
less complications. More patients are likely to start life prolonging treatments and claims for mesothelioma cases 
are more likely to settle in the patient's lifetime. 
Furthermore, a positive outcome and inclusion into the investigation pathway of PET scanning might provide 
other valuable information for patient care such as prognostication using baseline PET - TGV (total glycolytic 












Relevant expertise and experience 
 
Please outline the individual role of each member of the research team, highlighting the skills and experience of 
the team that make them well placed to carry out the work 
 
The Bristol Pleural Trials Unit has extensive experience in conducting randomised studies in patients with pleural 
diseases, with over 500 patients enrolled over the last 7 years. Most of these studies have been multicenter and 
conducted in over 20 UK centres. 
The Oxford CTU also has an excellent track record with high data quality delivery to Oxford based multi-centre 
randomised trials. Results of these trials have been published in high profile journals (NEJM 2011;365(6):518-26, 
NEJM 352(9):865-74, JAMA.13;307(22):2383-9, AJRCCM 170(4):377-82) and entered standard national treatment 
guidelines (Thorax. 2010 65(8):667-9, Thorax. 2010 2:ii32-40). 
Dr N Maskell is a Reader in Respiratory Medicine at University of Bristol and runs a tertiary pleural service, 
holding 3 grants to conduct randomised trials in other pleural diseases and has substantial expertise in trial 
design and delivery. 
Najib Rahman has conducted 3 randomised studies in pleural disease (n=650 total), two of which are published 
with first or senior authorship (NEJM 2011, JAMA 2012). He leads the Oxford Pleural Service and ORTU, and 
has experience of methodology and design of clinical trials, with an MSc in Clinical Trials (LSHTM). 
Professor Fergus Gleeson has an international reputation in respiratory radiology disease, and provides expertise 
in radiological outcomes. Professor Iain Lyburn runs the regional PET service in Cheltenham Cobalt Centre and 
has published widely in this field. Dr Anthony Edey, Consultant radiologist at North Bristol NHS Trust has a 
specialist interest in pleural based imaging and sits on the regional Mesothelioma MDT. 
Dr. Chris Rogers is co-director of Clinical Trials Evaluation Unit (CTEU) and a senior statistician. She has 
experience of leading several NIHR funded multi-centre trials. She will provide methodological leadership to the 
trial. 
Ms Sarah Smith is a specialist nurse in lung cancer and mesothelioma with over 10 years’ experience working in 
this field. She is also a member of the Avon Mesothelioma Group and will work closely with patients and relatives 
for their feedback and input. 
Dr D de Fonseka is a senior respiratory registrar with an interest in pleural disease. She would work closely with 



















• Set up phase (1st 3 months): 
o Ethical and regulatory approvals 
o Protocol finalisation and CRF design 
o Database design, testing and validation 
o Recruitment of trial specific staff to respiratory trials unit 
o Sign off of trial related documents at first TSC meeting 
• Initial recruitment phase (9 months) to include: 
o 9 months of recruitment (at a rate of 3-4 patients per month) 
o TSC meeting 6 months into recruitment 
 




• Further recruitment phase (12 months) to continue recruitment (upto 78 patients, at a rate of 3-4 patients 
per month) 
 
• Data entry, verification and checking to occur “live” during recruitment phase 
• TSCat 6 monthly intervals to review progress 
• Follow up of all patients for minimum of 12 months to obtain final clinical diagnosis (gold standard) 
 
Year 3: (12 months) 
 
• Further 3 months of recruitment to complete 24 months (78 patients in total) 




Year 4: (3 months) 
 
• Final TSC meeting 
• Final phase (3 months of year 4) to ensure all patients have completed 12 months follow-up. Data 
analysis, report writing, presentation of results and publication (middle of 4th year) 
 
 
Research management arrangements 
 
Please explain the practical arrangements for managing the research and its constituent components 
 
Inolvement of the Clinical Trials Evaluation Unit (CTEU) at Bristol has enabled us to ensure good trial 
management is achieved according to good clinical practise guidelines, for the duration of this trial. A trial 
manager based at Bristol CTEU will ensure smooth running of the trial across the recruitment centres as well as 
be a first port of call for trial related issues arising from other centres. 
 
Trial manager will ensure regular 6 monthly trial steering committee meetings to identify and resolve any 
practical issues that may hamper the progress of the trial. 
 
Trial manager  will ensure any new changes are relayed to the other recruiting centres and regular progress 
updates including recruitment targets achieved or not, are made available to all members of the research team. 
Research teams at other recruiting centres are overseen by the prinicpal investigator (PI) at each site, who in 





Has any work relevant to this proposal already commenced? No 
 
 
Success criteria and barriers to proposed work 
 
Please set out the measurements of success you intend to use and also the key risks to delivering this research 
and what contingencies you will put in place to deal with them 
 
Measurements of success – achieving the recruitment rate set out at 3-4 patients per month. 
 
If recruitment is significantly lower than the anticipated rate of 3-4/month in the initial 6 months since starting 




1.   Invite other sites to enrol in the trial to improve recruitment rates (we have four extra sites expressing 
interest if needed) 




As the follow-up period is clinical follow up that would happen as a part of routine clinical practice anyway, 
extending the recruitment period by a further 6 months and hence delaying follow-up by a further 6 months would 




Does the proposed research raise ethical issues? Yes 
 
 
If yes, discuss how these issues will be addressed. 
 
Ethics may question that with such a high sensitivity why PET-scanning is not offered as the first line investigation 
in this group of patients. Our pilot data is small and there is some selection bias in the patients who had biopsy 
following PET-scanning. Therefore, our data is not robust enough for a direct comparison against CT, which would 
be best achieved with a randomised controlled study as we have suggested. 
 
Ethics may also highlight the extra radiation dose received by the PET scanning but as these are a terminal 
group of patients, the longterm effects of the extra radiation is insignificant here. 
 
 
Please detail how and when you intend to get ethical review completed 
 
We hope to apply to Bristol REC in 8 weeks for ethical approval. 
 
 
Have any appropriate regulatory bodies already granted the 
necessary approvals? No 
 
Involvement of Clinical Trials Units 
Is Clinical Trials Authorisation required? Yes 
 
 
Is a Clinical Trials Unit (CTU) involved with this research proposal? Yes 
 
 
If yes, what is the name of the CTU? 
 
Please provide the name of the CTU involved. 
Bristol Clinical Trials Evaluation Unit 
 
 
Does the CTU hold a UKCRC registration number? Yes 
 
 






Please describe how you have worked with the CTU in developing your application and what support they will 
provide if funding is approved 
 
Dr Chris Rogers co-director of CTEU has appraised the research proposal, calculated the sample size for the 
study in discussion with the clinical investigators and has advised on the study design and statistical analysis. 
 
We would be relying heavily on CTEU throughout the trial. CTEU will provide the necessary research 
management support and staff for this project, such as a part-time trial manager, statistician and database 
manager. The trial manager will oversee the trial and attend trial steering committee meetings to ensure smooth 
running of the trial. 
A 24 hour web-based centralized randomization service is provided by the CTEU for randomization purposes. 
Database design, set up and management is provided by CTEU although data entry will be undertaken by the 
research fellow. All statistical analysis will be undertaken by the CTEU, in line with the analysis plan that they will 














Please describe links to NIHR networks, identifying, if appropriate, any benefits that have 
already accrued from working with networks 
 
We have established links with with members of the Avon Mesothelioma Foundation in 
preparation of this application. Particular input in the patient and public involvement 
section. 
We hope to disseminate our data at a Mesothelioma UK study day. 
Our study will be publicized in the British Thoracic Society(BTS) newsletter. If in the event 
recruitment opens to new centres other than those mentioned previously, we would advertise 
in the BTS newsletter. 
We hope to work closely with UKCRN 
 
 
Research Design Services (RDS) Involvement 
 
Please indicate, if applicable, which organisations (e.g. NIHR Research Design Service) you 





Please describe the RDS’s input 
 
Significant input from an RDS statistician, concentrating particularly in the methodology section 
but also help reviewing the rest of the application. Helpful input into how to improve the case for 
support and patient and public involvement sections of the application. 
 
Attending the grant application support workshop was very helpful. 
 
Involvement with other partners 














Patients should not eat any food for 6 hours prior to their appointment time, however 
it is important that they remain hydrated – water only. Light meal on the night prior to 
the PET scan and refrain from consuming alcohol. Medication can be taken as 
prescribed providing that it is not required to be taken with food. 
All patients must avoid exercise for at least 6 hours prior to their examination. 
Patients with diabetes: 
Type II diabetes 
PET study should preferably be performed late morning 
Patients must comply with the fasting rules above 
Type I diabetes 
Ideally an attempt should be made to achieve normal glycaemic values prior to the PET 
study, in consultation with patient and his/her attending medical doctor 
The PET study should be scheduled for late morning 
 
The patient should eat a normal breakfast at 7am and inject the normal amount of 
insulin. Thereafter the patient should not consume any more food or fluids, apart from 
the prescribed amount of water - adequate pre-hydration with 1 litre of water in the 2 
hours prior to injection of contrast.  
Parenteral nutrition and IV fluids containing glucose should be discontinued 4 hours 
prior to the PET examination. 
**IMPORTANT - Prior to arrival of the research patient please ensure that there is a 
signed copy of the patients consent form, an ARSAC certificate for the particular trial, 
ethics approval has been granted and you have read and understood the study 
protocol noting any variations such as FDG uptake time, which may be in variation to 
the protocol described below. 
1. On arrival take the patient through to the PET suite, explain procedure to 
patient and complete PET data acquisition form. Ask the patient if they have 
understood and whether they have any questions they wish to ask. Ask the 
patient to sign the data sheet to show that you have explained the procedure 
and they are happy to continue. 
2. Establish the patient’s weight and height. 
3. Enter the patient’s weight and height data into the automatic dispenser 
interface. 
4. Either ask the patient to lie supine on the couch in the Patient “hot” rest room 
and establish intra venous access using a cannula or insert a cannula whilst the 
patient is seated in the interview / preparation room. Insert the cannula into 
the forearm/antecubital fossa/hand on the opposite side to the site of 
pathology, with a triple-channel system (three-way tap) to enable saline flushes 




NB: Ensure that the injection site is chosen carefully so as not to interfere with 
any area on the scan which may be critical 
5. If the cannula is inserted in the interview room ask the patient to lie supine on 
the couch in the Patient “hot” rest room once IV access has been established. 
 
6. Take approx. 0.5 mls blood for a pre-scan glucose measurement (normal fasting 
value = 3-5 mmol) and, if you are not going to use it immediately, keep the line 
patent by flushing with 10 ml of 0.9% saline. 
 
7. Once the automatic system has completed dispensing, inject the activity into 
the patient using the ‘Radinject’ system  and then record the exact activity and 
time it was measured on the Data Acquisition form, then remove the IV access. 
8. If dispensing manually then calculate the required volume in order to 
administer the required dose (for the purpose of TARGET trial this should be 
less than 400MBq) of 18FDG by using the standard protocol.  When you have 
drawn up the required volume of FDG record the exact activity and time it was 
measured on the Data Acquisition form, then inject it followed by 10 ml of 0.9% 
saline flush, then remove the cannula. 
9. Make sure the patient is warm enough and allow him/her to rest quietly for the 
60 minute uptake period.  
10. At the end of the uptake period ask the patient to go to the toilet to empty 
his/her bladder. 
11. Position the patient on the scanning couch (supine, head first) with his/her 
head resting on the headrest.  Try to ensure that the patient’s head is not 
turned to one side or the other and explain the importance of keeping the head 
straight. 
12. If the patient is able, ask him/her to raise their arms above their head and place 
them on the arm support provided.  If required and the patient agrees, the 
arms can be placed within the Velcro arm straps / supports. Explain to the 
patient that the scan will take about 15-20 minutes in this position. If the 
patient is unable to hold their arms up above their head or thinks they might 
struggle to keep still, get them to hold their hands together and rest them 
anteriorly over the pelvis.   
13. Ensure that the patient is comfortable and warm enough. Explain to the patient 
exactly what will happen during their examination and explain the 
requirements on them to remain still. Explain to the patient that we can hear 
them at all times and will be watching them throughout the scan to ensure 
their safety. 
14. Using the gantry controls, raise the bed to a height of -150 and move the 
patient into the gantry. Ask the patient to close their eyes whilst you position 





15. Allow the patient to open their eyes if they wish and explain again that they 
need to remain still. 
16. Return to the control room and set up the pre – scan information. Select the 
patient from the scheduler and input their height and weight details, referrer 
details, FDG / Radiotracer details including time measured and time injected 
and blood glucose measurement details. 
17. Patient can be scanned using the standard clinical scanning protocol used at 
the each centre. Load the protocol and click ‘OK’ and wait for the control panel 
yellow scan button to flash. Press this button once. 
18. Adjust the length of the scan as required (i.e. lower orbits to mid-thigh), using 
the left hand mouse button to select length / move options / boxes on the 
scout view that has been produced. Click again on load and wait for the control 
panel white move button to flash. Press this button continuously until the 
yellow scan button starts flashing. Press the yellow button once to start the low 
dose CT acquisition. 
19. The white move button on the control panel will start flashing, press once and 
the PET acquisition will commence. 
20. Once the scan has completed the acquisition boxes will become active again. 
Click on the CT ‘free’ box (empty recon box) and position the guidelines on the 
half body image to outline the Lungs. Click on recon and ok. The lung images 
will then be reconstructed using a lung CT window. 
21. On the left hand screen go to the image tag at the top of the window and select 
‘create ranges’ which will run in the background. On the right hand screen click 
on the close scan icon and then ok. Release the patient from the scanner and 
explain any aftercare required. 
Once the images have reconstructed archive them to the PACS system and 
send them to the relevant reporting station. Complete all of the dose 
information on RIS and within the patients data sheets and send the patients 
folder to the reporting station. Please Note: at the end of the trial we will 




Scanner Settings for Half Body Examinations. 
Attenuation CT Scan Parameters 
 
KV   120 
MAs/slice  80 (max – actual will vary according to dose saving software) 
Rotation Speed 0.5 
Collimation  16x1.5mm 
Pitch   0.6 
Dose Right  Yes 
Slice Thickness  5 mm 
Increment  5mm 







Incidental findings on PET-CT 
Incidental, non-pleural based high uptake areas on the PET-CT scan is to be 
investigated at the attending clinician’s discretion. 
If the PET-CT scan detects a more accessible high up take area, which may be extra-
pleural (for example a liver metastases that is easily accessible), and the radiologist 
feels this is a better area for biopsy than the pleural lesion, the extra-pleural lesion can 
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Research for Patient Benefit 
 
Reference number PB-PG-1014-35052 
Lead Applicant Dr Nick Maskell 
 
Research Title Zoledronic acid in the management of malignant pleural mesothelioma - a 



















Malignant mesothelioma is an incurable cancer of the lung lining that 
usually develops as a result of previous asbestos exposure. This is an 
incurable disease with an average survival of 9 to 14 months from 
diagnosis. Treatment proven to prolong life is limited to one form of 
chemotherapy which only extends life by a few months, on average. 
 
Zoledronic acid (ZA) is a licensed drug that is commonly used for the 
treatment of bone disease, such as thinning of the bone (osteoporosis) and 
in cases where bone deposits occur from other cancers. This drug has 
been is use for a number of years with a good safety record. Animal 
studies in mice have shown ZA may have a role in the treatment of 
mesothelioma by slowing the disease. It is not a curative treatment but it 
may have a role in prolonging life. In animal studies where ZA was used in 
combination with certain chemotherapy regimens there appears to be an 
even greater effect. 
 
Unfortunately at this stage the drug is not licenced in mesothelioma, mainly 
due to the lack of human studies. We propose a preliminary study to 
assess the practicality of running a trial to establish the role of ZA in 
patients who have mesothelioma and are undergoing or eligible for 
chemotherapy. We plan to assess the benefit of giving ZA in addition to 
chemotherapy in half the patients and compare this with chemotherapy 
alone in the other half of the patients. Neither the patients nor the 
investigators will know what treatment they have been allocated until the 
end of the study. In addition, patients who decline to have chemotherapy 
will be offered the ZA drug alone to assess whether there is any benefit to 
having this ZA on its own. 
Total Research Cost 287,465.00 
 
 
The Department of Health, National Institute for Health Research (DH NIHR) is the Data 
Controller under the Data 
Protection Act 1998 (‘the Act’). Applicants for funding should be aware that information 
contained in this 
application might be shared with other DH NIHR bodies for the purposes of statistical analysis 
and other DH NIHR management purposes, including targeted communications with selected 
groups of researchers. Applicants may be assured that DH NIHR is committed to protecting 
privacy and to processing all personal information in a 






1. Research Details 
 
 
Research title Zoledronic acid in the management of malignant pleural mesothelioma - a feasibility study (Zol-A Study) 
 
 
Host organisation (which will administer any award) 
 
North Bristol NHS Trust 
 
 
Research duration 30 
 
 
Proposed start date if 
grant awarded 01/10/2015 
 
 
Application type Feasibility Study 
 
 
Themed call name Mesothelioma 
 
 





7. Patient and Public Involvement 
 
In this section it is important that you describe, in as much detail as possible, how patients and the public have 






Were patient and the public actively involved in either identifying the research topic/prioritising the 





If Yes, please tick the appropriate boxes below 
 
Involved in identifying the research topic/prioritising the research questions,Involved in preparing the Application 
 
 
Please further describe how patient and public involvement has informed and/or influenced the development of 
the application and how patients and the public have been actively involved. 
 
Identification of the research topic 
The UK government in conjunction with the NIHR recently funded a James Lind Alliance (JLA) Priority Setting 
Partnership (PSP) to identify research priorities in mesothelioma. The PSP comprised of patients, carers, health 
professionals and organisations involved in the care of patients with mesothelioma. The Lead Applicant (Dr 
Maskell) was a member of the PSP and the steering committee. Over 800 responses were received from 
patients, carers or health care professionals. These were then ranked and the role of Zoledronic acid (ZA) in the 
treatment of mesothelioma appeared in the top 50 questions that needed answering. In addition to this the final 
top 12 ranked questions were published in December 2014 at http://www.lindalliance.org/top-tens.asp. This 
highlighted two other questions pertinent to our research: 
Question Rank 11. Can PET-CT scans help to aid the assessment of response to treatment? 
Question Rank 12. How can the level of mesothelin be best incorporated in the diagnosis, response and 
progression of mesothelioma? 
 
PPI involvement in study design and development of the application 
During development of the research plan and preparation of this application, patients, carers and patient groups 
have been consulted. Drafts of the application have been presented to a focus group from the Avon 
Mesothelioma Foundation (a local mesothelioma charity and support group). This was made up of eight 
mesothelioma patients and 2 carers. We have amended the study design to reflect their views including their 
preference to have the ZA infusion on a different day to their chemotherapy and the addition of a further non- 
randomised observational arm of patients who declined chemotherapy but still wanted to receive ZA. As the 
numbers are likely to be small and our follow-up time constraints we have not randomised this arm, although this 
data will help with planning of a randomised non-chemotherapy group in the full study. 
The trial involves extra out-patient visits. Patient/carer feedback unanimously agreed that extra clinic visits would 
not be an issue, in fact they felt these visits would give them further opportunities to ask questions and to have 
more contact with the specialist hospital team. 
 
 
Please indicate the ways in which the public will be actively involved in the proposed research, by ticking all 
relevant boxes below. 
 
Management of the research (e.g. steering/advisory group),Developing participant information 
resources,Contributing to the reporting of the study report,Dissemination of research findings 
 
 
Please give more details, including how patient and public involvement will benefit the research, the reasons for 
taking this approach and arrangements for training and support. 
 
In addition to the input in the research design process outlined above, we plan to involve patients and carers 
during the set up and running of the trial as highlighted below. 
Patient/carer group will be involved in preparing the lay summary and patient information sheet for the study. In 
addition, we will be asking them for any further comments on the final protocol including identifying any practical 
issues that could be addressed to help support patients participating in this trial. 
The research team will also consult with the focus group periodically before any changes to the study protocol or 





Unfortunately due to the terminal nature of the disease and rapid deterioration it is difficult for a patient with 
mesothelioma to sit on the trial steering committee (TSC) for the duration of the trial. We have therefore 
approached a carer who will join the TSC. 
We intend to request help from the focus group in overseeing the writing of the final results of our research. The 
results will be presented to our focus group mentioned above. On a regional scale results will be presented at an 
Avon Mesothelioma Foundation study day, which is attended by patients and carers of mesothelioma in the 
South West region. 
We have also requested involvement of the Research & Innovation (R&I) team’s generic lay panel to review our 
patient information sheets and other literature that patients would come across. This would allow for an opinion 






8. Case for Support - Part 1 
 
 
Aims and objectives 
 
Describe the overarching aims of the research, outlining the research question which the work will address 
 
Malignant pleural mesothelioma (MPM) is an incurable cancer, which affects over 2500 people each year in the 
UK. It is an under-researched area and therefore has been given recent NIHR priority for funding. The aim of our 
research programme is to determine the role that Zoledronic acid (ZA), licenced for other conditions but not for 
mesothelioma currently, could have in the management of MPM. Zoledronic acid will be administered 
intravenously alongside chemotherapy. We also hope to address the question of whether there is a role for ZA 
alone in patients who decline chemotherapy. 
 
We ultimately plan to undertake a multi-centre, randomised controlled trial (RCT) of ZA and 
Pemetrexed/Cisplatin chemotherapy versus placebo and Pemetrexed/Cisplatin chemotherapy to determine if the 
addition of ZA increases progression free survival (PFS) and overall survival in this population, compared to 
chemotherapy alone. Furthermore, the future trial will be used to assess a number of secondary but important 




Prior to undertaking an adequately powered Phase III trial, however, there are a number of uncertainties that 
need to be addressed. The purpose of the current study is to establish the feasibility of the full trial and to assist 




1.   Presentation, recruitment, consent and randomisation rates of MPM patients at each site. 
2.   Acceptability of recruitment procedures, consent and randomisation, and data collection methods. 
3.   Acceptability of ZA in MPM patients, and the optimal timing and location for ZA administration. 
4.   Qualitative assessment in a subgroup of 15 patients to evaluate patients experience in the randomisation 
and recruitment process 
5.   Quantification of drop-out and data completeness rates 
6.   Estimates of outcome event rates eg. survival times, measures of mean response and outcome variance 
(continuous variables such as quality of life) and confidence intervals around estimates of proportions, 
categorical variables such as recruitment rates)to use for calculating full trial size and number of sites. 
7.   Measure of variation between patients and between sites and information required to assess the intra 




We hope the feasibility study we propose would give us the necessary information to design a robust phase III 
trial to evaluate the role of ZA in mesothelioma. 
 
 
Scientific abstract of research 
 
Please provide a structured summary which outlines the background to the research, the aims of the work, 
including the question to be addressed by this research, the plan of investigation and a summary of the potential 
benefits to patients and the NHS 
 
Background: 
   Malignant pleural mesothelioma (MPM) is an incurable primary pleural malignancy with an average survival of 9- 
14 months and a 3 year survival rate of only 8%. Currently only one form of treatment (Pemetrexed and Cisplatin 
chemotherapy) has been shown in an RCT to give a survival advantage. But even with this treatment only a 
further 10-12 weeks of life is gained on average. Due to the toxic side effects of this regime and the co- 
morbidites of those who are diagnosed with the disease a significant proportion of patients are not eligible for this 
regimen. 
Zoledronic acid (ZA) is an n-bisphosphonate that has been used for a number of years to treat bone related 
pathology such as osteoporosis, Paget’s disease and bone metastases in certain cancers such as breast and 
prostate cancer. Studies in animal models inoculated with mesothelioma cells have been promising showing a 
survival advantage in those receiving ZA. Animal studies have also demonstrated a synergistic effect between 




Despite the encouraging results from animal studies there remains a lack of human trials investigating the 
benefit of ZA in mesothelioma. This is a drug that is well tolerated wiht minimal side effects and is widely used 
currently 





We propose a double blind randomised controlled multi-centre feasibility study to investigate the practicality of 
the trial prior to embarking on a phase III trial. We aim to investigate recruitment rates, suitability of the research 
plan and extrapolate numbers needed to achieve a clinically and statistically significant difference in the primary 
endpoint (should a difference exist). 
 
 
Plan of investigation: 
 
Patients with a histocytologically confirmed diagnosis of mesothelioma who are offered chemotherapy, with a 
World Health Organisation (WHO) performance status of 0 or 1 will be our patient population. Those who are 
undergoing chemotherapy will be randomised to ZA or placebo in a 1:1 ratio. Those who decline chemotherapy 
will be offered ZA on its own. These patients will form a third non-randomised group. 
We propose a feasibility study to recruit 50 randomised patients over 1 year. 
Randomised patients will either receive 4mg of ZA in 100ml of 0.9% saline or a placebo in 100ml of 0.9% saline 
over a 15 minute period. Patients will receive the infusion within a 24-48 hour window prior to their 
chemotherapy. Non-randomised patients who accept ZA will have 4mg in 100ml of 0.9% saline every 3 weeks. 
 
Potential impact: 
This feasibility study will have direct bearing on the proposed full study, which is a large scale multi-centre double 
blind randomised controlled study to investigate the effects of ZA in mesothelioma. The feasibility study will 
provide valuable information regarding recruitment methods and rates, consent procedures, randomisation 
success and acceptance, patient derived qualitative information and numbers required to recruit for a statistically 
significant primary outcome, tolerability of the drug and the robustness of our research plan. 
The full study will have a signifcant impact in that if successful and a survival benefit with ZA is demonstrated, 
this would be a fairly safe drug that can be easily administered alongside chemotherapy with minimum side 
effects, to extend life in mesothelioma patients. 
 
 
Background and rationale 
 
What is the problem being addressed? 
 
Describe the background to the research, describing the limitations identified in the evidence base that the 
research is trying to address. 
 
Malignant pleural mesothelioma (MPM) is an aggressive and fatal tumour of the pleura that usually develops as 
a result of previous asbestos exposure. Although the import of asbestos was banned over two decades ago, 
mesothelioma remains a major clinical problem in the UK. Health and Safety Executive data for 2012 shows that 
mesothelioma caused 2,535 deaths in the UK [1]. Current treatment for MPM is very limited and average 
prognosis from diagnosis remains poor at 9 to 14 months [2]. Pemetrexed and Cisplatin chemotherapy is the 
only treatment proven to extend patients’ life expectancy [3]. The survival benefit is a modest 10-12 weeks on 
average and approximately 40% of patients are not fit enough to tolerate this treatment at presentation. Despite 
the chemotherapy treatment life expectancy remains poor with a 3 year survival rate of only 8% [4]. Hence the 
desperate need for other treatments that could improve the length and quality of life in these patients. 
 
Bisphosphonates are a synthetic analogue of naturally occurring pyrophosphate. Bisphosphonates are 
commonly used in the treatment of osteoporosis and other bone disorders such as Paget’s disease, due to their 
action on inhibiting osteoclast mediated bone resorption [5]. Nitrogen containing bisphosphonates (n- 
bisphosphonates) have been shown to inhibit various epithelial cancer cells in vitro, by inhibiting the mevalonate 
pathway [6]. Potential anti-tumour activity of bisphosphonates include reduced tumour angiogenesis, reduced 
tumour cell proliferation, migration, invasion and adhesion, increased tumour cell apoptosis and increased 
cytotoxicity of gamma-delta T cells, which subsequently leads to reduced tumour vascularization [7]. 
Several studies using n-bisphosphonates, particularly Zoledronate have shown a survival benefit in patients with 
breast cancer [8, 9]. In vivo studies on mice inoculated with mesothelioma cells, treated with bisphosphonates 
have shown a significant survival advantage [10], supporting the direct anti-cancer properties of bisphosphonates 





cell and non-small cell lung cancer, both showing a reduction in tumour burden and increased survival in mice 
treated with n-bisphosphonates [11, 12]. 
Zoledronic acid (ZA) is known to be a potent nitrogen containing bisphosphonate which has bone independent 
anti-tumour activity. In addition, when combined with certain chemotherapy agents such as Paclitaxel, Etoposide, 
Cisplatin and Irinotecan in lung cancers, it was shown to have an even greater synergistic effect in induction of 
apoptosis in vitro [11]. 
As human studies investigating the synergistic effect between ZA and chemotherapy do not exist, the optimum 
timing of ZA in relation to chemotherapy is still unknown. Murine models using subcutaneously injected breast 
cancer cells have shown the greatest effect on increasing apoptosis, reducing proliferation and 
neovascularization was seen when the cytotoxic drug was given 24 hours after ZA [7]. 
There remains an absence of evidence in the literature regarding the effects of ZA in mesothelioma in humans. 
Our institution recently completed a small pilot study investigating the effect of ZA in patients with advanced 
malignant pleural effusions, who were not on any other form of treatment (currently in submission to PLOS one). 
This small study included a few patients with mesothelioma and although it failed to show a significant treatment 
effect with ZA for all malignant pleural effusions, two of the six patients with mesothelioma given ZA showed a 
reduction in tumour bulk according to modified RECIST criteria, thereby highlighting the need to investigate the 
effect of ZA further in a study with exclusively mesothelioma patients. In addition, there are reports of ZA being 
used ‘off licence’ by certain centres on a patient to patient basis[13]. 
A double blind multi-centre RCT would be best placed to investigate the hypothesis that treatment with n- 
bisphosphonate ZA in addition to the standard chemotherapy (Pemetrexed and Cisplatin) confers a survival 
benefit to patients with MPM compared to chemotherapy alone. We propose a feasibility study prior to 
undertaking a full study to capture the data needed to inform the definitive trial. In our feasibility study a non- 
randomised third group will consist of patients who are fit for chemotherapy but have declined to have 
chemotherapy. These patients would be offered ZA in isolation. 
Soluble mesothelin related peptide (SMRP or Mesothelin) is a glycoprotein found on the surface of mesothelial 
cells that can be over expressed in mesothelioma. Studies have shown significant correlation between 
mesothelin levels in serum and tumour burden in mesothelioma [14]. We propose using serum Mesothelin as a 
biomarker for monitoring tumour response state in the study to assess its value in the full trial. 
Positron emission tomography computerised tomography (PET-CT) has proved itself a useful diagnostic and 
staging imaging modality in mesothelioma, due its ability to highlight areas of increased metabolic activity by 
uptake of 18-Fluorodeoxyglucose (18-FDG), which is used as a nuclear tracer for this form of imaging. Total 
glycolytic volume (TGV) has been shown to be a more robust measurement of total mesothelioma activity [17] 
and our centre has expertise in measuring the PET TGV because of our previous work on the SWAMP trial 
(currently in submission to British Journal of Cancer). A baseline PET-CT scan and a repeat PET-CT scan after 3 
cycles of chemotherapy will be performed and evaluated using PET response criteria in solid tumours 
(PERCIST) or methodology analogous to this to assess treatment response or not and if it should be used in the 
main trial [18]. 
 
 
Why is this research important in terms of improving the health of the public and/or patients and the 
NHS? 
 
Malignant pleural mesothelioma (MPM) is an incurable cancer, which is becoming more prevalent in the UK and 
represents a major public health issue. It is estimated that over 1% of men born in the UK in the 1940’s will die 
from mesothelioma and currently over 2500 new cases are diagnosed in the UK each year. Despite this, high 
quality research in this field is lacking. This has resulted in the UK Government commissioning the James Lind 
Alliance (JLA) to set up a Priority Setting Partnership to identify research priorities in mesothelioma [15]. After 
extensive consultation with the public, carers, patients and healthcare providers, 50 key questions were identified 
that required urgent research. This included the question ‘What is the role of Zoledronic acid in the management 
of mesothelioma?’. 
Our study will, by helping in improving the design of the full trial, also address two further JLA questions that 
were ranked in their top 12 research priorities in mesothelioma. These are: 
 
1.   Can PET-CT scans help to aid the assessment of disease response? 
2.   How can the levels of mesothelin be incorporated in the diagnosis, response and progression of 
mesothelioma? 
 
Zoledronic acid (ZA) is used in a number of different cancers for a variety of its properties. Animal studies with 
mice inoculated with mesothelioma cells who were treated with ZA have shown a clear survival benefit. 
Furthermore, ZA and certain chemotherapy agents such as Cisplatin appear to have a synergistic and additive 
effect. 
This research addresses an important question regarding the role of ZA in patients with mesothelioma. Apart 
from a small study in USA looking at the role of ZA in advanced mesothelioma (expected to report early 2016) 





good functional status who are able to have other life prolonging treatment as well. Despite the lack of any 
evidence in mesothelioma patients, this drug is used in a number of centres off licence, on a patient by patient 
basis. Therefore access to ZA across the UK is currently unequal. We hope this feasibility study will pave the 
way to a phase Ill trial that can answer the question 'What is the role of ZA in mesothelioma?' and if it is found to 
be of benefit it will provide robust evidence for the NHS to consider its routine use in this setting across the UK. 
As ZA has a good safety profile and is generally well tolerated it might also prove useful in those patients not 












Describe the proposed research plan, providing descriptions of the overall research design and a strong 
justification of sampling strategies, methods of data collection and analysis. 
 
It is vital to add as much detail as possible on design and methodology, including justification of sample size, 
power calculations and sample selection and exclusion criteria where applicable. 
 
Study design: 
We propose a multi-centre double blind randomised controlled feasibility study to compare standard first line 
chemotherapy (Cisplatin and Pemetrexed) plus Zoledronic acid (ZA) versus chemotherapy and placebo, in 
patients with histocytologically confirmed Malignant Pleural Mesothelioma (MPM). 
A third non-randomised group to this feasibility study would consist of patients with MPM who are fit enough to 
receive chemotherapy but have declined. They would be offered ZA (open label) on its own. We have included 
this arm to the study as per PPI feedback, that patients who decline chemotherapy should still have access to a 
potential treatment for MPM. We anticipate the number of patients in this third group will be small and hence we 
have not included a fourth placebo-without-chemotherapy group. Depending on the feasibility outcomes 
particularly recruitment rates to this arm, when designing the Phase III trial we can consider a four group trial. 
 
Population: 
Patients with a histocytologically confirmed diagnosis of MPM with a WHO performance status 0 or 1. 
 
Setting: 
Three hospitals in the South-West region of the UK; North Bristol NHS Trust (NBT) which would be the lead 
centre, Bristol Royal Infirmary (BRI) and Royal United Hospital (RUH), Bath. Patients will be recruited and 
managed by respiratory and oncology departments at the above hospitals. 
Inclusion criteria: 
-Histocytologically confirmed diagnosis of MPM 
-fit enough to receive chemotherapy (WHO performance status 0-1) 
-measurable disease on CT as per modified RECIST criteria (tumour thickness >5mm) 
Exclusion criteria 
-Not fit for chemotherapy due to performance status or other co-morbidities 
-Previous chemotherapy for MPM 
-IV bisphosphonates in the 3 months preceding randomisation 
-significant renal disease (calculated as a creatinine clearance of < 40 ml/min as per Wright’s formula (ref)) 
-Hypocalcaemia on baseline blood tests (defined as a level less than 2.20 mmol/L) 
-Pregnancy or lactation 
-Age < 18 years 
-Known allergy to bisphosphonates or excipients of its preparation 
-Severe untreated dental caries 
 
Patient identification and trial interventions: 
Patients will be identified from the local lung cancer and mesothelioma multi-disciplinary team (MDT) meetings 
and respiratory/oncology out-patient clinics. Patients who have a confirmed histological or cytological diagnosis 
of mesothelioma who are eligible for chemotherapy will be identified as potential candidates. 
When patients attend the out-patient clinic for their diagnosis following biopsy, they are usually given information 
about further management. These may very occasionally include surgical options, but usually consist of palliative 
chemotherapy or best supportive care. Those who are candidates for palliative chemotherapy and willing to 
proceed with chemotherapy will be approached by a member of the research team with a patient information 
leaflet regarding the trial. 
Patients are next seen when they attend to see the lung cancer/mesothelioma nurse specialists. The research 
nurse will again approach the patient to discuss the trial at this appointment. If the patient is happy to take part 
and meet the eligibility criteria they will be consented at this appointment. Following consent they will have their 
baseline investigations as below. A baseline PET-scan will be arranged between this appointment and their first 
cycle of chemotherapy. 
It is anticipated the patient’s next visit to hospital would be for chemotherapy therefore, patients will be 
randomised before this visit. 
Patients who decline chemotherapy following discussion with the respiratory physician or oncologist will be 





are interested in the trial will be given information pertaining to the third arm only. 
Baseline Assessment (before randomisation): 
-Baseline bloods (Serum mesothelin, FBC, Urea & Electrolytes, Calcium, Phosphate, Magnesium) 
-Baseline breathlessness Visual Analogue Scale (VAS) score 
-Baseline PET-CT scan 
Randomisation: 
Patients who are proceeding with chemotherapy, will be randomised to receive either ZA or placebo, using 
software developed at Bristol Clinical Trials Evaluation Unit (CTEU). Randomisation will be stratified by centre 
and minimised by histology; epithelioid or other. 
Patients declining chemotherapy but wishing to take ZA only arm will not be randomised as described earlier. 
 
Trial interventions: 
Randomised patients will receive either ZA or placebo with each cycle of chemotherapy. Prior to each cycle of 
chemotherapy all patients will have routine pre-chemotherapy bloods (FBC, U&Es, clotting screen) and trial 
bloods (Calcium, phosphate, Magnesium, Serum Mesothelin level). 
The dose of ZA will depend on the estimated creatinine clearance, as calculated using the Wright equation [16]: 
 
Estimated creatinine clearance (ml/min) as calculated by the Wright Equation Dose of Zoledronic acid (mg) 
≥60 4 
≥50- <60 3.5 
≥ 40-<50 3.3 
 
Zoledronic acid in 100ml of 0.9% sodium chloride or placebo in 100ml of 0.9% sodium chloride will be prepared 
ready for use as necessary depending on the randomised allocation. 
The drug will be delivered within a 24-48 hour window before each cycle of chemotherapy as a single dose, 
delivered intravenously over a 15 minute period. 
Patients in the non-randomised group who are not having chemotherapy would have ZA every 3 weeks, in the 
same manner as above. They will have routine and trial bloods checked 2-4 days prior to each cycle of ZA. 
Patients, clinical and research staff will be blind to allocation (except for patients in the open labelled third arm). 
Patients who experience a fall in serum calcium, magnesium or phosphate will be supplemented as necessary 
with oral agents. If necessary the next infusion maybe delayed or missed. 
If electrolytes remain persistently low despite supplementation, no further ZA or placebo will be administered and 
the patient included in an intention to treat analysis. Failure to complete the full course of treatment will be 
documented. 
All patients will have a repeat PET-CT scan after their third cycle of chemotherapy. 
Patients will have routine chest CT scans as per their usual care following 3 cycles of chemotherapy and post- 
completion of chemotherapy (usually after 6 cycles). Patients in the non-randomised 3rd arm will have CT scans 
after 3rd and 6th cycles of ZA. 
 
Outcome measures 
The feasibility of this study will be assessed using following criteria: 
 
1.   Presentation, recruitment, consent and randomisation rates of MPM patients at each site. 
2.   Acceptability of recruitment procedures, consent and randomisation, and data collection methods. 
3.   Acceptability of ZA in MPM patients, and the optimal timing and location for ZA administration. 
4.   Qualitative assessment in a subgroup of 15 patients (5 patients from the randomised group, 5 patients 
from the non-randomised group and 5 patients who declined to participate in the study) to evaluate 
patients experience in the randomisation and recruitment process 
5.   Quantification of drop-out and data completeness rates 
6.   Estimates of outcome event rates eg. survival times, measures of mean response and outcome variance 
(continuous variables such as quality of life) and confidence intervals around estimates of proportions, 
categorical variables such as recruitment rates)to use for calculating full trial size and number of sites. 
7.   Measure of variation between patients and between sites and information required to assess the intra 




Information gathered from the feasibility study will be used to design the definitive phase III trial and inform the 
choice of primary and secondary endpoints. 
Anticipated potential end points for the full trial are as below: 
 






• Rate of progression in MPM, as measured by modified RECIST criteria on CT, after 6 cycles post- 
chemotherapy. 
• Progression free survival 
• Overall survival 
• Tumour metabolic activity as determined by Total glycolytic volume (TGV) on PET-CT scans, after 3 
cycles of chemotherapy 
• Value of TGV or standard uptake value (SUV) in the assessment of disease response/progression 
• Serum mesothelin as a useful biomarker for monitoring disease and detecting treatment response 





We propose a sample size of 50 randomised patients (25 per group) recruited from three sites. 
The third non-randomised arm will be recruited in parallel and we anticipate 10-15 patients during the 12 months 
of recruitment. 
A study of this size would allow an assumed 40% consent rate (125 eligible, 50 recruited) to be estimated with a 
confidence interval of +/- 9%. 
 
Recruitment: 
Recruitment will be from three large NHS hospitals in the South West region; North Bristol NHS Trust (NBT) 
Bristol Royal Infirmary (BRI) and Royal United Hospital (RUH), Bath. North Bristol NHS Trust will act as the host 
and the lead recruiting centre. 




A recruitment rate of 4-5 patients per month from the 3 centres is anticipated over the 12 month period. This 
would allow us to recruit our target of 50 randomised patients in a 12 month period. 
 
Follow-up: 
Patients will have routine follow up with oncology as per their usual care, which is normally prior to each cycle of 
chemotherapy. Appropriate case report forms (CRF) will be filled at each visit. 
Patients in the ZA only non-randomised arm will have regular clinical follow up as per their usual care. 
All participants will have trial follow-up at 6 and 12 months from recruitment. 
CT scan evaluation: 
All CT scans will be evaluated using volumetric assessments. The CT scans will be reported using modified 
RECIST criteria as per current accepted staging criteria used in mesothelioma. 
 
PET-CT scan evaluation: 
These scans will be evaluated by a PET-CT specialist radiologist. Standard Uptake Value (SUV), TGV and PET 
Response Criteria in Solid Tumours (PERCIST) or methodology similar to this will be used for evaluation of the 
PET scans. 
Blood sampling: 
In addition to the routine pre-chemotherapy bloods patients would have as a part of their usual care, they will 
have additional bloods taken for extended electrolytes such as calcium, magnesium, phosphate and serum 
mesothelin levels. The additional bloods will be taken at the same time as their pre-chemotherapy bloods. 
Patients in the open labelled third arm will have the same bloods taken 3 weekly, prior to their next cycle of ZA to 
ensure electrolytes remain stable. 
 
Data Collection: 
Data will be collected on the appropriate CRFs at each research visit. All data collected as a part of the study will 
then be entered into a purpose-designed database developed by CTEU in Bristol. The database will include real 
time data queries for missing or incorrect data, to ensure data quality. 
 
Statistical analysis: 
As this is a feasibility study it is not powered to compare the outcomes between groups. 
Study outcomes will be described according to the allocated group (ie. by intention to treat). Binary outcomes 
(eg. recruitment and compliance rates) will be reported as a number and percentage and continuous outcomes 
will be reported as mean and standard deviation (or median and interquartile range if skewed). Survival rates will 
be estimated using the Kaplan-Meier method. Rates will be reported with 95% confidence intervals. These data 
will be used to inform the sample size calculation of the definitive phase III trial. 











Please describe your plans for disseminating the findings of this research. 
 
1. Our findings will be presented at national and international research conferences such as the British Thoracic 
Oncology Group (BTOG), British Thoracic Society and International Mesothelioma Interest Group (IMIG) to 
quickly inform the scientific and clinical community of any potential benefit this drug may have. 
 
2. We hope to publish the results of this study in an open access oncology journal such as Lancet Oncology so 
that oncologists managing patients with mesothelioma will have easy access. In addition once the protocol is 
finalized we plan to submit this to the ‘BMJ Open’ which is interested in publishing the protocols for NIHR funded 
studies. 
 
3. We will also present our findings at regional support group meetings such as the Avon Mesothelioma 
Foundation meetings and inform national support groups such as Mesothelioma UK, Clydeside Action on 
Asbestos and the British Lung Foundation. 
 
4. The focus group who helped in developing this application will also be notified either by writing or at another 
focus group meeting. 
 
 





Please describe how the outcomes of this research could be translated into the NHS and wider healthcare 
community to provide improvements in service delivery, patient health and/or wellbeing. 
 
The expected output of this feasibility study is the production of a dataset which will inform the planning and 
design of a full phase III multi-centre randomised controlled trial. This study will provide us with robust data to 
inform the application for a Health Technology Assessment (HTA) grant to support the full Phase III trial. 
The current treatment options for patients with newly diagnosed mesothelioma are severely limited. Zoledronic 
acid animal studies have looked promising but this has not been translated into human studies in patients with 
mesothelioma. The findings from this feasibility study will be published in a peer reviewed open access oncology 
journal providing rapid access to all healthcare professionals caring for patients with mesothelioma. 
In addition, this feasibility RfPB grant will help evaluate the role of serial mesothelin measurements and TGV 
PET-CT values in assessing possible response rates in patients with mesothelioma. 
One of the outputs of this study, the qualitative assessment data will provide us with essential patient derived 
information upon which the Phase III trial can be further improved on. 
The output of this study will prove invaluable in the design of the phase III study. It will identifypotential pitfalls 
and issues that we have not yet realised. It will inform us whether there is a need for a 4th arm to the Phase III 
study so that patients not having chemotherapy can be randomised to ZA or placebo. 
We anticipate that this work (feasibility study and subsequent full study) will inform future NICE guidelines on the 
management of MPM. 
 
 
Relevant expertise and experience 
 
Please outline the individual role of each member of the research team, highlighting the skills and experience of 
the team that make them well placed to carry out the work. 
 
The academic respiratory unit at North Bristol NHS trust/University of Bristol, has extensive experience in 
conducting randomised controlled trials (RCT) in patients with pleural diseases, a number of these trial are large 
UK multicentre trials. The unit has enroled over 500 patients with pleural disease into trials in the last 5 years. 
Dr Maskell is a Reader in Respiratory medicine at University of Bristol and runs a tertiary pleural service at North 
Bristol NHS Trust. He a leading pleural disease / mesothelioma researcher in the UK, currently holding 9 grants 
in this area. He currently sits on 11 Trial Steering Committees and has substantial expertise in multi-centre RCT 
design and delivery. He is the chair of the regional mesothelioma multi-disciplinary meeting and also co-chairs 
the British Thoracic Society (BTS) Mesothelioma Guideline group. 
Professor Iain Lyburn runs the regional PET service in the Cheltenham Cobalt Centre and has published widely 
in this field. He has previously participated in multi-centre mesothelioma RCTs and has extensive experience in 




reporting PET-CT scans. 
Dr Anthony Edey is a consultant radiologist at North Bristol NHS Trust with a specialist interest in pleural based 
imaging and sits on the regional Mesothelioma MDT. He is also a member of the BTS Mesothelioma guideline 
group and has experience in participating multi-centre RCTs. 
Dr Dangoor is an oncology specialist with a specialist interest in mesothelioma. He will be providing oncological 
input into this trial as well acting as the principal investigator for one of the research sites. 
Dr Chris Rogers is a Reader in Medical Statistics and the co-director of the Clinical Trials Evaluation Unit (CTEU) 
in Bristol. She will be providing us with methodological and statistical support in this trial. She is a co-applicant on 
several NIHR funded studies and has successfully conducted several multicentre RCTs in the past. 
Ms Sarah Smith is a specialist nurse in lung cancer and mesothelioma with over 10 years’ experience working in 
this field. She is a founder member and a trustee of the Avon Mesothelioma Foundation and will work closely 
with patient support groups. 
Dr de Fonseka is a clinical research fellow working towards a PhD in pleural disease. She has extensive 
experience in mesothelioma, helping to run the mesothelioma tertiary clinics and deputising on behalf of Dr 
Maskell at the regional mesothelioma MDT meetings. She also sits on the BTS Mesothelioma guideline group. 
















Set up phase - 3 months 
 
• Protocol finalisation 
• Ethical and regulatory approvals 
• CRF design 
• Database design, testing and validation 
• Recruitment of trial specific staff to respiratory trials unit 
• Sign off trial related documents at first TSC meeting 
 
Initial recruitment phase – 9 months 
 
• 9 months of recruitment at a rate of 4-5 patients per month 
• TSC meeting 6 months into recruitment 





Recruitment phase (3 months) 
 
• Continue recruitment for another 3 months at a rate of 4-5 patients per month 
• Continue data entry, verification and checking 
• TSC meetings at 6 month intervals to review progress 
 
Follow-up phase (9months) 
 
• Follow up of all patients up to 12 months from recruitment 
 
Statistical plan written and signed off by the TSC 
 
Year 3 
Follow-up phase (3 months) 
 
• Follow-up until all recruited patients have had 12 months follow-up (should complete at 3 months) 
• Data entry, verification and checking 
 
Analysis phase (3 months) 
 
• Data analysis 
• Writing up of results for publication 









Research management arrangements 




Please explain the practical arrangements for managing the research and its constituent components. 
 
The study is to be delivered by an experienced research team with a proven track record. The Chief Investigator 
(CI), Dr Maskell, has successfully conducted and completed several randomised controlled trials, some of which 
are NIHR funded. Dr Maskell will oversee the trial as the chief investigator but the trial co-ordinator will be 
responsible for the day to day running of the trial including liaising with other sites on a regular basis to ensure 
recruitment targets and project milestones are met. Any issues arising will be discussed with the CI as necessary 
and addressed in conjunction with the rest of the research team. 
Monthly progress meetings within the research team and 6 monthly TSC meetings will take place to ensure 
satisfactory progress of the trial. Trial steering committee will comprise of the co-applicants, principal 
investigators, patient representative and an independant member. 
We will work closely with the Clinical Trial Evaluation Unit (CTEU) to conduct a streamlined trial. We have 
worked closely with the director of the CTEU who has given input in the design of the study and we will liaise with 
her throughout the study to ensure the trial is conducted smoothly and robustly. 
 
 
Has any work relevant to this proposal already commenced? No 
 
 
Success criteria and barriers to proposed work 
 
Please set out the measurements of success you intend to use and also the key risks to delivering this research 
and what contingencies you will put in place to deal with them. 
 
As this is a feasibility study, the main purpose is to identify issues that may arise prior to designing a phase III 
study. The primary success criterion will be achieving the anticipated recruitment rates. Due to the nature and 
progression of the disease, limited numbers of patients take up chemotherapy. Some maybe opposed to the idea 
of a further drug, therefore numbers recruited maybe slow and small. Patients may be deterred by the idea of 
extra visits to hospital for the drug and scans which again may lead to slow recruitment. Although relatively safe, 
we are unaware of the side effects of the ZA alongside chemotherapy, which may lead to a number of patients 
dropping out of the trial early. 
Any issues identified from our pilot study would be used inform the design of the full phase III study so these can 
be anticipated and contingencies put in place prior to commencing the trial. 
 
 
Does the proposed research raise ethical issues? Yes 
 
 
If yes, discuss how these issues will be addressed. 
 
We do not anticipate significant ethical issues with regards to the running of this trial. Although this is a new drug 
in the mesothelioma arena, ZA has been around for a number of years with a good safety profile. It has been 
used in a number of metastatic malignancies as well non-malignant diseases such as osteoporosis with good 
tolerance. However, as the patients are NHS patients, as per the research governance framework we will obtain 
ethics approval and R&D approval at all research sites prior to the start of the trial. All research staff will be 
trained as per Good Clinical Practice (GCP) criteria. 
One ethical issue that was raised at the PPI meeting and has now been addressed is that patients who decline 
chemotherapy should not be deprived of the drug. The proposed third non-randomised group patients who have 
declined chemotherapy will be offered ZA open label. 
 
 
Please detail how and when you intend to get ethical review completed. 
 
We have allowed 3 months prior to the start of the trial for protocol finalisation and relevant approvals. All patient 
literature and the finalised protocol will be submitted to the Bristol Research & Ethics committee for approval. We 





Have any appropriate regulatory bodies already granted a 
favourable opinion? No 
 
Involvement of Clinical Trials Units 





Is a Clinical Trials Unit (CTU) involved with this research proposal? Yes 
 
 
If yes, what is the name of the CTU? 
 
Please provide the name of the CTU involved. 
Bristol Clinical Trials Evaluation Unit (CTEU) 
 
 
Does the CTU hold a UKCRC registration number? Yes 
 
 





Please describe how you have worked with the CTU in developing your application and what support they will 
provide if funding is approved. 
 
The director of the CTEU, who is also a co-applicant on this application, was approached at a very early design 
stage of this application. She has given us input in developing the study and with feasibility outcomes we should 
be aiming for. 
The CTEU is hosting the database and providing us with a database manager for this project. Furthermore we 






APPENDIX IV – SEMI STRUCTURED INTERVIEW THEMES  
 
1. Diagnosis 
- Patient understanding  
- Diagnostic methods 
- Information received about the diagnosis 





- Impact on quality of life?? 
 
3. Management  
- Chemo/no-chemo and reasons behind their decision 
- How they tolerated treatment and associated side effects 
- Radiotherapy treatment  
- Palliative care input 
 
 
4. Zol-A trial 
- Which arm do they think they are in (for non-randomised patients) 
- Their understanding of randomisation.  
- Randomised patients – do they think they received the treatment 
- Their thoughts on trial related procedures such as PET scans and extra visits for bloods 
- Did they have any concerns about having the PET scan which involves a radioactive dye? 
 
 
5. Prognosis and dying 
- Change in their outlook of life since the diagnosis 
- Thoughts about actual prognosis – how long to live 









APPENDIX V – ZOL-A STATISTICAL ANALYSIS PLAN 
 
1. INTRODUCTION TO SAP 
 
1.1 Scope 
This statistical analysis plan (SAP) details information regarding the statistical analysis of the 
Zol-A randomised controlled feasibility trial (RCT) and covers all analyses of trial data 
outlined in the study protocol, with the exception of the qualitative elements of the project. 
 
1.2 Editorial changes 
Any changes made to this SAP after approval must be clearly justified and documented as an 
amendment at the end of this document. The SAP should then be re-approved. 
 
1.3 SAP document approval 
The Chief Investigator should authorise this document. 
 
  
2. STUDY BACKGROUND AND OBJECTIVES  
 
2.1 Study background 
Zol-A is a multi-centre double blind parallel-group feasibility RCT comparing zoledronic acid 
(ZA) and placebo for the treatment of with malignant pleural mesothelioma (MPM) 
alongside chemotherapy.   The study also includes an ‘open treatment group’ of patients 
who decline randomisation and chemotherapy but consent to receiving ZA. 
 
2.2 Study objectives 
The aim is to establish the feasibility of the full multi-centre trial and to assist in its design. 
Specific objectives are to obtain accurate information on: 
• Presentation, recruitment, consent and randomisation rates of MPM patients at 
each site. 
• Acceptability of recruitment procedures, consent and randomisation, and data 
collection methods. 
• Acceptability of ZA in MPM patients, and the optimal timing and location for ZA 
administration. 
• Qualitative assessment in a subgroup of up to 150 patients to evaluate patients 
experience in the randomisation and recruitment process 
• Quantification of drop-out and data completeness rates 
• Estimates of outcome event rates e.g. survival times, measures of mean response 
and outcome variance (continuous variables such as quality of life)  
• Measure of variation between patients and between sites and information required 








No primary or secondary outcomes have been explicitly defined. Quantifiable feasibility 
outcomes are defined as follows: 
• Number of patients screened, approached and consented to the RCT or the open 
treatment group.  
• Timing of drug administration 
• Location of drug administration 
• Drop-out rate 
• Data completeness rates 
• Estimates of outcomes to inform the design and size of a full trial, i.e.  
- progression as assessed by modified RECIST criteria on CT)  
- standard deviation of quality of life measures (dyspnoea Visual analogue scale (VAS) 
scores and EQ5D and EQ5D VAS); 
- Tumour metabolic activity as determined by Total glycolytic volume (TGV) on PET-CT 
scan 
- Value of TGV or standard uptake value (SUV) in the assessment of disease 
response/progression 
- Serum mesothelin levels  
Additional outcomes not listed explicitly in the protocol that will be reported on are: 
• Adherence to study treatment and reasons for non-adherence 
• Rate of unblinding  
2.4 Changes to the study objectives during the course of the study (if required) 
Primary feasibility outcome was changed from 12 to 13 months. Some of the eligibility 
criteria changed slightly (but this may not be a change to the objectives) 
  
3. STUDY POPULATION 
The study population is adult patients with a new diagnosis of mesothelioma.  
The planned sample size for the trial is 50 randomised patients (25 ZA and 25 placebo) plus 
20 in the open treatment group over 12 months 
3.1 Flow of participants 
Participants are randomised into the RCT and undergo up to 6 cycles of chemotherapy plus 
study treatment. The baseline CT scan used in this study was the clinical scan performed in 
the immediate run up to diagnosis (within 8 weeks of trial entry). They have CT scans at 3 
cycles post treatment and again at 6 months from randomisation.  They have a PET-CT scan 
at baseline and again after 3 cycles and are followed up at till 6 and 12 months after 
randomisation.  Patients consenting to open treatment receive 6 doses of ZA without 
chemotherapy.  Otherwise the assessment pathway is the same.  
3.2 Characteristics of non-trial non-randomised patients 
Characteristics of patients who declined randomisation but consented to the open label 
treatment group will be compared to those who consented to randomisation. 
3.3 Randomisation 
Patients are randomised (1:1 ratio) to ZA or placebo. The allocation will be blocked using 
varying block sizes and stratified according to histological sub-type. 
3.4 Protocol deviations 
The following types of protocol deviation will be considered: 
• Trial patient received the alternative treatment to that allocated. 




• Trial patient did not receive study treatment according to the protocol, i.e. study 
treatment was not administered in approximately 3 weekly cycles, coinciding with 
chemotherapy. Note: Patients who delay chemotherapy delay study treatment. Patients 
who stop chemotherapy stop study treatment at that time.  
• Chemotherapy treatment was not in line with the study protocol, i.e. not 
combination treatment with Pemetrexed and Cisplatin/Carboplatin for a maximum of 6 
cycles.  
• Concomitant medication not in line with study protocol, i.e. supplementary calcium 
tablets (AdCal D3 one tablet twice a day) not prescribed. Note: patients who develop 
hypercalcaemia should stop taking the Adcal D3.  
• Calcium level not checked with each pre-chemotherapy blood test 
• Treatment allocation unblinded not in response to a request for unblinding or safety 
grounds 
Note it may be possible for patients to be classified as a protocol deviation for more than 
one reason.  
The frequency of each type of deviation will be tabulated by treatment allocation (reference 
Table T2) with full details given in separate listings (reference Table T3).   
3.5 Withdrawals 
Patients (or clinicians on their behalf) can withdraw from the study at any time post-
randomisation. In some cases patients were happy for data collection to continue, and 
therefore such patients will be included in the study analyses on an intention to treat basis 
(ITT), see section 3.6.   
Data on all withdrawals is captured on a specific case report form (CRF), and will be 
tabulated by treatment allocation (reference Table T4) with full details given in separate 
listings (reference Table T5).   
3.6 Analysis population 
The analysis population consists of all randomised patients excluding 
• Patients who died after randomisation but prior to any data collection. 
• Patients withdrawn who were unwilling for data collected to be used. 
The trial data will be presented by allocated group (ITT).  
3.7 Safety population 
The safety population will consist of the analysis population. Safety data will also be 




New variable Rules 
Proportion of patients 
eligible 
Number of patients meeting eligibility criteria / number of 
patients screened 
Proportion of patients 
consenting to RCT 
number of patients consenting to be randomised / number 
of patients meeting eligibility criteria and being approached 
for the trial 
Proportion of patients 
consenting to open 
treatment group 
number of patients declining randomisation but consenting 
to receive ZA treatment / number of patients meeting 
eligibility criteria and being approached for the trial 
Timing of drug 
administration 




New variable Rules 
Time to death (randomised 
patients) 
If death = yes then date of death – randomisation date  
Else date of last follow-up – randomisation date 
Time to death (open 
treatment group) 
If death = yes then date of death – consent date  
else date of last follow-up – consent date 
Survival indicator If death = yes then indicator = 1 
Else indicator = 0 
Time to disease progression If progression = yes then date of progression – 
randomisation date  
Else if progression = no and death = yes then date of death 
– randomisation date 
Else if progression = no and death = no date of last follow-
up – randomisation date 
Disease progression To be defined (based on modified RECIST criteria on CT) 
Time to disease progression 
(open treatment group) 
If progression = yes then date of progression – consent 
date  
Else if progression = no and death = yes then date of death 
– consent date 
Else if progression = no and death = no date of last follow-
up – consent date 
Progression free survival 
indicator 
If progression = yes then indicator = 1 
Else indicator = 0 
EQ-5D  Data from the EQ5D questionnaire will be used to derive a 
five digit ‘state’ from the mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression scores using the 
following: 
State = 10000*mobility score + 1000*self-care score + 
100*usual activities score + 10*pain/discomfort score + 
anxiety/depression score 
Each state will then be assigned a single summary index 
score according to standard scales.  These index scores 
are numerical and range from -0.59 to 1.00, with a score of 
1.00 denoting perfect health. 
If any of the five scores are missing, the state score will be 
missing.  
Adherence If chemotherapy = yes and study treatment = no then 
adherence = 0 
Else if chemotherapy = yes and study treatment = yes then 
adherence = 1 
 
 
4.2 Other variables 
New variable Rules 
Age (Operation date – DOB)/365.25 
BMI Weight (kg) / Height (cm)2 * 10,000 




Laterality of disease 
Mode of diagnosis 











New variable Rules 
Previous Pleurodesis 
IPC in -situ 






Baseline EQ5D VAS 
score 
 
Yes / No 
Yes / No 
Ia, Ib, II, IIIa, IIIb, IV 
Upper, mid and lower SUVmax 
Mesothelin level (nmol/L) 
 




5. STATISTICAL ANALYSES 
5.1 Baseline data 
Baseline (i.e. patient demography and past history) characteristics will be described by 
treatment group for patients in the analysis population. Tables T6 to T7 will be used as 
templates for this. 
Continuous variables will be summarised using the mean and standard deviation (SD) (or 
median and inter quartile range (IQR) if the distribution is skewed), and categorical data will 
be summarised as a number and percentage. The summary statistic headings given in Tables 
T6 to T7 are those we expect to use based on a-priori knowledge of the clinical 
measurements gained from previous studies. However, if distributional assumptions are not 
valid, changes will be made.   
Any imbalances in the characteristics of the patients at the start of the study will be 
described but statistical tests for baseline imbalance will not be carried out.  
Characteristics of patients in the open treatment group will also be described. 
5.2 Outcomes 
5.2.1 Adjustment in models 
As this is a feasibility study and not powered to test research hypotheses, no statistical 
comparisons between groups will be made. 
5.2.2 Analysis models 
• All outcomes listed in the study protocol will be presented in template tables. Details 
specific to each outcome are described as appropriate. 
• Binary or categorical outcomes will be presented as numbers and percentages of 
patients in each treatment group. Rates will be presented with 95% confidence 
intervals (95% CI).   
• Continuous outcomes will be summarised by the mean and SD in each treatment 
group, if distributions are approximately normal. If distributions are non-normal data 
will be summarised by the median and IQR or geometric mean (GM) if a logarithmic 
transformation provides an approximately normal distribution.  
• Time to event outcomes will be summarised by the median and IQR in each 
treatment group estimated using the Kaplan Meier method.  
• Continuous longitudinal outcomes will be summarised as means and SDs (or medians 
and IQRs if distributions are skewed) at each time point. Statistical significance 
5.2.7 Missing data 
In all tables missing data will be indicated by footnotes.  




Adverse events occurring in the study period for all patients in the safety population will be 
tabulated. 
Expected adverse events listed in the study protocol, with events that meet the serious 
criteria will be summarised. Such events are captured via the study CRFs.  
Unexpected serious adverse events (SAEs), i.e. events that are not listed in the study 
protocol that meet the serious criteria will be summarised separately. Such events are 
captured via separate SAE report forms and full details will also be given as listings, with 
events that are classified as possibly, probably or definitely related highlighted  
No formal comparisons between treatment groups will be made, as numbers of events are 
expected to be small.   
